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Abstract
Until 1983, third generation cephalosporins (3GCs) were thought to be
resistant to hydrolysis by all plasmid-mediated beta-lactamases. However,
TEM and SHV derived beta-lactamases have recently evolved which can confer
transferable resistance to 3GCs.
Six novel plasmid beta-lactamases, which confer transferable resistance to
3GCs have been identified and characterised. They have been compared
directly to the other 3GC hydrolysing beta-lactamases discovered
elsewhere. The criteria implemented to distinguish these different
beta-lactamases were: Km and Vrnax values for the hydrolysis of different
substrates, molecular weight, isoelectric focusing point (pi) and
susceptibility to inhibitors. The beta-lactamases TEM-E1, TEM-E2, TEM-E3,
and TEM-E4, were all TEM derived and, although they conferred a greater
transferable resistance to ceftazidime than cefotaxime, they hydrolysed
both these substrates with similar efficiencies. TEM-E2 was produced by an
organism which was isolated in Liverpool in 1982 and is, consequently, the
first example c£ transferable 3GC resistance. TEM-E3 was produced by
clinical isolates from two different London hospitals, and found to be the
same as TEM-10 which was discovered in the USA after the characterisation
of TEM - E 3 .
-ii-
TEM-E1 and TEM-E2 like enzymes mnld be
obtained spontaneously from a TEM-1 producing E.coli and, in the same way,
TEM-E4 like enzyme oould be obtained from a TEM-2 producing organism. Utilising the
same methodology a beta-lactamase, which conferred transferable resistance
to ceftazidime, was obtained from PSE-4, although such an enzyme has not
yet been reported in clinical isolates.
The fifth novel beta-lactamase, DJP-1 (pi 7.9), was produced by an
organism isolated in India which also produced TEM-1 and CAZ-6. This was
the first example of transferable 3GC resistance in Asia and the first
report of two transferable 3GC hydrolysing beta-lactamases being encoded
by the same plasmid. The characteristics c£ the sixth novel enzyme, BIL -1,
suggest that it was originally an E.coli chromosomal beta-lactamase.
Analysis of this strain revealed that the beta-lactamase (pi greater than
8.2) conferred transferable resistance to all beta-lactam antibiotics and
clavulanic acid.
Finally, two novel methods for the isolation and purification of
beta-lactamases were developed during these studies. Electro-dialysis of
beta-lactamases from polyacrylamide gel allowed rapid purification of
TEM-E2 frcm TEM-1. Fast Protein Liquid Chromatography System was employed
to separate beta-lactamase DJP-1 from the other beta-lactamases produced
by the host strain. In addition it was illustrated that different
beta-lactam molecules can induce a variety of different beta-lactamase
satellite bands which can be visualized by isoelectric focusing. Moreover,
it was also verified that these satellite bands were variants of the main
beta-lactamase protein.
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1.0. INTRODUCTION
A world without antibiotics is now unimaginable. A host of once
untreatahle infections are no longer regarded with concern. Mortality
from bacterial endocarditis was 100% before the advent of antibiotics;
effective treatment with antibiotics has now reduced this to between 15%
and 30%. Antibiotics have been the major medical discovery of all time and
have accelerated the advancement of medicine, notably organ
transplantations, hip replacements, major abdominal and cardio-thoracic
surgery, and the treatment of cancer (Dryden, 1 987).
Beta-lactam antibiotics have played a key role in reducing the impact of
life threatening diseases. However, over the last 30 years the bacteria
causing these Infections have become increasingly resistant to beta-lactam
antfhiotics. The main mechanism causing this resistance has resulted from
the production of beta-lactamases capable cf hydrolysing these drugs and
rendering them inactive. The pharmaceutical industry has constantly
responded to the emergence of these enzymes by developing new antibiotics
of greater sophistication and better beta-lactamase stability. However,
bacteria have a remafkahle ability eventually to counteract any type of
beta-lactam antibiotic, and this Thesis will demonstrate how this group of
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microorganisms has now overcome a group cf beta-lactam antibiotics which
were believed to be, in terms of sophistication and design, the "ultimate"
group of antibiotics - the third generation cephalosporins.
1.1. The discovery and development of penicillins.
The growth of this group cf antibiotics began with Alexander Fleming's
astute observatiCTi, that a contaminating mould was inhibiting the growth
cf staphylococcal colonies which had previously been inoculated onto the
agar plate (Fleming, 1929). This mould was identified as Penicillium
notatum. Fleming realised that a small molecular weight compound was
diffusing through the agar and was responsible for the antibacterial
properties. He predicted that this compound, which he called penicillin,
was cf clinical significance so he tried to obtain penicillin extracts by
u
fermenting Peniri 11 -irnnotatum. and crudely removing the whole cells. At
that time further investigation was generally impeded by the current
enthusiasm for the newly introduced sulphonamides. However, Fleming
continued to study the effects of the crude mixture and, in 1932, he
administered the crude antibiotic preparation to cure a pneumococcu s eye
infection which was preventing one of his medical students from
participating in his rifle team. This was possibly the first successful
clinical use cf a beta-lactam antibiotic. Further work on penicillin was
conducted by Heatley, Florey and Chain at Oxford which to led to their
first publication on the properties of penicillin in 1940 (Chain, et al..
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1940), followed, by a fuller account with impressive clinical evidence by
Abraham et al. (1941). However, it was the clinical trials conducted on
injured soldiers in the North African campaign of the war (Pulvertaft,
1943) which acted as a further stimulus to enhance penicillin production
at Oxford and by several British pharmaceutical companies. In the USA
pharmaceutical companies had started collaborative work on the production
of penicillin. This vastly increased penicillin output and marked the
foundation of the modern pharmaceutical industry.
1.1.1. Semi - synthetic penicillins.
In 1959 Beechams Research Laboratories in England developed the technology
cxrv
for obtaining large amounts of 6 - amino - penici 1 Ti c acid (6APA), the core
structure of penicillin. This opened up almost infinite prospects of new
antibiotic derivatives by simple acylation substitution of the 6 - Carbon of
the beta-lactam ring of 6APA (Batchelor., et al. 1959) (fig. 1).
Acylation of the 6APA, the penicillin nucleus, with different carboxylic
acid, chlorides or mixed anhydrides has permitted the semi-synthetic
modification of the penicillin side chain. Consequently, thousands of
semi-synthetic penicillins have since been prepared, mainly with a view to
increase the spectrum of these drugs and widen the groups of bacteria ahle
to be treated with penicillins, but only a few have proved to be of real
therapeutic value.
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Fig. 1. Structure of penicillins and
6-aminopenicillanic acid.
H H




Fig. 2. Structure of cephalosporins and
aminocephalosporanic acid.




Cephalosporins Aminocephalosporanic acid (7-ACA)
[C10H12N2O5S (272.28)]
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1.1.2. Beta - lactamases and the success of penicillins.
At the start cf the 1940s Abraham and Chain discovered that Escherichia
coli. produced penicillinase which could inactivate penicillin by
hydrolysis (Abraham and Chain, 1940). This discovery identified a
resistance mechanism which has been an important consideration throughout
the subsequent development of beta-lactam antibiotics.
Frcm 1945 to 1960 the increased use of penicillin led to the emergence of
penicillin resistant staphylococci. Over the subsequent years these levels
of resistance proliferated. Neu (1985) showed that more than 95% of
hospital isolates and 85% of community isolates of S.aureus produce
beta-lactamases conferring resistance to a wide range of beta-lactam
antibiotics.
1.1.3. Beta - lactamase stable penicillins.
In order to combat the increasing problem of penicillin resistance
Beechams released the semi - synthetic penicillin, methicillin, which was
highly resistant to staphylococcal penicillinases (Rolinson et al.. 1960).
This was followed by a number of other penicillin derivatives which were
resistant to staphylococcal penicillinases i.e. oxacillin, cloxacillin,
flucloxaci 11 in. However, like methicillin the antibacterial activity of
these drugs was limited to Gram - positive bacteria.
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1.1.4. The future of penicillins.
One cf the main factors which hindered the development of the penicillin
group of antibiotics was that the side chain determining the identity of
the penicillin is always at the same point on the molecule (fig. 1).
Consequently, there is far less scope for chemical modification. This
appears to be one cf the reasons why it has not been possible to design a
penicillin which has both penicillinase stability and a broad spectrum of
activity. Therefore, the penicillin group of antibiotics has not yet
reached the sophisticated levels obtained by the modern cephalosporin
antibiotics (see next section). This has since been overcome by the use of
An example of this is
beta-lactamase inhibitors in combination with a penicillin^
Augmentin which is a combination of amoxycillin and clavulanic acid
(Brogden et al.. 1981).
1.2. The discovery and development of cephalosporins.
The injectable antibiotic market in the USA grossed $1.3 billion in sales
in 1985, and 56% of these sales were for cephalosporins (Quenzer, 1987).
The development and growth of this group of antibiotics stems from
Professor Giuseppe Brotzu's observation in 1945, whilst Rector in the
Sicilian University of Cagliari, Sardinia, that sea water from a sewage
outlet appeared to be self-purifying. He hypothesised that this may be the
result of bacterial antagonism and, on further investigation, he isolated
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a fungus which was classified as Cephalosporinm acreroonium. Fluid cultures
cf this organism exhibited anti-bacterial activity and Brotzu had limited
success when treating typhoid and brucellosis with crude extracts of the
fungus. Unfortunately, no established scientific journal would accept his
findings, so in 1948 he formed a journal called the Lavori dell'istituto
d'Igiene di Cagliari which published his work in 1948. Brotzu's work may
easily have been lost in the reams of obscure scientific literature, had
it not been for Dr C.O.S. Blyth Brook, a former public health officer in
Sardinia during the war, who wrote to H.W. Florey telling him of Brotzu's
discovery.
1.2.1. The discovery of cephalosporin C.
In August 1948 a culture of the fungus was sent to Oxford, further
research revealed that the fungus produced not one, but seven different
antibiotics. Cephalosporins P1, P2, P3, P4, and P5 were isolated by
Burton and Abraham (1951) and were later found to have a steroid structure
similar to fusidic acid (Godtfredsen et al.. 1965). Cephalosporin N was
fcund to yield penicillamine on add hydrolysis (Newton and Abraham, 1954)
and was renamed adicillin. Newton and Abraham (1955) identified another
antibiotic from the culture fluids of Cephalosporinm acremonium and this
was designated cephalosporin C.
1.2.2. The importance of cephalosporin C.
The discovery of cephalosporin C received great attention, mainly because
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it was equally effective against strains of penicillin resistant and
penicillin sensitive staphylococci, but also because it had a wide range
of anti-bacterial activity. Further work illustrated that cephalosporin C
was highly resistant to hydrolysis by the staphylococcal penicillinase and
it oorapetitively inhibited the action of penicillinase on benzylpenici 11 in
(Abraham and Newton, 1956). This prototype cephalosporin was also non
toxic to mice and cured a streptococcal infection when given
subcutaneously (Florey, 1955). At this particular time the occurrence of
penicillinase producing strains of bacteria had begun to diminish the
effectiveness of penicillin and the vast potential of the "penicillinase
resistant" cephalosporin antibiotics was realized. Consequently, research
into cephalosporins proliferated in an eager attempt to obtain better
yields of the antibiotic and once this was achieved, increased
anti- bacterial performance by chemical modification.
1.3. Chemical modification of cephalosporins.
The cephalosporin nucleus contains several positions where chemical
modification can be made (fig. 2) and as a result of this many thousands
of cephalosporin antibiotics have been produced by various pharmaceutical
companies worldwide (Williams & Williams, 1 980).
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1.3.1. The first cephalosporins.
<\A
Cephalosporins are derivatives of 7 - aminocephalosporic acid (7-ACA)
(fig. 2), which is prepared by chemical cleavage of the side chain of
cephalosporin C. The first cephalosporin, oephalothin, became available in
the United States in 1964, this was a semi-synthetic cephalosporin and
developed by Chauvette et al. (1962). At approximately the same time
cephaloridine was introduced into the United Kingdom by Glaxo (Muggleton
et al.. 1 964) (fig. 3).
1.3.2, Primary design initiatives of cephalosporins.
Most cf the early modifications, such as cephacetrile, cephalothin, or
cephapicm, were directed at the 7-acyl group as it was soon realized that
this was the substituent which had a strong influence on anti-bacterial
activity. All three of these pioneering cephalosporins had acetoxymethyl
groups as their 3-substituents. However, such groups were prone to
esterases found in the body and cephalothin, cephapirin and cephacetrile
fKnusel et al.. 1970) were converted into their corresponding deacetyl
compound which had an inferior anti-bacterial action. This problem was
overcome by replacing the ester group at position 3. This led to the
development of cephaloridine (Muggleton, 1964) by Glaxo and cefazolin
(Symposium, 1973) which was introduced by Eli Lilley (fig. 3).
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Figure 3: The structure of cephalosporins
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1.3.3. Design of oral cephalosporins.
Further investigations showed that oral absorption of cephalosporins could
be achieved with an alpha amino group on the 7-beta-acyl substituent and
with a small uncharged group in position 3 (O'Callaghan, 1975). This led
to the introduction of cephalexin (Wick, 1967) by Glaxo which was the
first successful orally absorbed cephalosporin. Cephradine was later
introduced in 1973 (Gadebusch et al.. 1972) followed by cefaclor in 1978
(Neu and Fu, 1 978) (fig. 3).
1.3.4. Design of beta - lactamase resistant cephalosporins.
As the future success a£ some of the earlier cephalosporins appeared to be
threatened by their susceptibility to beta-lactamases, the further
development c£ the cephalosporin group c£ antibiotics is an on-going story
of designing beta-lactamase stable molecules with an ever increasing
spectrum of anti-bacterial efficacy. Like the penicillins, significant
improvement in resistance to beta-lactamase hydrolysis has relied on
manipulations which involve steric effects in the vicinity of the
7-beta-acyl position. A lot of the earlier cephalosporins possessed a
-CH2- next to the amide link, and this was accompanied by sensitivity to
the beta-lactamases of Gram-negative organisms, (i.e. cephaloridine or
cephalothin), but this decreased as more bulky groups were introduced at
the 7-beta-acyl position, i.e. cefotiam. The incorporation of a side chain
alpha carbon atom into a ring in order to increase steric bulk lowers the
general activity af the cephalosporin. Similarly, multiple substitutions
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cf the alpha carbon atom with alkyl and aryl groups to increase steric
bulk have a detrimental effect on activity. This, in general, can be
overcome by the introduction of certain polar substituents, which increase
resistance to beta-lactamases and increase the spectrum of anti-bacterial
activity. Cephalexin, which has an alpha amino substituent, has moderate
resistance to beta-lactamases, although it does not have a significant
spectrum a£ anti-bacterial activity. Cefamandole and cefonicid demonstrate
that an alpha hydroxyl group is more effective in this position and these
two drugs have an increased resistance to beta-lactamases along with a
broader spectrum of activity (reviewed by Hoover, 1983) (fig. 4).
1.3.5. Cefuroxime.
The next increase in beta-lactamase stability was achieved with oefuroxime
which was introduced by Glaxo (O'Callaghan et al.. 1976). This differed in
structure from cefamandole but had much the same intrinsic level of
anti-bacterial activity against a wide spectrum of organisms (fig. 4).
However, cefuroxime has a broader spectrum of resistance to
beta-lactamases than cefamandole (Richmond and Wotton 1976) which was
achieved by an 2-oxyimino group on the 7-beta-acyl substituent. The furyl
ring was shown to have an activity advantage over phenyl and thienyl
groups (reviewed by Hoover, 1983). Glaxo have since launched an oral
cefuroxime preparation, cefuroxime axetil, which is an esterified
derivative of cefuroxime (Williams and Harding, 1984).
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activity includes Ps. aeruginosa
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1.3.6. Ceohamvcins.
Another group of beta-lactamase stable compounds have emerged with
similarities to cephalosporins. These beta-lactams are called the
cephamycins of which cefoxitin was the first to be used clinically
(Birnhaum et al.. 1978). These compounds possess a 7-alpha methoxy group
which provides stability to the beta-lactam ring from beta - lactamase
hydrolysis. Their resistance to beta-lactamases has been demonstrated on
many, occasions (Fu and Neu, 1978 and 1979). Although cephamycins exhibit
high resistance to beta-lactamases their potency has since been found to
be limited by the presence of a substituent at the 7-alpha position.
(Stapley et al.. 1 979) (fig. 4).
1.3.7. Design of broad spectrum and beta-lactamase stable cephalosporins.
The next series of cephalosporins to be developed had similar resistances
to beta-lactamases as cefoxitin, but these new drugs had a much higher
antibacterial activity over an even broader range of bacterial species.
The majority of these cephalosporins have a 7-beta- (2-aminothiazol-4-yl)
acetylamino side chain, and the alpha-carbon atom is incorporated into a
oxyimino grouping. The potential for achieving unusually high activity
against Gram-negative bacteria through the use of this 7-beta-heterocyclic
substituent was illustrated by cefotiam. The acquisition of beta-lactamase
resistance by the incorporation of the alpha carbon atom into a oxyimino
grouping was predicted by the structure-activity relationships of
-15-
cefuroxime. Cefotaxime, ceftLzoxime, cefmenoxime, ceftriaxone, cefodizime,
and oefpirome all have the same 7-beta and -alpha carbon substituents.
However, their 3 - substLtnents vary enormously from a single hydrogen atom
(oeftizQxime) to a methyl - tetrazolethio group (cefmenoxime). These six
compounds all exhibit similar in vitro activity and resistance to
beta-lactamases, therefore, such properties must be achieved independently
of the 3 - substituent (reviewed by Hoover, 1 983) (fig. 4).
1.3.8. Design of ceftazidime.
Anti-bacterial activity declines with the increase in the bulk of the
alkyl group on the alpha carbon cf the 7-beta-substituent, however, there
is a fairly broad structural latitude. Consequently, ceftazidime, which
was introduced by Glaxo in 1981 (Muggleton, 1981), had an alkyl group
carrying a carboxyl function at this particular position, which is
somewhat similar to carbenicillin. Introduction of a carbaxyl group on the
7-beta-side chain lowers Gram-positive activity but, in this case,
significantly increased activity against some Gram-negative bacteria
including Pseudomonas spp.. Thus, ceftazidime has better activity against
clinical isolates of Pseudomonas aeruginosa than azloci 11 in (Wise et al..
1980). The discovery cf ceftazidime was a major breakthrough because it
was stable against the majority of the then known beta-lactamases (Simpson
et al.. 1982). In addition, ceftazidime had a broad spectrum of
anti -bacterial activity which included activity against P.aeruainosa
(Klingeren, 1981). This organism was resistant to the earlier
cephalosporins because of intrinsic rather than enzymic resistance
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mechanisms. Only 3% of clinical isolates of Pseudomonas spp. produce
beta-lactamases (Williams et al.. 1984). Therefore, beta-lactam resistance
in most strains was caused by the inability of the drug to penetrate the
outer membrane (Yoshimura and Nikaido, 1982). There were some other
beta-lactams to rival the anti-pseudomonal activity of ceftazidime. One
such antibiotic is cefsulodin, but this drug is extraordinary because it
has poor activity against bacteria other than P.aeruginosa (Tsuchiya et
al., 1 978) (fig. 4).
1.4. The mode of action of cephalosporin antibiotics.
The mode of action a£ benzylpenicillin has been studied in much detail and
because of similarities in structure, it is believed to typify the
bactericidal mechanisms exhibited by all the penicillins and
cephalosporins. Tipper and Strominger, (1965) observed that S.aureus
treated with penicillin contained large amounts of non-crossed linked
peptidoglycan units. This was confirmed by Waxman et al. (1980) when they
identified linear peptidoglycan in penicillin treated cells. This led to
the conclusion that penicillins and cephalosporins inhibited the
transpeptidase enzyme, which catalyses the final cross linking of the
peptide side chain of the nascent peptidoglycan (Tipper and Strominger,
1965). This cross linked peptidoglycan is essential to the bacterial cell
as it provides rigidity and protection. More recent studies (reviewed by
Spratt 1980, 1983) showed that, in addition to transpeptidase, both
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D-alanine carboxypeptidase and peptidoglycan endcpeptidase have been found
sensitive to penicillin. It is thus apparent that bacteria possess a
number of enzymes that are sensitive to beta-lactam inhibition.
Cooper (1956) observed that radio labelled penicillin binds to the cell
membrane and that this attachment was associated with the killing action
of beta-lactams. This led to the characterisation of penicillin binding
proteins (PBPs). Different species of bacteria possess different types of
PBPs - (reviewed by Livermore, 1987), but the Escherichia coli PBPs have
been studied in the most detail and, so far, seven have been
characterised.
1.4.1 Characterisation of E.coli PBPs.
PBPs 4, 5 and 6 are thought to be unconnected with the antibacterial
effect of cephalosporins and penicillins. However, PBPs 1-3 produced a
variety cf morphological effects when bound to beta-lactams. Blockage of
PBP 1a and 1b leads to cell lysis. However, bacterial mutants deficient in
either one cf these PBPs grow normally, presumably the other protein can
compensate for its loss. Obstruction cf PBP-2 leads to the formation of
large osmotically stable round cells which lyse slowly after several
of
hcurs. Inhibition cf PBP-3 induces filamentation^E.coli by specifically
inhibiting cell division without affecting cell lysis (reviewed by Spratt,
1 983).
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1.5 Antibacterial activity of cephalosporins.
Table 1 shows the antibacterial activity of cephalosporin antibiotics.
This is only a rough guide as many species show wide strain variations. In
some cases, where activity is stated as good there may be a few strains
which are resistant. The table avoids minimum inhibitory concentration
(MIC) values as these vary slightly from laboratory to laboratory, and can
be affected dramatically by the size of the inoculum (Brook et al.. 19891.
This makes comparisons difficult.
The early cephalosporins, such as cephaloridine, had moderate activity
against staphylococcal beta-lactamases, but were unstable against
Gram-negative beta-lactamases. Cefazolin had improved antimicrobial
activity over cephaloridine against Gram-negative organisms, but
cephaloridine had higher activity against Gram-positive bacteria (Wick and
Preston, 1972; Acter et al.. 19771. The next group of cephalosporins
represented by drugs like cephalexin were stable to Gram-positive
beta-lactamases and possessed moderate resistance to Gram-negative
beta-lactamases. The cephalexin group of drugs had a spectrum of
antibacterial activity similar to the cephaloridine-like compounds, but
with a somewhat lower degree of activity against most species. However,
as these cephalosporins can be oral preparations, cephalexin-like drugs
et al.,
have attained wide popularity (Garrard 1981).
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These earlier cephalosporins filled the therapeutic gap which resulted
from the emergence cf staphylococcal beta-lactamases which were capahle of
inactivating penicillins.
The later cephalosporins such as those grouped with cefuroxime and
cefotaxime had a better activity against Streptococci spp., Neisseria
spp., and Haemophilus spp. The cefotaxime group of antibiotics were hailed
as the ultimate beta-lactams of their time. They had excellent activity
against a broad spectrum of bacterial species which included Pseudomonas
spp. (Slack, 1981). Cefotaxime and ceftazidime were also resistant to
nearly all the known plasmid mediated beta-lactamases of that time
(Richmond, 1980; Simpson et al.. 1982, respectively). However, such
complacency was unjustified, as over the last seven years, there has been
an increasing number of reports of plasmid mediated beta-lactamases which
have the ability to confer transferable resistance to cephalosporins from
4
both the cefotaxime and the cefuroxime groupsAantibiotics.
1.6 Classification of cephalosporins.
Table 2 shows the classification of cephalosporins into three different
generations and, although this scheme produces broad generalisations, it
is the most widely used method of categorizing the cephalosporin group of
anti-bacterial agents. However, the grouping of the drugs into generations
suggests that each new generation represents a general advance in all
aspects of the cephalosporin characteristics, rather than fairly specific
- 21 -
Table 2. Classification of cephalosporins (taken from Uri and Actor,
1 983).


































(a) = cephamycin. (b) = oxacephamycin
t Second generation cephalosporins introduced after 1983 are discussed in
text.
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modifications to one or more properties (Win-jams, 1987). Indeed, changes
in -the chemical structures of cephalosporins which increase activity
against one group of organisms normally hai/ean adverse effect on the
activity against another species.
To illustrate this the first generation cephalosporins are more active
against Gram-positive bacteria, However, the second generation have a
greater spectrum of activity and increased resistance to beta-lactamases,
and correspondingly
/they have less potency against Gram-positive bacteria. Similarly, the
third generation cephalosporins (3GCs) have a wider spectrum of activity
against Gram-negative and Gram-positive bacteria along with greater
stability against beta-lactamases, but their in vitro activity against
Gram-positive microbes is weaker than the first and perhaps the second
generation cephalosporins (Uri and Actor, 1 983).
Other classification schemes have been devised. Williams (1987) proposed a
more accurate method c£ categorizing parenteral cephalosporins based on
antimicrobial activity, stability to beta-lactamases, stability to
mammalian esterases, and variations in pharmacological properties.
However, this scheme produces rather artificial distinctions between
cephalosporins and has not been widely adopted.
It is probable that if a new cephalosporin is introduced which has
significant advantages over the 3GCs, it will be designated as a fourth
generation cephalosporin.
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1.7. Bacterial resistance to cephalosporins.
Resistance to cephalosporin antibiotics can arise from:
a. Modification of the targets which are responsible for the
anti-bacterial action of cephalosporins.
b. Inability of the cephalosporin to reach the microbial target.
c. Inactivation of the cephalosporin by beta -lactamases.
1.7.1. Cephalosporin resistance caused bv target modification.
It has been explained previously that cephalosporins must interact with
PBPs to exert their anti-bacterial action. However, PBPs can either be
replaced or undergo modification to reduce their affinity for
cephalosporins and consequently provide protection from these drugs.
a. PBP modification in Streptococci sop.
been
PBP modification has shown to be the mechanism of resistance in strains of
A
Streptococcus faecium highly resistant to cephalosporins. The strains of
Sfaecium were demonstrated to produce PBP-5 which reacts very slowly with
beta-Iactams (Fontana et al.. 1983). Penicillin resistance, mediated by
PBP modifications, has also been reported in Streptococcus pneumoniae
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(Handwerger and Toraasz, 1986; Zighelboim and Tomasz, 1 980).
b. PBP modifications in Haemophilus and Neisseria-
Neisseria gonorrhoeae was found to exhibit intrinsic resistance to
cephalosporins and penicillins by decreasing beta-lactam binding to PBP-1
and PBP-2 (Dougherty et al.. 1980, 1981). Parr and Bryan (1984) reported
that intrinsic resistance in Haemophilus influenzae resulted from reduced
affinity of PBP-3a and 3b for benzylpenicillin. Serfass et al. (1986)
reiterated these findings, and reported that intrinsic cephalosporin
resistance in isolates a£ Hinfluenzae was caused by reduced affinity of
PBP-5. PBP-5 corresponded to PBP-3b in Parr and Bryan's publication
(Livermore, 1 987.)
1.7.2, Cephalosporin resistance caused bv PBP replacement.
Beta-lactam resistance can also occur where an additional PBP is produced
which is unaffected by the presence of penicillins or cephalosporins. It
has been shown that methicillin resistant strains of Staohvlococcus
aureus, which are also resistant to cephalosporins, produce an additional
PBP (PBP-2') which is not present in methicillin sensitive isolates
(Hartman and Tomasz, 1984; Ubukata et al.. 1985). Although many
methicillin resistant S.aureus produce penicillinase this contributes
little to their resistance to beta-lactamase stable beta-lactam
°F
antibiotics (Spratt, 1989). Consequently, the acquisition PBP-2' appears
A
to be the major mechanism of methicillin resistance which is being
observed in increasing numbers of S.aureus isolates, and probably
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responsible for the emergence of methicillln resistant S.aureus in many-
hospitals (Cookson and Phillips, 1988; Kayser, 1975; McGowan, 1988).
1.7.3. Impermeability mediated cephalosporin resistance.
Permeability is often proposed as the mechanism of resistance once all
other potential resistance mechanisms have been discounted. However, there
is strong evidence to suggest that the outer membrane, in Gram-negative
bacteria, can shield PBPs from the actions of cephalosporins. The less
sophisticated wall structure of Gram-positive bacteria implies that this
layer must be much more permeable to the diffusion of cephalosporins.
Indeed, Williamson et al. (1983) showed that the PBPs of Group D
streptococci were completely exposed. Consequently, the rest of this
section will be concerned with impermeability mediated resistance in
Gram - negative bacteria.
The survival cf Gram-negative bacteria depends on their ability to absorb
nutrients and excrete waste products. However, the bilayer region of the
outer membrane provides a relatively impermeable barrier to hydrophobic
solutes and presumably to hydrophilic solutes. Consequently, Gram-negative
bacteria have developed porins which are a class of proteins that produce
water filled non-specific transmembrane diffusion channels (reviewed by
et al.
Nikaido, 1989). Nikaido H983) showed that these porin channels were theA
predominant pathway for the diffusion of beta-lactams into E.coli cells.
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a. Porins and cephalosporin resistance.
Porins function either individually or, more often as trimers (Nakae et
al.. 1979), and many different types of porins have been identified
(reviewed by Hammond et al.. 1984). Indeed, porins have been characterised
in thirty two species of Gram-negative bacteria (Hancock, 1987). The two
most significant E.coli porins are Omp F and Omp C (Nikaido et al.. 1983b
and mutants which produce reduced quantities cf these two porins were more
resistant to many cephalosporins compared to the wild type strains (Harder
et al.. 1981; Jaffe et al.. 1982; Sawai et al.. 1982). As yet there has
been no conclusive evidence to suggest that the genes controlling the
porin production are transferable between bacterial cells.
b. Impermeability resistance in Pseudomonas aeruginosa.
P.aeruginosa has a broad spectrum of resistance which suggests a
non-specific resistance mechanism such as impermeability. The extent of
this impermeability is Illustrated by the fact that although P.aeruginosa
isolates are frequently considered sensitive to third generation
cephalosporins such as ceftazidime and cefcperazone, they have MICs up to
100 fold greater than E.coli (Livermore, 1987). However, it appears that
this impermeability is independent of the porins present for the following
reasons. Firstly, P.aeruginosa produces large amounts of a porin (protein
F) which has been shown to form large pores (Hancock et al.. 1979). This
particular phenomenon may be explained if most of the pores were partially
closed (Hancock, 1986). Secondly, resistant and sensitive P.aeruginosa
isolates produce similar quantities of protein F (Livermore, 1984) and
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thirdly, some porin deficient mutants cf P.aeruginosa have been shown to
have reduced outer membrane permeability with no corresponding increase in
beta-lactam resistance (Gilleland and Farley, 1982; Nicas and Hancock,
1983). Consequently, impermeability mediated cephalosporin resistance in
P.aeruginosa can be explained by either a complex control of porin
channels and/or an additional barrier separating the outer membrane and
PBPs (Livermore, 1987). Godfrey et al. (1984) actually showed that the
resistance phenotypes cf permeability mutants of P.aeruginosa correlated
to changes within the lipopolysaccharide.
1.8. Beta-lactamase mediated resistance to cephalosporins.
The bacterial production cf beta-lactamases is considered to be the most
prominent and widespread mechanism of resistance to cephalosporin
antibiotics.
1.8.1. Richmond and Svkes method of classifying beta-lactamases.
Richmond and Sykes (1973) proposed one of the most widely accepted
classification schemes. The beta-lactamases cf Gram-negative bacteria were
subdivided into five groups by virtue of their substrate specificity
(penicillinase or cephalosporinase), genetic derivation (plasmid or
chromosomal), and susceptibility to inhibitors. The largest,
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and constantly growing group of beta-lactamases are the R-plasmid mediated
beta-lactamases. These are classified into Groups HI and V. These two
groups provide insufficient criteria for the classification of such a
large and diverse group of enzymes (Amyes, 1987). This problem was
elucidated by the development of analytical isoelectric focusing as a tool
for the beta-lactamase identification (Matthew et al.. 1975). This
distinguished beta-lactamases by their isoelectric focusing point (pi) and
consequently revolutionised the classification of plasmid mediated
beta-lactamases (Medeiros, 1984). This has led to the publication of many
tables which differentiate the plasmid mediated beta-lactamases by listing
their pi, molecular weight, substrate profile and susceptibility to
inhibitors. However, almost immediately after such tables are published
other novel beta-lactamases have been characterised and the tables rapidly
become dated (see Amyes, 1989 for the most recent tabulation of the
properties of plasmid mediated beta-lactamases).
a. Disadvantages of the biochemical classification of beta-lactamases.
The main criterion used by the Richmond and Sykes scheme is substrate
profile which is normally expressed as an enzymic rate of hydrolysis or
Vmax related as a percentage to the rate obtained with a standard
beta-lactam substrate. The listing of such data has allowed the enzymes to
be segregated into groups of carbenicillinases, oxaci 11 i nases or broad
spectrum enzymes. However, this scheme does not take into account the
enzymes affinity for different substrates (Km), and the listing of
hydrolysis data without referring to the Km has been criticised on many
occasions (Amyes, 1987; Bush and Sykes, 1986; Livermore, 1987).
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In addition hydrolysis data determined by different laboratories can show
considerable variations. Also as so many beta-lactamases have similar pis
it is becoming increasingly difficult to use isoelectric focusing as a
method c£ differentiating novel beta-lactamases. Lastly, the Richmond and
Sykes scheme does not consider sequence homology relationships between
different beta-lactamases.
1.8.2. The Ambler method of beta - lactamase classification.
Over the last 10 years, there has been a significant increase in the
technology associated with molecular probing, amino acid and nucleotide
sequencing which has provided a wealth of information on the amino acid
sequences c£ many beta-lactamases. This information has been utilized in
this second method of classification which groups both Gram-positive and
Gram-negative beta-lactamases into three or may be five distinct Classes
(table 3). Ambler (1980) devised this method of classification and
introduced the Class A and Class B beta-lactamases.
a. Class A beta-lactamases.
Class A beta-lactamases have a serine residue at their active site and
they have molecular weights of around 29000. These enzymes show
significant amino acid homology and are either penicillinases or broad
spectrum beta-lactamases. Class A enzymes show considerable homology with
D-alanine carboxypeptidase which is one of the target sites of penicillin
action in Bam'bus spp.. This has led to the theory that the target sites
of penicillin action (PBPs) share a common evolutionary origin with
-30-
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beta-lactamases (Asoh et al.. 1986; Waxman et al.. 1982; Yocum et al..
1979). This hypothesis has been reinforced by the studies showing that the
secondary and tertiary structures of the beta - lactamase of Bacillu s
licheniformis (another Class A enzyme) is similar to the PBP of
Streptomyces R6 despite limited amino acid homology (Kelly et al.. 1986;
Samraoui et al.. 1986). Class A also includes the TEM and SHV-derived
beta-lactamases.
b. Class B beta - lactamases.
Class B beta-lactamases include metal 1o-enzymes such as Rar-mns oereus U
oephalosporinase which requires a metal oafactor which is normally Znll,
but other ions can substitute (Davies and Abraham, 1974). These enzymes
show insignificant amino acid homology with the enzymes from Class A.
£L Class C beta - lactamases.
This group was added by Janrin and Grundstrom, (1981). These enzymes were
serine beta-lactamases but their amino acid sequence around the active
site was very different from that of the Class A proteins. Class C
beta-lactamases favour cephalosporin hydrolysis, and share no sequence
homology with the Class A beta-lactamases (Bergstrom et al.. 1982; Jaurin
and Grundstrom., 1981; Knott - Hunziker et al.. 1982).
d. Class D beta - lactamases.
The nucleotide sequence of the PSE-2 beta-lactamase was determined by
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Huovinen et al. (1988a) and this was found to have distinct homology with
the sequence of OXA-2 which was deduced by Dale et al. (1985). However,
Huovinen et al. (1988a) suggested that as neither of these enzymes
exhibited structural similarities with the TEM-1 or amp C beta-lactamases
they should be classified into a new Class. In addition to this, Jacoby
(1988) has partly sequenced PSE-1 and Ouellette (1988) has sequenced
OXA-1. Jaooby (1988) demonstrated that the amino acid sequences cf OXA-1/2
and PSE-1/2 showed greater homology between each other than TEM-1.
Consequently, the OXA and PSE enzymes appear to be related by amino acid
sequence homology but not by substrate specificities. Levesque (1988) has
also reported that the sequence of OXA-5 shows greater homology with the
previously discussed PSE and OXA enzymes than with TEM-1. Therefore,
Jaooby (1988) and Huovinen et al. (1988a) have suggested that OXA-1, 2, 5,
and PSE-1, 2 belong to a new Class of beta-lactamases in the Amhler system
- Class D. DNA-DNA hybridisation studies suggest that other OXA and PSE
enzymes may be allocated to this new Class. Although hybridisation studies
have illustrated that PSE-4 shows homology with other PSE enzymes, the
recent nucleotide sequencing of this gene has revealed that it has 50%
nucleotide homology with TEM-1 (Boissinot and Levesque, 1990).
Consequently, PSE-4 appears atypical of the other PSE beta-lactamases as
it is more related to the Class A beta-lactamases.
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e. Class E beta - lactamases.
It has been suggested that the metallo-enzyme, L-1, produced by
Xanthomonas maltnphilia should be designated to this new Class. This is
because the N-terminal amino acid sequence and the biochemical properties
of the L-1 beta-lactamase show no similarity to those of the Bacillus
cereus II metallo-beta-lactamase in Class B (Bicknell et al.. 1985)
f. The use of DNA probing in the Ambler classification method.
Probing experiments facilitate the classification of beta-lactamases in
this scheme as they infer the degree of nucleotide homology between
beta-lactamase genes. Today DNA probing is widely used to distinguish
different beta-lactamases and with the introduction of non - radioactive
beta-lactamase probes (Carter et al.. 1987) the utilization of such
procedures will increase. However, discrepancies have already occurred
concerning the hybridization of a TEM-1 probe with OXA-2 (Cooksey et al..
1985). This hybridization was later discounted when no significant
homology could be detected between the amino acid sequences of TEM -1 and
OXA-2. Ouellette et al. (1987) proposed that the cross hybridisation
recorded by Cooksey et al. (1985) may have been caused by either the
plasmid encoding OXA-2 containing a silent copy of TEM-1, or because the
TEM-1 probe contained more than 200 base pairs outside the TEM-1
structural gene. Consequently, to some extent the efficacy of probing
depends on the nature and length of the probe (Bush, 1988). Therefore, the
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methodology and the type c£ probes used to detect specific beta-lactamase
genes must be standardized.
Table 4 illustrates some of the relationships between different
beta-lactamases which have been demonstrated by the use of DNA probes.
g. Advantages and future use of the Ambler classification.
The main advantage in the classification of beta-lactamases by their amino
add sequence is that such data are not susceptible to the huge variations
seen with biochemical calculations. Ultimately to categorize a particular
beta - lactamase into a specific Class, the amino acid sequence of the
enzyme has to be determined. Although the determination of amino acid
sequence data requires extensive experimentation, in time it will probably
be recognized as the only efficient method of concluding the novelty of a
beta-lactamase, and this in turn will complement the Ambler system of
classifying beta - lactamases.
1.8.3. Chromosomal beta-lactamases which confer cephalosporin resistance
in Gram - negative bacteria.
Matthew and Harris (1976) reported that virtually all Gram-negative
bacteria produced chromosomally mediated beta-lactamases. Depending on the
host strain, these beta-lactamases are either expressed basally or they
are inducible. For example, Escherichia coli and Shigella and Proteus
mirabilis spedes produce basal levels of cephalosporinase regardless of
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Thhle 4. OSIA-hcmology of beta-lactamase genes.
Beta-lactamase. Horology. Reference.
HM-1 TEM-2, ILE-1 Levesque et al. (1987)
Huovinen et al. (1988b)
TEM-1 TEM-2, QXA-2(*) Gooksev et al. (1985)
TEM-1 TEM-3, 4, 5, 6, and 7 Sougakoff et al. (1988)
CKA-l (CKA.-2) Ouellette arrl Ray (1986)
QXA-1 QXA.-4 Huovinen et al. (1988b)
Levesque et al. (1987)
Ouellette et al. (1988).
CKA.-2 (CKA.-3) Boissinot et al. (1987)
Houvinen et al. (1988b)
PSE-1 PSE-4, CARB-3 Levesaue et al. (1987)
Houvinen et al. (1988b)
PSE-2 QXA-6, (QXA-5) Huovinen et al. (1988b)
RQB-1 None Levesque et al. (1987)
SHV-1 (LCR-1), (QXA-2), Bisessar and James (1988)
(CEP-1)
SHV-1 SHV-2 Huovinen et al. (1988b)
CHEO-1 Nbne(@) Shales et al. (1986)
(*) = Explained in section 1.8.2f.
(@) = There is strong inminological evidence that CHEO-1 is SHV derived
(Vedel et al. 1989).
Beta-lactamases in parentheses hybridised weakly.
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the presence of a beta-lactam antibiotic. Such beta - lactamases are
unimportant in conferring cephalosporin resistance (Livermore, 1987).
a. Cephalosporin resistance caused bv inducible chromosomal
cephalosporinases.
Species such as Pseudomonas aeruginosa Entercbacter cicacae. Enterdbacter
aerogenes produce inducible beta-lactamases (Sykes and Smith, 1979). These
beta-lactamases were responsible for the resistance to many of the early
cephalosporins. Rosselet and Zimmerman (1973) proved that the induction of
these beta-lactamases was the mechanism of cephalosporin resistance as
they showed that mutants which produce only basal levels of these enzymes
remain sensitive to cephaloridine.
Most Gram-negative bacteria, which produce inducible cephalosporinases,
are sensitive to 3GCs but are resistant to the first and second generation
cephalosporins. This does not result from an ability of the 3GCs to resist
hydrolysis by such cephalosporinases, rather that 3GCs are much poorer
inducers of these beta-lactamases (Curtis et al.. 1986; Livermore and
Yang, 1987). Indeed, if secondary inducers are added to the media
resistance to 3GCs increases (Bryan et al.. 1984). However, this response
is not seen with mutants which are capable cf producing only basal amounts
of the enzyme (Bryan et al.. 1 984).
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b. Cephalosporin resistance caused bv the selection of SDM.
Bacterial species, which produce inducible cephalosporinase, can produce
spontaneous stably derepressed mutants (SDM) at a frequency of between
10"5 and 10"10 according to the species, strain and selection
conditions (Phiiippon, 1987; Wiedemann, 1986). These mutants have the same
broad spectrum of resistance as strains which produce high levels of
cephalosporinase after induction and consequently, confer resistance to
all generations of cephalosporins (Curtis et al.. 1986). However, because
the high enzyme activity c£ SDM confer resistance to the challenge of the
newer cephalosporins the selective advantage of the SDM may allow them to
out grow the susceptible bacteria (Livermore, 1987). This phenomenon has
also been demonstrated to be the cause a£ emergence of resistance during
the therapeutic use of the third generation cephalosporins.
c. Emergence of cephalosporin resistance in therapy.
The emergence of such resistance during therapy was rare prior to the use
of third generation cephalosporins (Sugarman and Pesanti, 1980). However,
the following examples illustrate the selection of SDM during therapy.
King et al. (1983) demonstrated a reduced sensitivity to ceftazidime
during treatment of P.aeruginosa: Paull and Morgan, (1986) showed the
emergence of ceftriaxone resistance whilst treating P.aeruainosa in cystic
fibrosis patients; Dworzack et al. (1987) showed that six out of 49
strains, from 44 patients on broad spectrum cephalosporin therapy had
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become resistant as a result of the selection of SDM; Follath et al.
(1987) showed that in 18 patients resistant strains of initially sensitive
Gram-negative bacteria emerged during therapy with a third generation
cephalosporin.
In addition to these studies Hopkins et al. (1987) demonstrated that it
may not only be the selection of derepressed mutants which cause
resistance to third generation cephalosporins, but other factors may also
be involved. Hopkins and Towner (1990) later demonstrated that changes in
outer membrane proteins were responsible for the enhanced cefotaxime
resistance in certain strains of Enterobacter aeroaenes.
d. Biochemical characterisation of cephalosporinases.
The beta-lactamases produced by SDM in P.aeruginosa, and Ent.cloacae
confer high level resistances to the later cephalosporins. Further studies
with Ent.cloacae revealed that this species produced at least three
different types of chromosomal cephalosporinases (Seeberg et al.. 1983;
Minami et al.. 1980a) which conferred resistance to all generations of
cephalosporins. These enzymes hydrolysed the first generation
cephalosporin but had no detectable hydrolytic activity against the later
generation cephalosporins. Then and Angehrn (1982) showed that these
"unhydrolysahle cephalosporins" inhibited the enzyme's hydrolysis of the
chromogenic cephalosporin nitrocefin. It was consequently hypothesized
that these cephalosporinases were trapping and inactivating the
non-hydrolysable cephalosporins (Then and Angehrn, 1982; Gutmann and
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Williamson, 1983). However, Vu and Nikaido (1985) concluded that this
mechanism could not explain the high level of resistance conferred by-
strains overproducing these cephalosporinases. They proposed that
conventional hydrolysis assays were performed with beta-lactam
concentrations which were too high to be a realistic reflection of the
physiological situation within the bacterial cell. Subsequently, they
performed assays at much lower beta-lactam concentrations and revealed
that these "non-hydrolysable" substrates were slowly hydrolysed. However,
Sanders and Sanders (1986) suggested that trapping and hydrolysis were not
mutually exclusive mechanisms for beta-lactamase mediated resistance. It
was hypothesised that if a substrate was slowly hydrolysed it would be
found primarily in biological inactive complexes (Murakami and Yoshida,
1985; Sanders and Sanders, 1986). This mechanism prevents the build up of
active drug in the cell. In addition, the poor penetration of
cephalosporins into Gram-negative cells promotes the protection afforded
by the enzyme, so that slow hydrolysis of poor substrate drugs can also be
a very efficient mechanism of resistance (Sanders, 1989).
These cephalosporin specific beta-lactamases are also resistant to
clavulanic acid (Bush, 1988). Consequently, if the genes encoding these
enzymes become incorporated into plasmid DNA this would create a huge
threat to the future therapeutic use of beta-lactam antibiotics.
e. Chromosomallv mediated cefuroximases.
Inducible chromosomal cefuroximases are produced by Proteus vulgaris
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(Aspiotis et al.. 1986; Matsubara et al.. 1981) and Pseudomonas cepacia
(Hirai et al.. 1980), whereas Pseudomonas pseudomallei produces
oonstLtutively low levels of the enzyme (Livermore et al.. 1987). These
enzymes are sensitive to clavulanic acid inhibition and have high activity
against cefuroxime and cefotaxime.
f. Broad spectrum chromosomal beta - lactamases.
Metalloenzymes.
Xanthomonas maltoohilia produces an unusual chromosomal beta-lactamase
called L-1 which is Zn n dependent and hydrolyses most penicillins and
cephalosporins as well as imipenem. This enzyme is acknowledged as being
responsible for the wide spread resistances associated with X maltnphilia
(Saino et al.. 1982). X maltophilia has been reported to produce one
other type of chromosomal beta-lactamase called L-2, but this enzyme does
not confer such a broad spectrum cf resistances and is not thought to be a
metallo- enzyme (Saino et al.. 1 984).
Several, other imipenem hydrolysing beta-lactamases have been described and
because of their dependence on Zn n and their susceptibility to EDTA have
been suggested to be chromosomal metalloenzymes, These include those
beta-lactamases produced^Flavobacterium odoratum (Sato et al.. 1985)
Legionella gormanii (Fujii et al.. 1986) and Bacteroides fragilis
(Cuchural et al.. 1986; Yotsuii et al.. 1983). Each of these enzymes have
a very bread spectrum of activity and hydrolyse almost all cephalosporins,
and they are resistant to inhibition by clavulanic acid (Sanders, 1989).
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Klebsiella enzymes.
The broad spectrum chromosomal enzymes of Klebsiella spp. show slightly
higher rates cf hydrolysis for penicillins than for cephalosporins. Many
of these enzymes hydrolyse and confer resistance to cloxacillin, the
oxyiminocephalosporins and aztreonam. They generally have no activity
against cephamydns, ceftazidime or imipenem and provide no protection
against these beta-lactams. The klebsiella chromosomal enzymes are also
sensitive to inhibition by clavulanic acid (Sanders, 1989). Klebsiella
spp. chromosomal beta-lactamases have strong similarities with the SHV-1
and TEM-1 plasmid mediated beta-lactamases. Amino acid homology studies
based on the sequences of TEM-1, SHV-1, and LEN-1 (a chromosomal
beta-lactamase cf Klebsiella pneumoniae) have inferred that the rather
K.oneumoniae confined SHV-1 beta-lactamase could have evolved from the
K.pneumoniae chromosomal beta-lactamase. Also the 68% amino acid sequence
homology between SHV-1 and TEM-1 implies that the ubiquitous TEM
beta-lactamase may have evolved from the SHV-1 beta-lactamase (Barthelemy
et al.. 1 988a).
1.9. Cephalosporin resistance conferred bv plasmid mediated
beta-lactamases.
Beta-lactamases encoded by transmissible plasmids were first reported by
Datta and Kontomichalou (1965). The genes encoding these enzymes provide a
greater threat to beta-lactam therapy because they can transfer from one
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bacterial cell to another, and often into different species of bacteria.
This spread of resistance is enhanced if the gene is encoded by a
transposon. These freely transferable DNA fragments can move easily
between different plasmids or between the plasmid and chromosome (Hedges
and Jacob, 1974). Medeiros (1989) listed 13 beta-lactamases which were
encoded by transposons.
The number c£ plasmid mediated beta-lactamases has increased rapidly since
1979: when Matthew et al. (1979) described 11 different types. Payne
described 28 different types in 1986 and today approximately 60 different
plasmid encoded beta-lactamases have been characterised.
1.9.1. Cephalosporin resistance conferred bv plasmid encoded
beta - lactamases (ore- 1 9831.
Most of the earlier plasmid mediated beta-lactamases such as TEM-1/2,
OXA-1, 2, 3, and PSE-1, 2, 3, 4, hydrolyse cephaloridine, cephalothin,
cefamandole and cefazolin (Glaxo, 1980). From studies with these enzymes
in the same host strain (Escherichia coli J53-2), these beta-lactamases
provide protection from each of the cephalosporins described above.
However, none of the enzymes conferred resistance to ceftazidime or
cefotaxime (Glaxo, 1980). Consequently, until 1 983, the only
beta-lactamases oonferring third generation cephalosporin resistance were
chromosomally encoded beta - lactamases.
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1.9.2. Cephalosporin resistance conferred bv plasmid encoded
beta - lactamases (post- 1 983).
Before 1983 the only beta-lactamase conferred resistance to broad spectrum
cephalosporins had been reported to be because cf chromosomally mediated
beta-lactamases. In 1983 Shah and Stille reported a number of Escherichia
coil and Klebsiella pneumoniae strains which were more sensitive to
cefoxitin than 3GCs. This had previously only been reported by Hart and
Percival (1982). Such strains justified further investigation and Knothe
et al. (1983) concluded that these strains carried plasmids which
encoded transferable resistance to 3GCs, although the resistance
mechanism was not determined.
a. Identification of SHY-2.
Kliebe et al. (1985) performed further studies on the strains reported by
Knothe et al. (1983) and identified that SHV-2 was responsible for the
transferable cefotaxime resistance. Consequently, SHV-2 was the first
reported example of a plasmid encoded beta-lactamase which conferred
transferable resistance to a 3GC. This beta-lactamase had the same
isoelectric point as SHV-1 (pi 7.7) and heteroduplex analysis revealed
extensive homology between SHV-1 and SHV-2. The hypothesis that SHV-2 had
derived from SHV-1 was substantiated by the isolation of a cefotaxime
resistant mutant which produced an enzyme identical to SHV-2 (Kliebe^
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1985). Comparison c£ the amino acid sequence c£ SHV-1 (Barthelemy et al..
1988a) and SHV-2 (Bartheleray et al. 1988b) revealed that these two enzymes
only differed by a single amino acid substitution. This substitution
allowed SHV-2 to hydrolyse broad spectrum cephalosporins due to an
increased affinity for such compounds (Kliebe et al.. 1 985).
b. Identification of TEM-3 (CTX-1).
In July 1984 a multi resistant K.rineumoniae strain was isolated from the
wound of a patient hospitalized for five months in an intensive care unit
at Clermont-Ferrand, France. Its complex resistance phenotype to
beta-lactam antibiotics was found to be attributable to the production of
a beta-lactamase of pi 6.3. This enzyme was called CTX-1 (Sirot et al..
1987), and later renamed TEM-3, when DNA probing studies showed it was a
b
TEM derived enzyme (Sougakaff et al.. 1988). During 1985 10% (89 isolates)
c£ K.pneumoniae strains isolated from patients in intensive care units in
Clermont-Ferrand were suspected to produce the same enzyme. This was
verified in 50 of the strains and the incident was reported as "an
epidemic of antibiotic multiply-resistant strains of K.pneumoniae
producing a new beta - lactamase" (Sirot et al.. 1 987).
More than 300 miles away in Paris, a similar outbreak of 3GC resistant
K.pneumoniae was occurring at the same time. The outbreak included three
different intensive care units and spread from one unit to another and
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then to four wards. The resistance to 3GCs also resulted from a
transferable beta-lactamase of pi 6.3 with identical properties to TEM-3
(Brun-Buisson et al.. 1987). Ccnsequently, TEM-3 was the first reported
example cf a TEM derived enzyme which caused transferable resistance to a
3GC. However, it is possible that such enzymes have been present in
bacterial populations long before this initial discovery.
c. Amino acid sequence of TEM-3.
When Sougakaff et al. (1988| determined the amino add sequence of TEM-3,
they found the beta-lactamase differed in two amino acids from that of
TEM-2. At residue 104 (Ambler numbering system, 1980) glutamic acid
(TEM -1) was substituted for lysine (TEM-3), and at residue 238 glycine
(TEM-2) was substituted by a serine (TEM-3).
The ability to change the catalytic activity of TEM -1, by altering key
amino acid residues was first illustrated by Hall and Knowles (1976),
although these substitutions were not the same.
d. Other TEM derived enzymes.
During 1986 and 1987, TEM-4 (Paul et al.. 1989), TEM-5 (Petit et al..
1988), TEM-6 (Bauernfeind and Horl, 1987) and TEM-7 (Gutmann et al.. 1988)
were identifed. The genes encoding each of these beta-lactamases
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hybridised with a TEM probe, thus verifying that they exhibited homologous
nucleotide sequences with TEM-1/2 (Sougakoff et al.. 1988). The first
reported example cf transferable resistance in the UK was identified at
the Royal Hallamshire Hospital by Spencer et al. (1987). This enzyme was
called RHH-1 (later renamed TEM-9) and although the resistance was
transferable no plasmid could be extracted and visualized. All these
are
beta - lactamases detailed in table 53.
A
e. Selection cf mutant enzymes cf TEM-1 which confer rpsistanop to broad
spectrum cephalosporins.
Further work revealed that it was possible to obtain 3GC hydrolysing
beta-lactamases spontaneously from TEM-1/2 producing organisms. Sougakoff
et al. (1988) and Gutmann et al. (1988) both obtained a beta-lactamaseA
which resembled TEM-7 from a TEM-2 producing strain. These mutant
beta-lactamases are detailed in table 51.
1.9.3. Plasmid mediated beta-lactamases - epidemiological studies.
Table 5 summarises nine beta-lactam resistance surveys which have been
conducted at different centres around the world. The majority of the
surveys have investigated the beta-lactamases produced by ampicillin
resistant strains, and the table only shows the percentages of E.coli and
K1 ehsi pi 1 a spp. which produce TEM-1, TEM-2, or SHV-1 "potentially" plasmid
mediated beta-lactamases.
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Thble 5. Summary of Anpicillin resistance surveys illustrating the




















E.ooli 110 16 67 0 1 Simpson et al.
K.meumoniae 63 18 8 8 78 (1980), England.
E.coli 94 0 94 1 0 Roy et al. (18831.
Klebsiella soo. 46 9 44 4 61 Spain.
E.ooli 130 13 78 4 13 Simpson et al.
Klebsiella sod. 44 61 0 0 39 (1986),Germany
Mexico, Airman
Colcmbia.
E.ooli 90 . 72 . - Carter et al.
(1987), England.
E.ooli 47 . 85 _ 2 Huovinen et al.
K.meurnoniae 9 - 67 - 33 (1988b), USA.
E.coli 104 24 73 2 0 *Reid et al.
Klebsiella sod. 23 70 22 4 9 (1988), Scotland
E.ooli 96 . 85 1 - Jouvenot et al.
Klebsiella sod. 41 - 17 0 - (1987), France.
E.ooli 27 - 74 ("TEM") 4 Wiedemann et al.
Klebsiella sod. 78 - 23 ("TEM") 67 (1989), Germany.
y
- = not mentioned in survey. Study of cephaloridine resistant
organisms. "7EM" = both TIM-1 and TEM-2.
A very small proportion of these strains produce both SHV-1 .and a TIM type
of beta-lactamase, lb maintain the simplicity of the table such strains
are registered more than once.
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The surveys Illustrate that TEM-1 is responsible for the vast majority of
ampicillin resistance in E.coli. and it confers a significant amount of
resistance in Klph.qjplla spp.. SHV-1 is far more ubiquitous in Klebsiella
spp. than E.coli which confirms the view that SHV-1 was derived from the
klebsiella chromosomal beta-lactamases. TEM-2 is found in very few strains
of ampicilUn resistant klebsiella or E.ooli. TEM-1 and TEM-2 have almost
identical biochemical characteristics and only differ by one amino acid
residue. However, the TEM-2 gene has not even approached the success
achieved by the TEM-1 gene.
Consequently, TEM-1 appears to have a selective advantage over other
plasmid mediated beta-lactamases including TEM-2. This success could be
attributed to its efficient hydrolysis of penicillins and cephalosporins
along with it being encoded by particularly promiscuous transposons and
plasmids. However, it is possible that in the physiological environment of
the bacterial cell TEM -1 may exhibit an advantage over other plasmid
mediated beta-lactamases which we cannot detect (Amyes, 1989).
I
1.10. Clinical implications cf transferable resistance to broad spectrum
cephalosporins.
The following section forecasts the potential threats which these enzymes
may present to the future therapeutic use of third generation
cephalosporins.
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1.10.1. Treatment of Klebsiella infections.
Klebsiella spp. are a renowned source of transferable antibiotic
resistance (Casewell and Phillips, 1981), and several outbreaks caused by
multi-resistant Klebsiella pneumoniae have been reported in the 1970s
(Thomas et al.. 1977; Petroche.ilnu, et al.. 1977; Rennie and Duncan, 1977;
Courtney et al. 1980). In the 1980s such outbreaks have probably been
reduced because cf the introduction of third generation cephalosporins.
However, table 5 shows that most of the TEM or SHV derived enzymes occur
more frequently in Klebsiella spp. than any other species. Consequently,
these beta-lactamases could seriously jeopardize the future success of the
later cephalosporins, such as cefotaxime, ceftazidime or aztreonam, in
treating Klebsiella spp. infections.
1.10.2. Spontaneous occurrence of TEM and SHV derived beta-lactamases.
It has been discussed that 3GC hydrolysing beta-lactamases could occur
spontaneously in SHV-1, TEM-1 or TEM-2 producing organisms. As TEM-1/2 and
SHV-1 have been illustrated to be the most wide spread plasmid mediated
beta-lactamases there is a high proportion cf strains which are potential
producers of 3GC hydrolysing beta-lactamases. Consequently, it would be
fair to expect high levels cf these 3GC hydrolysing enzymes in bacterial
populations.
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1.10.3. The occurrence cf TEM and SHV derived beta-lactamases related to
third generation cephalosporin utilization.
The use c£ bread spectrum cephalosporins in the UK is very low, and a
study cf 14 000 Enterobacberiaceae strains isolated in the UK between 1985
and 1987 yielded only one pLasmid mediated 3GC hydrolysing beta-lactamase
(Spencer et al.. 1987). However, the amount cf the 3GCs used in France is
much higher than in the UK. In particular, the isolated examples detailing
outbreaks cf these enzymes have occurred in areas of intense 3GC usage.
Therefore, the more extensive the use cf 3GCs the higher the probability
cf 3GC hydrolysing enzymes evolving. Thus, as general resistance to the
earlier cephalosporins increases, more broad spectrum cephalosporins will
be used. In conclusion, this predicament could yield many more examples of
transferable resistance and novel enzymes in the future.
1.10.4. Occurrence of different tyres of TEM or SHV derived
beta -lactamases.
Sevai different plasmid mediated 3GC hydrolysing beta-lactamases have been
discussed in this Introduction, these were all Identified between 1983 and
1987. All cf these beta-lactamases probably differed from TEM-1/2 or SHV-1
by only a few amino acid residues. Therefore, for the reasons stated
earlier, it is fair to assume that over the next few years, many more of
these enzymes will evolve. These new enzymes will all have different
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specificities and may confer even broader resistance profiles to
cephalosporins. In the future the transferable 3GC hydrolysing
beta-lactamases have the potential to create huge problems for the future
use of 3GCs.
1.11. Aims of this Thesis.
1. To establish the origin of 3GC hydrolysing beta-lactamases.
2. To characterise any novel 3GC hydrolysing beta-lactamases identified
in clinical isolates.
3. To establish how long these beta-lactamases have been in bacterial
populations.
4. To create a method for classifying the 3GC hydrolysing
beta -lactamases.
5. To devise quicker and more convenient methods for the separation
and purification of beta - lactamases.




The standard bacterial stains used in this thesis are shown In table 6 and
the standard bacterial plasmids are detailed in table 7. Details of the
strains producing standard beta-lactamases are shown in table 8. All
strains were maintained at - 70°C in nutrient broth with 10% glycerol
v/v. The API 20E system (API System, S.A., France) was used for the
identification of bacterial strains.
2.2. Antimicrobial agents.
The antimicrobial agents used in this Thesis, along with their suppliers
are listed in table 9.
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Ibble 6. Standard bacterial strains.
Bacterial strain. Markers. Reference.
E.ooli K12 J62-2 (EP55) pro' his"_trp " lacVif2-Bachmann (1972)
E.ooli K12 J53-2 (EP53) pro" met lac+rif* Bachmann (1972)
E.ooli K12 SA 10 (EP257) met" S. G. B. Anyes
Tdhle 7. Standard bacterial plasmids.
Plasmid Iferkers. Size (Kb). Reference,
designation.
R1 (DP 6) Ap Cm Rn Sm Su incFII 89 Meynell and Datta (1966)
RP4 (DP 42) Ad Km lb incP-I 52 Datta et al. (19711
R6K (DP 43) Ap Sin inc X 38 Kontamichalou et al. (1970)
DP Numbers denotes D.Payne culture collection.
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Tbhle 8. Beta-lactamase producing strains.
Bacterial strain B-lactamase Plasmid. Original reference for
and Number. produced. B-lactamase or source.
E.ooli J53-2 DP43, 2T&E TEM-1 R6K Hedges et al. (1974)
E.ooli J53-2 DP43, 2137E TEM-2 RP4 Hedges et al. (1974)
E.ooli J62-1 DP189 TEM-3 pCF04 Sirot et al. 119871
Brun-Buisson et al. (1987)
E.ooli J53-2 DP193 TEM-4 pLD16 Paul et al. (1989)
E.ooli J53-2 DP70 1EM-5 pCFF14 Petit et al. (19881
E.ooli J53-2 DP314, 3491E TEM-6 Bauernfeind et al. (1987)
E.ooli J62-1 DP187 TEM-7 Gutmann pt al. (1988)
E.ooli J53-2 DP41, 2639E TEM-9 Spencer et al. (19871
E.ooli J53-2 DP211 1EM-10 pJPQIOO Cuinn et al. (1989)
E.ooli J53-2 DP37, 2651E TLE-1 pM3204b Medeiros et al. (1985)
E.ooli J53-2 DP38, 2141E SHV-1 R1010 Petrocheilou et al. (1977)
E.ooli J53-2 DP192 SHV-2 pUD17 Kliebe et al. (1985)
E.ooli J53-2 DP191 SHV-3 pUD18 Jarlier et al. (1988)
E.ooli J53-2 DP324 SHV-5 pAFF-1 Gutmann et al. (1989)
E.coli J53-2 DP44, 2505E 7EM-1,TLE- 1 Glaxo culture collection
E.ooli J53-2 SA319 CKA-2 R46 Bale and Smith (1974)
P.aeruainosa RJ21 AR34 PSE-1 Rbtthew and Sykes (1977)
P.aeruginosa RJ21 AR35 PSE-2 Matthew (1978)
E.ooli J53-2 DP2 PSE-4 R1818 Furth (1975)
|8 CF 504, DP68 TEM-1,
TEM-5
SHV-1
K.aerogenes DP36, 1976E SHV-1
$'IsIk DP39, 1957E TEM-1,SHV-
K.meumoniae DP40, 1082E K-1
E.ooli D31 AR39 CEP-1
Ent. cloacae P99 Type B (*)
Ent. cloacae Type A (*)
pCFF14 Petit et al. (1988)
Glaxo culture collection
1 Glaxo culture collection
Marshall et al. (1972)
R22Ka Bobrowski et al. (1976)
Flailing et al. (1963)
Seeberg et al. (1983)
DP Numbers denote D.Payne culture collection.
E Numbers denote Glaxo Group Research culture collection.
AR. timbers denote A.Reid culture collection.
SA Numbers denote S.G.B. Amyes culture collection.
(*) ChraTDsaral beta-lactamases as classified by Seeberg et al. (1983).
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E.R. Squib and Sons, Middlesex.
SrithKline Beecham Pharmaceuticals.
Roussel laboratories Ltd., Middlesex.
MSD Ltd., Herts.
Glaxo Group Research Ltd. Greenford, Middlesex.
Roche Products Ltd. Herts.
Glaxo laboratories Ltd. Greenford, Middlesex.
Glaxo Group Research Ltd. Greenford, Middlesex.
E.R. Squibb and Sons, Middlesex.
ShiithKline Beecham Pharmaceuticals.
Bristol Laboratories, Middlesex.
Glaxo Group Research Ltd. Greenford, Middlesex.
Lepetite f Milan, Italy.
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2,3. Media.
All growth media, both agar and broth, were sterilized by autoclaving at
15 pounds/square inch for 15 minutes.
2.3.1. Complex media.
The following complex media were used; Nutrient broth No.2 (CM67),
Isosensitest Broth (CM473), Diagnostic Sensitivity Test Agar (CM261), all
supplied by Oxoid, Basingstoke, Hants.
2.3.2. DM minimal medium agar plates (DM acrari.
Double strength minimal salts medium was prepared as described by Davies
and Mingioli (1950) (table 10). 50ml of double strength DM was then
supplemented with the appropriate amount of the required amino acid stock
solutions to achieve the final concentrations as shown in table 11. The
appropriate amounts of antibiotics were then added. Finally, 2.5ml of a
20% glucose solution was added and the volume made up to 60ml with sterile
distilled water. This solution was mixed and added to 40ml of molten
Bacteriological Agar No1 (1g of agar/40ml distilled water) and, after
gentle mixing, the plates were poured.
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Tbble 10. Preparation of double strength Eavis and Mingioli basal medium.






Tible 11. Amino acid solutions.
Solution Strength of stock Final concentration
solution. in EM agar.
L-histidine (EEH) 5mg/ml 5Cmg/L
L-methionine (EDH) 5mg/ml 5Cmg/L
L-proline (BCH) 5mg/ml 5Ctrg/L
L-tryptophan (Sigma) 2mg/ml 5Ctrg/L
All amino acid solutions were sterilised by steaming for 30 minutes.
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2.4. Antibacterial drug susceptibilities.
Susceptibility tests and minimum inhibitory concentrations (MICs) of
antibacterial drugs were determined on solid media containing the
appropriate concentrations of antimicrobial drugs. An inoculum of 10
colony forming units (cfu)/ml was used in each case. In some experiments
the MICs of ampicillin, ceftazidime and cefotaxime were additionally
measured in the presence of clavulanic acid (2mg/L) or sulbactam (2mg/L).
2.5. Conjugation experiments.
In all mating experiments 0.1ml of an overnight culture of the donor
strain was mixed with 1ml of an overnight culture of the recipient strain
in 4.5ml of nutrient broth, as described previously by Amyes & Gould
and then harvested by centrifugation and resuspended in 5.6ml of DM media.
(1984). This mixture was then incubated at 37°C tor 6 hours >E. coli
A
J53-2 transconjugants of the clinical strains were selected on agar
containing the appropriate amounts of rifampicin and beta-lactam
antibiotic. Transfers from E.ooli J62-2 to E.coli J53-2 were performed in
the same way but the E.ooli J53 - 2 transconjugants were selected on DM agar
containing proline (50mg/L), methionine (50mg/L) and ceftazidime (4mg/L).
Transconjugants resulting from transfers from E.coli J53-2 to E.coli K12
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SA10 were selected on DM agar containing methionine (50mg/L) along with
the appropriate beta-lactam antibiotic. E.coli J62-2 transconjugants
produced from conjugation of E.coli K12 SA10 with E.coli J62-2 were
selected on DM agar supplemented with histidine (50mg/L), tryptophan
(50mg/L), proline (50mg/L) and the appropriate antibiotic. Transfer
frequencies were calculated as follows;
Transfer = Number of transconiugant cells / ml
frequency Number of donor cells / ml
2.6. Mutation experiments.
In the spontaneous mutation experiments 10ml of nutrient broth was
inoculated with a colony of the particular strain under investigation and
either grown statically or on an orbital shaker at 3 7°C. The broth
cultures were subjected to a range of growth conditions. The cells were
then harvested by centrifugation at 4500rpm for 15 minutes (Heraeus Christ
Bactifuge). The resultant pellet was resuspended in 1 ml of sterile
distilled water and 0.1ml aliquots cf this suspension were inoculated onto
nutrient agar containing varying concentrations of different selection
agents. These plates were incubated for 24-48 hours and over this period
all the resistant colonies were purified on identical drug containing
nutrient agar plates. The integrity of these mutant colonies was checked
by API 20E analysis, and as most of the parent strains were E.coli J53-2
- 60-
or R.roli .T62- 2. the auxotrophic requirements of the mutant strains were
also tested. Once the mutant strains had satisfied these two criteria
their resistance profile was determined and their beta-lactamases examined
by IEF. Those mutant strains producing a different beta-lactamase from the
parent strain were characterised in more detail.
In those experiments studying the effects of methotrexate or
metronidazole, the 10ml of nutrient broth was inoculated with 0.1ml of a
16 hour broth culture of the particular strain under investigation.
A full list of the different factors incorporated into each of the
mutation experiments are shown in tables 13 and 19.
2.7. Preparation of crude beta - lactamase preparations.
One litre of nutrient broth, in a two litre conical flask, was inoculated
with the particular strain producing the beta-lactamase under
investigation. In the case of ceftazidime resistant strains, the bacteria
were grown in the presence of ceftazidime (4mg/L). The culture was
incubated for 16 hours at 37°C on an orbital shaker. The culture was
then harvested by oentrifugation at 6000g for 15 minutes at 4°C (Sorvall
RC-5B Refrigerated Superspeed Centrifuge, Du Pont Instruments). The
resultant bacterial pellet was resuspended in 10ml of 25mM sodium
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phosphate buffer (pH 7.0) and centrifuged at 4500 rpm for 15 minutes
(Heraeus Christ Bactifuge). The final cell pellet was resuspended in 1ml
of 25mM sodium phosphate buffer (pH 7.0). This sample was suspended in an
ice/water bath and subjected to two 30 second treatments of
ultrasonication (8um), with a one minute cooling period between treatments
(MSE Soniprep 150 MSE Instruments, Crawley). The resultant lysate was then
cleared by centrifugation at 32 OOOg for 30 minutes at 4°C (Sorval). The
supernatant was removed and could be stored successfully for up to 3
years.
2.8. Assessment of beta-lactamase activity of beta - lactamase
preparations.
Thirty three ul of the beta-lactamase extract was mixed with 100ul of a
nitrocefin solution (50mg/L) in a microtitre tray. The time taken in
seconds for the mixture to change colour from yellow to red was taken as
an indication of the beta-lactamase activity of the enzyme preparation.
2.9. Analytical isoelectric focusing of beta-lactamases.
Beta-lactamases were identified by analytical isoelectric focusing as
- 62 -
described by Matthews et al. (1975). The extracts were focused on a thin
layer polyacrylairade gel containing carrier amphalines. The composition of
the gel is shown in table 12. The beta-lactamase preparations were first
examined by wide range IEF employing a broad range arapholine (3.5-10 pH).
If the beta-lactamase of interest had an acidic pi it was subsequently
re-examined on a gel containing a 1:1 mixture of 4-6 and 3.5-10 pH
ampholines. Alternatively, if the beta-lactamase had an alkali pi it was
re-examined on a gel containing a 1:1 ratio of 9-11 and 3.5-10 pH
ampholines. In all cases novel beta-lactamases were focused along side
beta-lactamases of known pi (table 8). Samples cf the beta-lactamases were
loaded near the anode on the surface of the gel. The amount of each
extract applied depended on its activity; for each second of activity
possessed by the extract (see section 2.8) 1ul of the sample was applied.
2.10. Determination of the molecular weight of beta-lactamases.
The method of gel filtration was employed to determine the molecular
weights cf the different beta-lactamases investigated in this study. This
was achieved with a Sephadex G-75 column as described by Andrews (1964).
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Tdble 12. Carposition of IEF gel for the analysis of beta-lactamases.
Material. Supplier. Volume Final
used (ml). concentration.
5% tetramethyl-ethylenediamine Sigma 0.2 0.25mg/L
(TIMED) in distilled water.
40% arrpholines w/v (various LKB 2.0 2% w/v
pH ranges).
Acrylamide (100g) plus BCH 9.0 acrylamide 75g/L
methylene hisacrylamide bisacrylamide 2g/L
(2.7g) in water (300ml).
Distilled water. 25.0
Riboflavin (20mg/L). Sigma 4.0 2mg/L
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2.10.1. Preparation of the Seohadex G-75 column.
Sephadex G-75 (Pharmacia) was swollen with the appropriate volume cf 25mM
sodium phosphate buffer (pH 7.0) at 100°C for an hour. The slurry was
allowed to cool and then poured carefully into an LKB gel filtration
column (50 X 1.5cm2). When the column was full, the top was connected
and the flow started in a upward direction with a LKB peristaltic pump.
After the initial pouring of the gel the column was left to equilibrate
for 48 hours with 25mM sodium phosphate buffer (pH 7.0). Following this
period a flow rate of 15ml/hour was maintained by adjusting the speed of
the peristaltic pump.
2.10.2. Calibration of the Sephadex G-75 column.
Before the column was used to determine the unknown molecular weights of
beta-lactamases it had to be calibrated with proteins of known molecular
weight. Therefore, 10mg each cf cytochrome C (12.38 Kd), chymotrypsinogen
(25.5 Kd) ovalbumin (45.0 Kd) and were dissolved in 1ml of 25mM sodium
phosphate buffer (pH 7.0) and applied to the column. Following the
application of the standard proteins 100 fractions were collected by an
Ultrorack fraction collector. Each fraction contained 2ml of the elutate.
The absorbance of each fraction at 280nm was measured to give a rough
estimate of the amount cf protein in each fraction. The absorbance reading
was then plotted against fraction number. This gave three well separated
peaks and the fraction which corresponded to the pinnacle of each peak
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represented the elution position of that particular standard molecular
weight protein. Therefore, the molecular weight of each of the standard
proteins was plotted against its representative fraction number to give a
standard curve. This was used to determine the unknown molecular weights
of the different beta-lactamases.
2.10.3. Determination of the molecular weight of beta-lactamases.
One ml cf beta-lactamase sample, prepared as described in section 2.7, was
applied to the Sephadex G-75 column. The settings of the peristaltic pump
and fraction collector were maintained at exactly the same parameters as
those used in the calibration procedure. Once again 100 2ml fractions were
eluted from the column. A nitrocefin spot test assay was performed on each
of the fractions to ascertain which of the tubes contained the
beta-lactamase. The hydrolytic activities of those fractions exhibiting
beta-lactamase activity were then assayed spectrophotometrically by
measuring the rate of hydrolysis of nitrocefin (1Cf 4M). The activity of
each fraction was plotted against its fraction number, and the molecular
weight of the enzyme was determined from the standard curve. This was
achieved by calculating the molecular weight which corresponded to the
fraction exhibiting the greatest beta-lactamase activity. Once the
molecular weight had been determined, all the fractions containing
significant beta-lactamase activity were pooled and used for the
spectrophotometric assays described in section 2.11.
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2.11. Kinetic studies.
For all spectrophotometric assays either a Pye Unicara SP1800 uv/vis
Spectrophotometer or a Perkin Elmer Lambda 2 Spectrophotometer were used.
Both these machines had thermostatically controlled cell carriers and an
automatic cell change facility, all measurements were performed at 37°C.
Kinetic measurements were performed only on beta-lactamases which had been
partially purified by gel filtration and which had originated from E.coli
transconjugants.
2.11.1. Determination of Vmax and Km.
The rates cf hydrolysis of cephalosporins were measured at concentrations
between 0.01 mM and 0.1 mM, whereas the rates of hydrolysis of penicillins
were measured at concentrations between 0.1mM and 1mM. The reciprocals of
the rate of hydrolysis values obtained in these assays were plotted
against the reciprocal of the substrate concentration. The Km and Vmax
values for the hydrolysis of a particular beta-lactam by a particular
beta-lactamase were then obtained by the Lineweaver-Burk (1934) method.
The Vmax values were normalised with respect to ampiciilin as proposed by
Bush and Sykes (1986). The efficiency of hydrolysis of a particular
substrate was determined from the ratio of Vmax/Km and the relative
efficiency of hydrolysis of the enzyme was calculated as outlined by Sykes
et al. (1981), as follows;
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Relative = Efficiency of hydrolysis of substrate X 100
efficiency. Efficiency of hydrolysis of ampicillin
2.11.2. Measuring beta - lactamase inhibition.
The ID^q value is defined as the amount of inhibitor required to reduce
the hydrolytic activity of an enzyme by 50%. The ID^q values for the
beta-lactamase enzymes were determined by spectrophotometric assay.
Firstly, the rate of hydrolysis of nitrocefin (10" 4M) by the
beta-lactamase was measured. This procedure was then performed in the
presence of 10" 8M of the potential inhibitor and repeated with
increasing concentrations of the inhibitor until inhibition approached
1 00%.
Percentage inhibition was then plotted against log concentration of
inhibitor and the concentration of inhibitor which gave 50% inhibition was
calculated from the graph.
2.11.3. Specific activities.
Protein concentrations were determined by the method of Waddell (1956) and
specific activities were expressed as nmoles substrate hydrolysed per
minute per mg of protein (nmoles/min/mg).
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2.12. Isolation of plasmid DNA.
Overnight broth cultures (4.5ml) were harvested by centrifugation
(4000rpm, 15 minutes, Christ Bactifuge). The method of Takahashi and
Nagano (1984) was then followed to extract and visualise plasmid DNA.
2.12.2. Restriction of plasmid DNA bv restriction endonuclease enzymes.
The method c£ Takahashi and Nagano (1984) was used to prepare plasmid DNA
for restriction by endonucleases. For each restriction digest, 4.6ul of
10X concentrated restriction buffer (Boehringer Mannheim, SuRE/Cut
buffers) was added to 40ul of the plasmid preparation followed by 5-10
units cf the restricting enzyme (Boehringer Mannheim). The reactions were
left for between 1 and 18 hours at 37°C.
The amount of restricted plasmid sample electrophoresed depended on the
size of the agarose gel used.
2.12.3. Agarose electrophoresis of plasmid DNA.
Horizontal slab gel electrophoresis was performed by the method of
Meyers et al. (1976). Both large (14 by 25 X 0.5cm) and small (Bio-Rad
Mini Sub Cell) horizontal slab gels were used for the electrophoresis of
plasmid preparations. The gels consisted of between 0.5% and 1% agarose
(Sigma) in Tris-acetate buffer (40mM Tris - acetate, 2mM disodium EDTA,
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pH 7.9). Electrophoresis was performed with the gels submerged in
Tris- acetate buffer at 70V overnight for the large gels and at 100V for 2
hours with the mini-gels. The gels were stained in a 0.75mg/L solution of
ethidium bromide for 15 minutes and then briefly washed in water. The DNA
was visualized over a long-wave ultra-violet light source (Ultra-violet
Products Inc., Cambridge).
Before the analysis of each DNA sample, loading buffer was added to each
preparation to create a ratio of loading buffer to sample of 1:4
respectively.
2.12.4. Sizing of DNA bands on agarose gels.
The sizes cf restricted fragments were determined by running standard
molecular weight markers in parallel with the samples. Lambda DNA
restricted with Hind III (Gibco BRL) and (J) X 174 RF DNA (Gibco BRL)
restricted with Hae HI were used for this purpose. The sizes of intact
plasmids were determined by running plasmids of known sizes (table 7)
along side the clinical plasmids of unknown size.
The distance travelled by DNA through the gel is inversely proportional to
the logarithm cf its molecular size. Consequently, the unknown sizes could




3.1 Spontaneous selection cf beta-lactamases which confer resistance to
3 GC s.
The genes responsible for the transferable 3GC resistance discussed in the
Introduction may have resulted from simple mutation of the common TEM
beta-lactamase genes. In order to test this hypothesis, mutation
experiments were performed. The mutation procedure (section 2.6) was used
to investigate which of the strains in table 13 would yield 3GC
hydrolysing beta-lactamases when subjected to the selective pressure of
ceftazidime, and in some cases, cefotaxime. Both anaerobic and aerobic
cultures were examined. In some experiments the broth cultures were grown
in the presence of very low levels of ceftazidime, for long incubation
periods, in an attempt to mimic the environment faced by a bacterium
infecting a patient on ceftazidime therapy.
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Thhle 13. Bacterial strains and growth conditions used to obtain mutant
beta-lactamases (conditions for experiments 1-9 are listed on the
following page).
Experiment number (see following page)
Strain. Beta-lactamase
produced. 1 2 3 4 5 6 7 8 9
E.ooli J53-2 2136E TEM-1 + + + +a + + +
E.coli J53-2 2137E TEH-2 + + + +a + + +
E.ooli J53-2 2141E SHV-1 + + + - + -
E.coli J53-2 2651E TLE-1 + + +
E.ooli J53-2 AR273 PSE-4 - - - - +a +
E.ooli JE2-2 Nc TEH-1 - - - - +a -
E.ooli 2505E TEH-1
TLE-1
+ +b + - + -
K.meumoniae 1957E TEM-1
SHV-1
+ + + - + -
K.aeroaenes 1976E SHV-1 + + +
/
+ -
a = Denotes an experiment which yielded rtutant beta-lactamases.
b = Culture grown in the presence of a range of ceftazidime concentrations
(7.5 x 10"2 - 2.5 X 10" ntg/L).
N.B. scire of these experiments may have been performed more than once.
+ denotes that the strain was tested.
- denotes that the strain was not tested.
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Experimental conditions discussed in table 13.
1. Anaerohic, 80 hours incubation, static, cultures grown in the presence
of 0.001 mg/L of ceftazidime. Mutants selected on ceftazidime (4mg/L).
2. Aerobic, 80 hours incubation, shaken, cultures grown in the presence of
0.001mg/L of ceftazidime. Mutants selected on ceftazidime (4mg/L).
3. Anaerohic, 70 hours incubation, static. Mutants selected on ceftazidime
(8mg/L).
4. Aerobic, 24 hours incubation, shaken. Mutants selected on ceftazidime
(2, 4 or 10mg/L).
5. Aerobic, 20 hours incubation, shaken. Mutants selected on ceftazidime
(0.8, 4, 1 Omg/L).
6. Aerobic, 20 hours incubation, shaken. Mutants selected on ceftazidime
(2mg/L).
7. Aerobic, 8 hours incubation, shaken. Mutants selected on ceftazidime
(1mg/L).
8. Aerobic, 22 hours incubation, shaken. Mutants selected on cefotaxime
(1 mg/L).
9. Aerobic, 21 hours incubation, shaken. Mutants selected on cefotaxime (1
or 2mg/L) or cefuroxime (20 or 40mg/L)
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As the vast majority of the beta-lactamases which conferred 3GC resistance
had occurred in Klebsiella spp. both Klebsiella spp. and Escherichia coll
strains, which produced the TEM-1 beta-lactamase, were examined for their
ability to produce mutants. Many of the strains which produced a TEM
derived 3GC hydrolysing beta-lactamase also manufactured SHV-1. Therefore,
strain 1957E was investigated in order to identify whether SHV-1 exhibited
any synergistic effect on the mutation capabilities of the TEM-1
beta - lactamase to a 3GC hydrolysing enzyme. Both TEM-1 and TEM-2
beta--lactamase producing strains were investigated because the origin of
the new TEM-like enzymes was not clear. A strain of E.coli producing TLE-1
vas also studied, as TLE-1 has been shown to be closely related to the TEM
resistance gene (Levesque et al.. 19871. The strains producing SHV-1 were
investigated to ascertain whether other 3GC hydrolysing SHV-derived
beta-lactamases could be obtained. The E.ooli producing PSE-4 was examined
to establish whether the selective pressure of 3GCs could produce
spontaneous changes in beta-lactamases other than the TEM or SHV-1 related
beta -lactamases.
3.1.1 Mutant beta-lactamases ohtainef) spontaneously from the TEM-1
produced by E.coli J62-2 Nc.
The particular growth conditions which gave rise to these mutants are
shown in table 13.
a. Rationale for studying E.coli J62-2 Nc.
Klebsiella pneumoniae CF504 was a clinical strain isolated in
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Clermont- Ferrand, France. It was resistant to ceftazidime and cefotaxime
and the gene encoding this resistant determinant was located on a 150kb
plasmid (pCFF14) (Petit et al. 1988). IEF studies showed that this strain
also produced the TEM-1 beta-lactamase as well as the TEM-5 enzyme. This
strain was conjugated with the rifampicin - resistant E.coll J62-2 and the
transoonjugants were selected on agar plates containing rifampicin and
ceftazidime. The transconjugants were purified and their integrity
checked. Analysis of the plasmid DNA revealed that the E.coli J62 - 2
transoonjugant of Klebsiella pneumoniae CF504 had lost the 150Kb plasmid
(pCFF14), which has been shown to encode the TEM-5 beta-lactamase (Petit
et al. 1988), and possessed only a 100Kb plasmid along with two smaller
plasmids (fig. 5). This transconjugant reverted to the normal
characteristics of a TEM-1 producing E.coli J62-2 strain. This strain
(denoted as E.coli Nc) was then used as the parent in the spontaneous
mutation experiments. The rationale for this was that there should be a
higher chance of obtaining a 3GC hydrolysing mutant enzyme from a plasmid
encoded TEM-1 beta-lactamase gene found in a strain which was host to a
TEM-like 3GC -hydrolysing beta-lactamase, rather than a standard laboratory
strain hosting a TEM-1 beta - lactamase gene.
b. Selection of Mutants.
Overnight broth cultures were plated onto ceftazidime-containing plates.
The ceftazidime resistant mutants grew on plates containing 0.8 and 4mg/L
of ceftazidime. These mutants appeared at a frequency of 1 in 109, and
following purification the strains were examined for any change in
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Fig. 5. Plasmid profiles c£ strains producing Mutant beta-lactamases A or
B along with their E.coli J53-2 transconjugants and the original
transconjugants of K.pneumoniae CF504 (0.7% agarose) .
ABCDEF GH
e.
A. E.coli J53-2 transconjugant producing Mutant beta-lactamase B; B.
E.ooli J53-2 transoonjugant prcducing Mutant beta-lactamase A; C. Original
mutant E.ooli J62-2 producing Mutant beta-lactamase A; D. Original mutant
E.coli J62-2 producing Mutant beta-lactamase B; E. E.coii J62-2 Nc,
transoonjugant a£ K.pneumoniae CF504 (ceftazidime sensitive, wild type
strain used in mutation experiments); F. E.coli J62-2 Nb, transcon jugant
of K.pneumoniae CF504 (ceftazidime resistant); G. R6K; H. R1818.
76
beta-lactamase profile. In all the colonies studied, ceftazidime
resistance was associated with the mutation of the TEM-1 beta - lactamase
gene to produce one of two different beta-lactamases (Mutant
beta-lactamase A and Mutant beta-lactamase B). Twenty mutant colonies were
examined and the beta-lactamases which they produced were characterised.
The ratio of the occurrence of Mutant beta-lactamase A to Mutant
beta-lactamase B was 4:1. The genes encoding the mutant beta-lactamases
were transferred by conjugation into E.coli J53-2 with selection of the
transconjugants on ceftazidime containing agar plates (table 14). The
acquisition of the plasmids elevated the MIC c£ ceftazidime for the E.coli
J53-2 recipient more than 60 fold from 0.13 to 8-16mg/L (tables 22 and
27). The transferability of the resistance determinant confirmed that the
mutation had occurred in the plasmid encoded genes and not in the
chromosome. Both the original mutants and their E .coli J53-2
transconjugants possessed the 100Kb plasmid, but the two smaller plasmid
bands were seen only in the original mutant strains (fig. 5).
c. Isoelectric Focusing.
Mutant beta-lactamase A focused as a doublet band at pi 5.3 with an
additional weak TEM-1 enzyme band. Mutant beta-lactamase B had a pi
marginally above the TEM-1 enzyme but below the TEM-7 beta-lactamase
(fig. 10).
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Tbble 14. Transferability of nutant beta-lactamases A and B to E.ooli
J53-2.
Wild 1ype Mutant pi Mutation Transfer frequency
strain. B-lactamase. frequency. per donor"1".
E.ooli Nc A 5.30* 1.0X10"9 1.6X10"7
E.ooli Nc B 5.41 1.0X10"9 5.4X10"8
"^Ceftazidime (4mg/L) used as the selecting agent in minimal media agar
containing proline and methionine.
*Doublet band
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d. Minimum Inhibitory Concentrations.
E.coli J53-2 transconjugants expressing the mutant enzymes were all
resistant to ampicillin, carbenicillin, cephaloridine, ceftazidime, and
aztreonam. However, they were sensitive to all other cephalosporins tested
including cefotaxime (tables 22 and 27). Clavulanic acid and sulbactam
both overcame the resistance to a similar extent when ceftazidime was used
as the principal antibiotic. However, clavulanic acid was seen to be the
slightly more efficient beta-lactamase inhibitor when ampicillin was the
principle antibiotic (tables 22 and 27).
e. Biochemical Profiles of the Mutant beta-lactamases A and B.
The two mutant enzymes had molecular weights similar to the
TEM-1 beta-lactamase (table 25). The substrate profiles of Mutant
beta-lactamases A and B are compared to TEM-1 in table 23. The profiles
were similar to TEM -1 for ampicillin, carbenicillin and cephaloridine.
However, both mutant enzymes showed a low, but significant, rate of
hydrolysis of ceftazidime and cefotaxime, whereas the TEM-1 enzyme showed
no hydrolysis cf either of these substrates. The relative Vmax and the Km
values for these enzymes against a number c£ beta-lactams were determined.
These values were combined to give the relative efficiency of hydrolysis
values (rel Vmax/Km, ampicillin = 100%) which takes into account
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both the hinding and the hydrolysis capabilities of the enzyme with a
particular beta-lactam. Mutant beta-lactamase B had similar efficiency of
hydrolysis values for ceftazidime and cefotaxime and Mutant beta-lactamase
A hydrolysed cefotaxime more efficiently than ceftazidime (table 24). This
is a paradox because both enzymes confer a far greater resistance to
ceftazidime. Both enzymes were inhibited by clavulanic acid with ID^gS
similar to TEM-1 (table 26).
3.1.2, Mutant beta-lactamase selected from the TEM-1 produced bv E.coli
2136E.
Only one ceftazidime resistant colony was obtained from the experiments
conducted with this strain. The conditions which yielded the strain which
produced this mutant beta-lactamase are shown in table 13. The strain was
selected on a plate containing 2mg/L of ceftazidime (mutation frequency
1in 10^). The MIC of ceftazidime for the sensitive strain used in these
tests was 0.06mg/L, the increase in MIC c£ the mutant strain to 4mg/L was
demonstrated to be caused by the production of Mutant beta-lactamase B. No
other mutant beta-lactamases were obtained from organisms producing TEM-1.
3.1.3. Mutant beta - lactamases selected from E.coli 2137E.
The strains producing these mutant beta-lactamases were identified on
plates containing 4 or 2 mg/L of ceftazidime. The conditions which gave
rise to these mutant beta-lactamases are shown in table 13. In these
experiments two types cf spontaneous mutants were identified. The first
type was produced at a mutation frequency of 1 in 5 x 10® and produced
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Mutant beta-lactamase C which had the same pi as TEM-2 (fig. 6). The
strains producing Mutant beta-lactamase C were approximately 60 times more
resistant to ceftazidime than the original sensitive strain and more than
8 times more resistant to aztreonam. This mutant strain became sensitive
to ceftazidime in the presence of clavulanic acid
(2mg/L) or sulbactam (2mg/L) (table 15) which strongly suggested that the
ceftazidime resistance was conferred by Mutant beta-lactamase C.
Attempts to transfer this ceftazidime resistance were performed with
kanamycin or ceftazidime as the selecting agents. Transferable resistance
to kanamycin and ceftazidime oould be demonstrated when ceftazidime was
used as the selecting agent However, the ceftazidime resistance could not
be transferred to an E.coli J62-2 recipient when kanamycin was the
selecting agent (table 16).
The second type of mutant beta-lactamase selected from the TEM-2 produced
by E.coli 2137E was Mutant beta-lactamase D. Isoelectric focusing of this
enzyme revealed that Mutant beta-lactamase D focused marginally above
TEM-2 (fig. 19). The genes encoding for this beta-lactamase could be
transferred to an E.coli K12 (SA 10, methionine deficient) recipient
strain with a concomitant transfer of resistance to ceftazidime. The
E.ooli K12 (SA10) transconjugants selected on kanamycin or ceftazidime
were all resistant to ceftazidime and produced Mutant beta-lactamase D
(fig. 19). However, the frequency of transfer of ceftazidime resistance
was 600 times greater with kanamycin as the selecting agent than when the
selection was performed with ceftazidime (table 16). This phenomenon was
studied in greater detail.
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Fig. 6. IEF of Mutant beta-lactamase C and Mutant beta - lactamase E.
A. E.ooli J53-2 producing TEM-1; B. Original ceftazidime resistant E.coli
J53-2 mutant producing Mutant beta-lactamase E; C. Ceftazidime resistant
E.coli J62-2 transoonjugant of original E.coli J53-2 mutant selected on
kanamycin; D. E.coli J53-2 (AR273) producing PSE-4, used as the sensitive
strain in mutation experiments; E. E.coli J53-2 (2137E) producing TEM-2,
used as the sensitive strain in mutation experiments; F. Original
ceftazidime resistant E.ooli J53-2 mutant producing Mutant beta-lactamase
C; G. E.ooli J62-2 transconjugant cf original E.ooli J53-2 mutant selected
on kanamycin (ceftazidime sensitive); H. E.coli J62-2 transconjugant of
original E.coli J53-2 mutant selected on ceftazidime.
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Thble 15. MECs conferred by Mitant beta-lactamase C and the irutant
beta-lactamases produced from K.pneumoniae 1957E (10 inoculum).
Minimum Inhibitory Concentrations (rtg/L)
Beta-lactam E.coli E.coli J53-2 Klebsiella Klebsiella Klebsiella
antibiotic. J53-2 producing 1957E 1957E 1957E
(TEM-2) p-lactamase C Mitant 3a Mitant 5a
Ampicillin >250 >250 >250 >250 >250
A +clav 2 4 ND ISD ISD
B +sulb >250 >250 ND ISD ISD
Carbenicillin >250 >250 >250 >250 >250
Cephaloridine 16 32 64 250 32
Cephalexin 1 8 8 16 8
Cefoxitin 0,.5 4 4 4 2
Cefuroxime 1 2 4 8 4
Ceftazidime <0,,06 4 0..25 4 8
A +clav <0.,06 0,.13 ND ND NO
B +sulb <0.,06 0..5 ND ND ND
Cefotaxime <0.,06 <0.,06 <0. 06 0.13 0,
Ceftriaxone <0. 06 <0.,06 <0. 06 0.13 0,
Aztreonam <0. 06 0. 5 <0. 06 0.25 0,
imipenan 0. 13 <0. 06 0. 13 <0.06 0,
A +clav = in canhination with 2mg/L clavulanic acid.
B +sulb = in combination with 2mg/L sulbactam. ND = Not done.
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Tthle 16. Transferability of Mutant beta-lactamases.
Wild Mutant pi Mutation Transfer frequencies










D 5.61 1X10"9 5.2X10"9 3.5X10"6
E 5.30 1X10"7 1.1X10"7 2.2X10"3
no transconjugants vere detected when kanarrycin and ceftazidime were
used in oarbination as the selecting agents.
+transoonjugants were sensitive to ceftazidime.
CAZ-1 = 1mg/L of ceftazidime added to the nutrient agar to select for
transconjugants.
Km-40 = 40mg/L of kanamycin added to the nutrient agar to select for
transconjugants.
Rf-25 = 25mg/L rifampicin added to the nutrient agar to select for
transconjugants.
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Fig. 7. Conjugation experiments involving the transfer of the Mitant
beta-lactamase D gene.














Selection on Km Selection on CAZ
MF: 3.5 X 10~6 5.2 X 10"9




Conjugation with Conjugation with
E.coli J62-2. E.ooli J62-2.
/ \ / \
/ \ / \
/ \ / \
/ I J. \
Selector: Km CAZ Km CAZ
MF: 4.6X10'7 6.0X10"9 2.2X1CT7 1.2X10"9
MIC, CAZ: 8-32 16
Km = Kanamycin
CAZ = Ceftazidime
MF = Kfeting frequency.
MIC, CAZ = Minirnim inhibitory concentration of ceftazidime in mg/L (105
inoculum).
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The E.oali K12 (SA10) transconjugants selected on kanamycin were then
conjugated with E.coli J62-2 and the transconjugants were selected on agar
containing the appropriate nutrients and either ceftazidime or kanamycin.
Once again much lower mating frequencies were recorded when the E.coli
J62-2 transoonjugants were selected on ceftazidime. This procedure was
repeated for the E.coli K12 (SA10) transconjugants selected on
ceftazidime, and again the number of transconjugants selected on kanamycin
was far greater than the number selected on ceftazidime (fig. 7).
a. Resistances conferred bv Mutant beta - lactamase D.
An E.coli J53-2 strain producing Mutant beta-lactamase D was sensitive to
cefotaxime and aztreonam but resistant to ceftazidime. This strain was
sensitive to ceftazidime in the presence of clavulanic acid (2mg/L)
demonstrating that the ceftazidime resistance was mediated by Mutant
beta - lactamase D (table 33).
b. Biochemical characterisation of Mutant beta - lactamase D.
Mutant beta-lactamase D hydrolysed cefotaxime and ceftazidime at low, but
significant rates (table 34). However, Mutant beta-lactamase D had much
higher affinity for cefotaxime than ceftazidime (table 35). Table 36 shows
that Mutant beta-lactamase D hydrolyses cefotaxime more efficiently than
ceftazidime, although the enzyme conferred far greater resistance to
ceftazidime. The molecular weight of Mutant beta-lactamase D was estimated
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to be similar to that of TEM-1 (table 25).
c. Plasmid analysis.
Mutant beta-lactamase D was encoded by a plasmid of 52Kb, which was
identical to the size of the RP4 plasmid which encoded TEM-2 in the
original strain (fig. 18). EcoR I digests of each of these plasmids
yielded a linear restriction fragment of 52Kb (fig- 21), and
demonstrated that they were indeed the same plasmid.
3.1.4. Mutant beta-lactamase obtained from E.coli J53-2 DP'Z fPSE-41.
The conditions which led to the production of these mutants are
illustrated in table 13. The spontaneous ceftazidime resistant mutants
were obtained at a frequency of 1 in 108. The ceftazidime resistance,
exhibited by these strains, was transferable to an E.coli J62-2 recipient,
and ceftazidime resistant transconjugants could be selected with either
kanamycin or ceftazidime. However, the frequency of transfer was far
greater when kanamycin was the adopted selection agent (table 16). Both
the original mutant strain and the E.coli J62-2 transconjugant produced
Mutant beta-lactamase E which aligned directly with the PSE-4 enzyme
produced by the original strain (fig. 6).
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a. Resistances conferred bv Mutant beta - lactamase E.
The E.ooli J53-2 and the E.ooli J62-2 transconjugant strain, which both
produced Mutant beta - lactamase E, were approximately 60 times more
resistant to ceftazidime than the sensitive strain. These strains were
sensitive to ceftazidime and ampicillin in the presence of clavulanic acid
(2mg/L) or sulbactam (2mg/L), illustrating that the ceftazidime resistance
was beta - lactamase mediated (table 17).
b. Biochemical characterisation of Mutant beta - lactamase E.
The hydrolytic activities of Mutant beta - lactamase E and PSE-4 were
determined for a range of beta-lactam substrates. The Vmax, Km and Vmax/Km
values for these substrates were similar for both the PSE-4 and Mutant
beta-lactamase E. Neither beta-lactamase had any measurable hydrolytic
activity against cephradine, oefuroxime, cefotaxime, or ceftazidime (table
18). Their ID5q values for clavulanic acid were also similar (table 26)
and high concentrations of ceftazidime (10"3 M) had no inhibitory effect
on the ability of either beta-lactamase to hydrolyse nitrocefin. Table 25
shows that there was no significant difference between the molecular
weights of Mutant beta - lactamase E and PSE-4.
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Ihhle 17. MICs conferred by Mitant beta - lactamase E (10"^ inoculum).














Ampicillin >250 >250 >250 4
A +clav 8 8 MD 2
B +sulb 16 32 ND 4
Carbenicillin >250 >250 >250 4
Cephaloridine 4 4 4 2
Cephalexin 4 4 8 2
Cefoxitin 2 4 8 2
Cefuroxime 4 4 8 2
Ceftazidime 0.13 8 8 <0.06
A +clav <0.06 0.5 ND 0.13
B +suib <0.06 <0.06 ND <0.06
Cefotaxime <0.06 <0.06 <0.06 <0.06
Ceftriaxone <0.06 <0.06 0.13 <0.06
Aztreonam <0.06 0.13 0.25 <0.06
Imipenam 0.06 0.25 0.25 0.13
A +clav = in combination with 2mg/L clavulanic acid
B +sulb = in combination with 2mg/L sulbactam
ND = Not done.
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Tbble 18. Kinetic parameters of PSE-4 and Mitant beta-lactamase E.
Beta-lactam substrate
Beta-lactamase. MP PEN CARB CER CED CXM CAZ CIX
Vtbx:
PSE-4 100 106 124 27 UM EM UM EM
Enzyme E 100 111 186 28 UM EM UM EM
PSE-4 200 166 263 400 UM EM UM EM
Enzyme E 167 167 313 333 UM UM UM UM
*Rel Vmax/Km
PSE-4 100 128 94 14 UM UM UM UM
Enzyme E 100 111 99 14 UM EM UM UM
Values expressed as a percentage of the value for ampicillin.
Vm Values in uM.
EM = Unmeasurahle because hydrolysis of substrate too lew.
MP = ampicillin; PEN = penicillin; CARB = carbenicillin; CER =
cephaLoridine; CED = cephradine; CXM = cefuroxime; CAZ = ceftazi dine
CIX = cefotaxime.
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3.2. Investigation cf the effects of methotrexate or metronidazole on the
production of mutant beta - lactamases.
The strain expressing TEM-9 had been isolated from a patient undergoing
anti-leukaemic and metronidazole therapy. Consequently, the ability of
methotrexate and metronidazole to mutate beta-lactamases to enzymes which
confer resistance to ceftazidime was investigated.
Metronidazole is only activated in the absence of oxygen, therefore,
both anaerobic and aerohic cultures were examined. Nevertheless, only
one cf the experiments shown in table 19 produced stable ceftazidime
resistant mutants.
3.2.1. Mutant beta-lactamases produced by K.pneumoniae 1957E.
When K.pneumoniae 1957E was grown anaerobically in the presence of
metronidazole (table 19), ceftazidime resistant mutants were selected
which possessed slightly different beta-lactamase profiles from the
original strain (fig. 8). As similar numbers of mutants were also selected
from control cultures, containing no metronidazole, it was assumed that
metronidazole did not have any significant effect on the mutation of the
beta-lactamases produced by strain 1 957E.


















































From table 19 (previous page).
(a) These experiments were first conducted by adding the potential mutagen
at the same time as the bacterial inoculum. They were then repeated adding
the potential mutagen two hours after the bacterial inoculum (in all other
experiments the potential mutagen was added at the same time as the
bacterial inoculum).
(b) All the cultures investigated in these experiments also contained
25mg/L methotrexate.
(c) Strains which yielded mutant beta-lactamases under these conditions
(see text for details).
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Fig. 8. Isoelectric focusing of mutant beta-lactamases obtained from
K.pneumoniae 1957E.
B C D E F
A.; B.; C.; D.; Mutant beta-lactamases produced by ceftazidime resistant
type 3a mutants obtained spontaneously from K.pneumoniae 1957E; E.
Beta-lactamases produced by K.pneumoniae 1957E, original strain used in
mutation experiments; F. Mutant beta-lactamases produced by ceftazidime
resistant 5a mutant obtained spontaneously from K.pneumoniae 1957E.
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K.pneumoniae mutant 5a was characteristic of one of the two types of
mutants obtained in this experiment (mutation frequency 1 in 10^). It
was 32 times more resistant to ceftazidime than the original K.pneumoniae
1957E (table 15), but transfer of this resistance could not be achieved.
The 5a mutant strains produced a beta-lactamase nf similar pi to Mutant
beta - lactamase B (fig. 8).
The other type of ceftazidime resistant mutant, K.pneumoniae mutant 3a,
was obtained at approximately the same frequency. This mutant was 16 times
more resistant to ceftazidime than the original 1957E strain (table 15),
and the ceftazidime resistance could not be transferred. When the
beta - lactamase profiles of the sensitive strain and mutant 3a were
compared by isoelectric focusing, it was apparent that both strains
produced a TEM -1 band cf equal intensity. However, the mutant 3a strain
produced a far larger SHV-1 band. This might be explained by the induction
effect of ceftazidime on the production of SHV-1.
3.3. Selection of enhanced 3GC resistance from beta-lactamases already
conferring 3GC resistance.
Experiments were performed to examine whether it was possible to
spontaneously select for a beta-lactamase conferring a broad spectrum of
3GC resistance from an enzyme already mediating a narrow or low degree of
3GC resistance.
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3.3.1. Selection of enhanced ceftazidime resistance from Mutant
beta - lactamase E.
Mutant beta-lactamase E confers only low level resistance to ceftazidime,
therefore, these experiments attempted to mutate the Mutant beta-lactamase
E gene to produce an enzyme which would confer greater ceftazidime
resistance. As described previously, aliquots of an overnight culture of
E.coli J53-2 producing Mutant beta-lactamase E were plated onto nutrient
agar, plates containing ceftazidime (64 or 125mg/L). However, no
ceftazidime resistant colonies were detected.
3.3.2. Selection of cefotaxime resistance from TEM-E1.
TEM-E1 confers resistance to ceftazidime but not to cefotaxime (see
section 3.4.1). Therefore, aliquots of an overnight culture of E.coli
J53-2 producing TEM-E1 were plated onto agar containing cefotaxime
(8mg/L). However, no cefotaxime resistant colonies were detected.
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3.4. Plasmid mediated beta-lactamases identified in clinical isolates
which confer resistance to 3GCs.
3.4,1. Beta - lactamase TEM-E1.
This beta-lactamase was produced by the ceftazidime resistant E.coli 7891
which was isolated in Belgium in 1987 (table 20). This enzyme was
designated TEM-E1, because it had TEM-like qualities and it was
characterised in Edinburgh.
a. Conjugation experiments.
The beta-lactam resistances expressed by E.coli 7891 were transferred to
an E.coli J53-2 recipient with ceftazidime as the selecting agent (table
21). Both the original clinical isolate and the transconjugant possessed
two plasmid DNA bands (sizes 31Kb and 3Kb) and TEM-E1 was believed to be
located on the 31Kb plasmid which was designated pUK720.
b. Antibiotic sensitivities.
The MIC data (table 22) shows that both the clinical strain and the E.coli
J53-2 transoonjugant were ceftazidime resistant. The strains expressing
the novel enzyme were seen to be sensitive to ceftazidime in the presence
of clavulanic acid (2mg/L) or sulbactam (2mg/L). Clavulanic acid was the
more efficient inhibitor when used in combination with ampicillin, but the





TEM-E3(N H)5.55.coli8001 TEM-E3(R H)5.55 TEM-E45.61 DJP-17.90 BIL-18.80
Ent.cloacae7923 S.marcescens7919 E.coli





UK Belgium India Pakistan
1987 1982 1987 1987 1987 1989 1989
Noceftazidime NS Ampicillin Cephalexin Cefuroxime Gentamicin Metronidazole NS NS NS Amikacin Cefotaxime
pUK720 pUK721 pUK722 pUK723 pUK724 pUK725 Noname designated.
NS=notspecified NMH=orthMiddlesexH spital RMH=oyalMarsdenH pital
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Tbhle 21. Transfer of clinically derived plasmid mediated beta-lactamases
into E.coli J53-2.
Donor strain. Beta- pi. Selectors Transfer frequency




E.ooli 8001 TEM-E3(M4H) 5.55


















Thhle 22. MICs of E.coli strains harbouring Mutant beta-lactamase B and
beta-lactamase TEM-E1
J3-lactam Mininum Inhibitory Concentrations
(rag/L)








Ampicillin >250 >250 >250 4 4
1
+ clav ND 2 2 ND 2
2
+ sulb ND 4 8 ED 4
Carhenicillin >250 >250 >250 4 8
Cephaloridine 32 16 32 2 4
Cephalexin 4 4 8 4 4
Cefoxitin 1 1 1 2 2
Cefuroxine 2 1 2 2 2
Ceftazidime 4 8 32 <0.06 <0.13
1
+ clav ND 0.06 0.25 ND 0.13
2
+ sulb ND 0.13 0.25 ND <0.06
Cefotaxime <0.06 <0.06 0.13 <0.06 <0.06
1
+ clav ND <0.06 <0.06 ND 0.06
2
+ sulb ND <0.06 <0.06 ND <0.06
Ceftriaxone <0.06 <0.06 0.13 <0.06 <0.06
Aztreonam 0.13 0.5 0.5 <0.06 0.13
Imipenan 0.13 0.5 0.5 0.13 0.25
Augmentin 16 16 16 8 8
1 + clav = in ocmbination with 2mg/L clavulanic acid
2 + sulb = in examination with 2rrg/L sulbactam
* = produces TEM-E1. ND = not done
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two inhibitors seemed to be equally effective when 3GCs were used as
substrates. A comparison of the resistance profiles conferred by TEM-E1
and Mutant beta-lactamase B revealed distinct similarities (table 22).
c. Isoelectric focusing.
Isoelectric focusing revealed both the E.coli J53-2 transconjugant and
E.coli 7891 produced a beta-lactamase which focused between TEM-7 (pi
5.41) and TEM-1 (pi 5.4) (fig. 9). Further isoelectric focusing analysis
revealed that TEM-E1 aligned directly with Mutant beta-lactamase B
(fig. 10).
d. Biochemical characterisation.
The substrate profiles of the TEM-1, TEM-E1, and Mutant beta-lactamase B
are shown in table 23. The profiles are similar for carbenicillin,
ampidllin, and cefuroxime. However, the TEM-E1 and Mutant beta-lactamase
B showed a low but significant rate of hydrolysis of ceftazidime and
cefotaxime, whereas the TEM-1 enzyme showed only a minute hydrolysis of
either of these substrates. The relative efficiency of hydrolysis
(Vmax/Km, ampici 111 n = 100%) values for TEM-1, TEM-E1 and Mutant
beta-lactamase B for five beta-lactam substrates are shown in table 24.
TEM-E1 hydrolysed ceftazidime more efficiently than cefotaxime, and Mutant
beta-lactamase B had similar efficiency of hydrolysis values for both of
these substrates. However, both these enzymes conferred a far greater
resistance to ceftazidime than to cefotaxime.
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Fig. 9. Isoelectric focusing pattern cf the plasmid encoded beta-lactamase
derived frcm strain 7891, compared with the enzymes TEM-1, TEM-2 and TEM-7
over a narrow pH range.
A B C D E F
A. E.ooli J53-2 producing TEM-2; B. E.coli J53-2 transconjugant of E.coli
7891 producing TEM-E1; C. E.coli BM694 producing TEM-7; D. as B; E.
E.coli 7891 producing TEM-E1; F. E.coli J53-2 producing TEM-1.
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Fig. 10. Isoelectric focusing patterns of mutant enzymes and
beta-lactamases from clinical isolates over a narrow pH range.
A. E.coli J53-2 producing PSE-4; B. E.coli J53-2 producing Mutant
beta-lactamase A; C. E.coli J53-2 producing TEM-E2 and TEM-1; D. E.coli
J53-2 producing TEM-1; E. E.ooli J53-2 producing Mutant beta-lactamase B;
F. E.ooii J53-2 producing TEM-E1; G. E.coli J53-2 producing TEM-7; H.
E.coli J53-2 producing TEM-2.
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Thhle 23. *Relative rates of hydrolysis of beta-lactamases TEM-
TEM-E2 and the Mutant enzymes A and B.
Beta-lactamases.
Beta-lactam TEM-E1 Enzyme 1EM--E2 Enzyme TEM-1
antibiotic. B A
Arpicillin 100.0 100.0 100 .0 100.0 100.0
Cafbenicillin 29.8 17.4 19,.3 26.3 10.9
Cephaloridine 42.1 68.0 41..6 38.2 18.0
Cefuroxime 0.25 0.55 0..22 0.52 0.014
Ceftazidime 0.31 1.11 0.,23 0.92 0.017
Cefotaxime 1.48 1.36 0. 58 2.27 0.014
Values expressed as a percentage of the value for
ampicillin.
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Thble 24 ^Relative efficiency values for TEM-E1, 1EM-E2, and the Mitant
enzymes A and B.
Beta-lactam Beta-lactamases,
antibiotic.
TEM-E1 Enzyme TEM-E2 Enzyme HM-1
B A
Anpicillin 100.0 100.0 100.0 100.0 100.0
Carbenicillin 18.0 7.0 9.0 16.0 18.0
Cephaloridine 134.0 76.0 78.0 00 o 110.0
Ceftazidime 1.1 2.1 0.69 3.3 UM
Cefotaxime 2.5 0.9 1.5 6.1 0.16
Values expressed as a percentage of the value for anpicillin.
LM = Unmeasurahle because of insufficient hydrolysis of substrate.
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The molecular weight of TEM-E1 was indistinguishable from Mutant
beta - lactamase B and TEM-1 (table 25).
e. Inhibition studies
When assayed for the hydrolysis of nitrocefin, both TEM - E1 and Mutant
beta-lactamase B were sensitive to inhibition by clavulanic acid (table
26).
These data revealed that Mutant beta-lactamase B and TEM-E1 were
essentially similar. Consequently, it was concluded that they were the same
enzyme.
3.4.2. Beta - lactamase TEM-E2.
The ceftazidime resistant isolate of Klebsiella oxvtoca 5445 was isolated
in 1982 from the hlood and cerebrospinal fluid of a baby in the Neonatal
Intensive Care Unit of Liverpool Hospital (table 20). Previous to the
isolation of this strain, the intensive care unit had a number of
fatalities in neonates owing to a gentamicin resistant K.oxvtoca 5446.
This strain was ceftazidime sensitive and produced TEM-1. K.oxvtoca 5446
was eradicated for some months and then K.oxvtoca 5445 appeared, which was
resistant to both gentamicin and ceftazidime. The clinicians suggested
that the ceftazidime sensitive K.oxvtoca 5446 may have remained in areas
where it had been exposed to sub-MIC levels of ceftazidime' and this had
eventually yielded the ceftazidime resistant K.oxvtoca 5445. On initial
analysis c£ K.oxvtoca 5445, the ceftazidime resistance was not thought to
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Mutant beta-lactamase A 23.5
Mutant beta-lactamase B 24.0









Mutant beta-lactamase E 26.0
BIL-1 29.0
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Thhle 26. Concentratiais of clavulanic acid required to inhibit the









Mitant beta-lactamase A 0.7





Matant beta-lactamase E 0.6
HHi-1 1995.0
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be mediated, by a beta-lactamase, because only TEM-1 was detected. Five
years later the research of this Thesis revealed that the strain produced
TEM-1 along with an additional beta-lactamase which focused as a doublet
band at pi 5.3.
a. Conjugation experiments.
Hie gaies encoding the TEM-1 and the doublet band beta-lactamases could be
transferred by conjugation to a recipient strain of E.coli J53-2 with a
concomitant transfer of resistance to ceftazidime. Similar transfer
frequencies were obtained when ceftazidime (4mg/L), ampicillin (20mg/L) or
ceftazidime (4mg/L) and ampicillin (20mg/l) were used as selectors (table
21). This illustrated that the TEM-1 and doublet band beta-lactamases were
probably encoded by the same plasmid. The ceftazidime resistance was
demonstrated to be encoded by a transferable plasmid designated pUK721.
The size of plasmid pUK721 was originally calculated as 103Kb, but the
correct size of pUK721 was found to be 141Kb (fig. 11, and fig. 12 for
calculation).
b. Antibiotic sensitivities.
Both the original clinical isolate and the E. coli J53-2 transconjugant
were resistant to ceftazidime but sensitive to cefotaxime and ceftriaxone.
Both the transconjugants and the clinical strain became sensitive to
ceftazidime in the presence of clavulanic acid (2mg/L) or sulbactam
(2mg/L). However, clavulanic acid was the more efficient inhibitor when
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Fig. 11. Agarose gel electrophoresis of pUK721 and standard plasmids
(0.5% agarose).
A. R6K; B. RP4; C. R1; D. E.coli J53-2 transconjugant of K.oxvtoca 5445;
E. K.oxvtoca 5445.
1 1 0
Fig. 12. Graph demonstrating the determination of the size of plasmid
pUK721 encoding TEM-E2.
Distance travelled in agarose gel (mm)
*
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used in combination with arapicillin. The two inhibitors were similar in
their activity when 3GCs were used as the principal antibiotic (table 27).
It was also observed that the E.coli J53-2 transconjugant of K.oxvtoca
5445, which produced TEM-1 and the doublet beta-lactamase, exhibited a
similar beta-lactam resistance profile to an E.coli J53- 2 strain producing
Mutant beta - lactamase A (table 27).
c. Isoelectric focusing.
The K.oxvtoca 5445 isolate and the E. coli J53-2 transconjugant produced
identical beta-lactamase bands. Both strains produced a band which
oo-focused with TEM-1 and a novel beta-lactamase which focused as a
doublet band at pi 5.3. This novel beta - lactamase, TEM-E2, was clearly
distinguishable from the other 3GC hydrolysing beta-lactamases (fig. 13)
Further analysis cf the TEM-E2 beta-lactamase demonstrated that it had an
identical focusing position to Mutant beta-lactamase A (fig. 10).
d. Purification of the TEM-E2 beta - lactamase.
As it was assumed that the TEM-1 band cf K.oxvtoca 5445 had little bearing
on the ceftazidime resistance, it was necessary to purify the TEM-E2
beta - lactamase (doublet band at pi 5.30) from TEM-1.
A method of electrodialysis was adopted to purify TEM-E2 from TEM-1. The
protocol for this novel method cf beta-lactamase purification is discussed
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Tkhle 27. MICs of E.coli strains harbouring Matant beta-lactamase A and
beta-lactamase TEM-E2.
Beta-lactam Minimum Inhibitory Concentrations (rag/L).
antibiotic. Mitant A Controls
J62-2 J53 *5445 J62-2 J53-2
mutant trans xJ53
Ampicillin >250 >250 >250 4 4
'
+ clav ND 2 8 ND 2
2
+ sulb ND 4 250 ND 4
Carbenicillin >250 >250 >250 4 8
Cephaloridine 8 16 64 2 4
Cephalexin 4 4 8 4 4
Cefoxitin 2 1 4 2 2
Cefuroxime 2 0.5 4 2 2
Ceftazidime 4 16 32 <0.06 <0.13
I
'
+ clav ND 0.13 0.25 ND 0.13
2
+ sulb ND <0.06 0.5 ND <0.06
Cefotaxime 0.06 0.06 0.25 <0.06 <0.06
1
+ clav ND <0.06 <0.06 ND 0.06
2
+ sulb ND <0.06 <0.06 ND <0.06
Ceftriaxone <0.06 0.13 0.13 <0.06 <0.06
Aztreonam 0.25 0.5 1 <0.06 0.13
Imipenan 0.13 0.5 0.25 0.13 0.25
Augmentin 8 16 32 8 8
1 + clav = in ocnibination with 2mg/L clavulanic acid




Fig. 13. Isoelectric focusing pattern of the plasmid encoded
beta-lactamase derived from strain 5445 (TEM-E2), compared with enzymes
PSE-4, TEM-1, TEM-2, and TEM-7, over a narrow pH range.
A. Paeruginosa PA08 producing PSE-4; B. E.ooli J53-2 producing TEM-E2 and
TEM-1; C. E.ooli J53-2 producing TEM-1; D. E.ooli BM694 producing TEM-7;
E. E.coli J53-2 producing TEM-2.
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below. Two ml c£ crude beta-lactamase solution were prepared from the
E.coli J53-2 transconjugant of K.oxvtoca 5445 (as described in section
2.7). This preparation was spread onto an analytical IEF polyacrylamide
gel containing a 1:1.5 ratio of pH 6-8 and pH 4-6 ampholines. Care was
taken not to cover the area of the gel where the beta-lactamase bands
focused. Once the beta-lactamases had been focused a 1cm strip of filter
paper, previously soaked in a 0.5mg/ml solution of nitrocefin, was placed
from the cathode to the anode of the gel. This allowed the identification
of the required plasmid beta-lactamase band so that it could be cut out of
the gel. The portion of the gel extracted was then placed in dialysis
tubing with a minimal amount cf 25mM sodium phosphate buffer (pH 7.0). The
dialysis sack was placed in the cathode reservoir of a Bio Rad Mini Sub
Cell with 25mM sodium phosphate buffer (pH 7.0) as running buffer. A
charge of 150 volts was applied for 10 minutes. The dialysis sack was then
removed and the purity of the fraction was analysed by IEF.
The TEM-E2 preparation, purified by electrcdialysis, is shown in fig. 14.
It appears to have retained a small amount cf TEM-1 activity, however, it
is possible that this small TEM-1 band may be a satellite band of TEM-E2.
Indeed, IEF cf Mutant beta-lactamase A reveals a doublet band, which is
Identical to TEM-E2, along with a similar small TEM-1 beta-lactamase band
(figs. 10 and 14). Therefore, this technique provided a quick and easy
method for the separation and purification of beta-lactamases,
particularly when the host strain produces more than one such enzyme with
similar isoelectric focusing positions.
1 1 5




A B C D E
A. E.ooli J53-2 producing TEM-1; B. TEM-E2 beta-lactamase, purified from
TEM-1 by electrodialysis; C. E.ooli J53-2 transconjugant of K.oxvtoca 5445
producing TEM-1 and TEM-E2; D. K.oxvtoca 5445 producing TEM-1 and TEM-E2;
E. E, coli J53-2 producing Mutant beta - lactamase A.
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e. Biochemical characterisation of TEM-E2.
The rates of hydrolysis c£ a number of beta-lactam substrates by TEM-E2,
Mutant beta-lactamase A, and TEM-1 are compared in table 23. None of the
enzymes had any measurable activity against cefuroxime. TEM-1 had no
activity against ceftazidime, but showed some affinity for cefotaxime.
Both TEM-E2 and Mutant beta-lactamase A showed similar activity against
both 3GC substrates, but had greater activity with cefotaxime. All three
enzymes had similar activities for ampicillin, carbenicillin and
cephaloridine. However, TEM-E2 and Mutant beta-lactamase A showed a low
but significant rate of hydrolysis of ceftazidime and cefotaxime, whereas
the TEM-1 enzyme showed negligible hydrolysis of either of these
substrates (table 23). All three enzymes exhibited similar relative
efficiency of hydrolysis values (Vmax/Km, ampicillin = 100%) for
ampicillin, carbenicillin, and cephaloridine. Mutant beta-lactamase A and
the TEM-E2 enzyme hydrolysed cefotaxime more efficiently than ceftazidime
(table 24) although both enzymes conferred greater resistance to
ceftazidime. When assayed for the hydrolysis of nitrocefin TEM-E2 and
Mutant beta-lactamase A were sensitive to inhibition by clavulanic acid
(table 26). The molecular weight of TEM-E2 (purified by electrodialysis
from an analytical IEF gel) was 23,500. Under the same experimental
conditions, the molecular weight of the TEM-1 enzyme was 22,000 (table
25). When the crude TEM-E2 enzyme preparation (i.e with the TEM-1 enzyme)
was analysed by gel filtration, fractions were taken from the Sephadex
G-75 column either side of the peak of beta-lactamase activity. Each of
these fractions were examined by IEF to ascertain whether the TEM-1 and
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the doublet band could be separated by virtue cf their molecular weight.
However, examination of each of these fractions showed that they all
exhibited both the TEM-1 band and the doublet band. This confirms that the
TEM-1 band and the doublet band had very similar molecular weights.
Biochemical characterisation of TEM-E2 and Mutant beta-lactamase A
revealed that they were the same enzyme.
3.4.3. Beta - lactamase TEM-E3.
In 1987 a ceftazidime resistant strain of E.coli (serotype ONT H9) was
isolated from two patients in the same ward at the North Middlesex
Hospital, London (NMH) (table 20). This strain was later isolated on the
ward mop and the bed pan washer. E.coli 8001 (E.coli ONT H9) was
demonstrated to exhibit transferable resistance to ceftazidime by Drabu gt
al. (1989). The work of this Thesis showed that the transferable
resistance resulted from a plasmid mediated beta-lactamase which was
designated TEM-E3 (NMH).
A similar beta-lactamase was shown to be produced by Enterobacter cloacae
7923 which was isolated at the Royal Marsden Hospital, London (RMH) (table
20). This beta - lactamase was designated TEM-E3 (RMH).
a. Conjugation experiments.
The beta-lactam resistances expressed by E.ooli 8001 were transferred to
an E.ooli J53 - 2 recipient strain with either carbenici 11 i n or ceftazidime
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as the selecting agents. A similar frequency cf transfer was observed for
either selector (table 21). Both the original E.coli 8001 and its
transoonjugant possessed a 110Kb plasmid (pUK722) and it was assumed that
this plasmid carried the ceftazidime resistance determinant.
The beta-lactam resistance expressed by Ent. cloacae 7923 was also
successfully transferred to an E.coli J53-2 recipient strain. Both the
transoonjugant and the original clinical strain possessed a 100Kb plasmid
(pUK723) and this was thought to encode for the beta-lactam resistance
expressed by the transconjugant strain. Fig. 15 shows the plasmids
encoding TEM-10, TEM-E3 (NMH), and TEM-E3 (RMH). The sizes of the TEM-E3
plasmids were determined separately by agarose gel electrophoresis in
parallel with standard molecular size markers.
b. Antibiotic sensitivities.
Plasmids pUK722 and pUK723 conferred ceftazidime resistance in the E.coli
J53-2 recipient strains. Both the transconjugants showed only a minor
increase in resistance to cephalexin, cefuroxime and cefotaxime when
compared to the E.coli J53-2 recipient strain. However, plasmids pUK722
and pUK723 conferred a significant increase in aztreonam and ceftazidime
resistance (table 28). The ampicillin, ceftazidime and cefotaxime
resistances conferred by the clinical isolates and transconjugants were
considerably diminished in the presence of clavulanic acid (2mg/L) and
sulbactam (2mg/L) (table 29). The beta-lactam resistance exhibited by the
E.coli J53-2 transconjugants of Ent. cloacae 7923 and E.coli 8001 were
compared with the MICs cf E.coli J53-2 strains producing TEM-5, TEM-9, or
1 1 9
Fig. 15. Agarose gel electrophoresis of plasmid DNA from E.coli J53-2
transconjugants producing TEM-E3 or TEM-10 (0.6% agarose).
B D
Kb
A. R6K plasmid; B. E.coli J53-2 transconjugant of Ent. cloacae 7923; C.
E.ooli J53-2 transoonjugant of E.coli 8001: D. E.coli J53-2 transcon jugant
of the clinical isolate producing TEM-10.
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Icible 28. MICs (nng/L) of E.ooli J53-2 transoon]ugants expressing TEM-E3,
TEM-10, iEM-5 and TEM-9 (measured at 105 inoculum).
Beta - lactamase
Beta-lactam TEM-5 TEM-E3 HM-E3 TEM-10 TEM-9 E.ooli J53-2
substrate. (NMH) (RMH) (recipient)
Ampicillin >500 >500 >500 >500 >500 4
Cephalexin 8 16 8 8 16 4
Cefoxitin 4 8 4 4 2 2
Cefuroxime 64 8 8 8 8 2
Cefotaxime 1 1 0.5 0.5 2 <0.06
Ceftazidime 32 125 125 64 250 0.13
Aztreonam 2 32 64 32 64 <0.06
Imipenan 0.5 0.25 0.5 0.25 0.25 0.25
1SMH = North Middlesex Hospital
KMH = Boyal ffersden Hospital
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Thhle 29. Effects of beta-lactamase inhibitors on strains producing
TEM-E3.
Mininum Inhibitory Concentrations (mg/L)
Beta-lactam E.ooli 8001 E.coli 8001 E.cloacae E.clcacae
ant i hi otic. X E.coli 7923 7923 X
J53-2 E.ooli J53-2
Axpicillin >250 >250 >250 >250
A +clav 4 8 16 8
B -i-sulb 4 4 64 16
Ceftazidime 64 64 250 125
A +clav 0.13 0.25 0.5 0.25
B +sulb <0.06 0.5 2 0.5
Cefotaxime 1 1 2 1
A +clav <0.06 <0.06 0.13 <0.06
B +sulb <0.06 0.25 <0.06 <0.06
A +clav = in ocrribination with 2mg/L clavulanic acid
B +sulb = in conbination with 2mg/L sulbactam
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TEM-10. This illustrated distinct similarities between the Ent. cloacae
7923 and E.coli 8001 transconjugants and the strain producing TEM-10.
However, the E.coli J53-2 strain producing TEM-5 differed from the other
transoonjugants as it conferred a greater resistance to cefuroxime than
any c£ the other transconjugants listed in table 28, also TEM-5 did not
confer any significant resistance to aztreonam.
c. Isoelectric focusing.
Isoelectric focusing revealed that the E.coli J53-2 transconjugants of
Ent. cloacae 7923 and E.coli 8001 produced beta-lactamases of identical
pis, and which focused marginally above TEM-5 and TEM-9 but below TEM-2
(fig. 16). These novel beta-lactamases were designated TEM-E3 (RMH) and
TEM-E3 (NMH) respectively. Isoelectric focusing also illustrated that
TEM-E3 aligned directly with TEM-10 (fig. 17). These six enzymes all
focused over a range of 0.5 pi units. Therefore, further biochemical
analysis was required to confirm these differences and similarities.
d. Biochemical characterisation of TEM-E3.
TEM-E3 (NMH), TEM-E3 (RMH) and TEM-10 had similar kinetic constants for
all the beta-lactam drugs assayed. Their Vmax values, for the hydrolysis
of ceftazidime, were more than 10 times greater than the Vmax values
determined for cefuroxime or cefotaxime. However, these enzymes had much
greater affinity for cefotaxime than any of the other beta-lactam
substrates tested and, consequently, they hydrolysed this substrate fairly
efficiently (tables 30-32).
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Fig. 16. Isoelectric focusing of TEM-E3 (NMH) and TEM-E3 (RMH) over a
narrow pH range.
| _ _ • -
A BCDEF GHI
A. E.ooli J53-2 producing TEM-E2; B. E.coli J53-2 producing TEM-1; C.
E.coli J53-2 producing TEM-E1; D. E.coli J53-2 producing TEM-7; E. E.coli
J53-2 producing TEM-9; F. E.ooli J53-2 producing TEM-5; G. E.coli J53-2
producing TEM-E3 (NMH); H. E.coli J53-2 producing TEM-E3 (RMH); I. E.coli
J53-2 producing TEM-2.
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Fig. 17. Isoelectric focusing of TEM-E3 compared to TEM-10, TEM-9 and
TEM-5 over a narrow pH range.
A. E.ooli J53-2 producing TEM-10; B. E.coli J53-2 producing TEM-9; C. same
as A; D. E.coli J53- 2 producing TEM-5; E. same as A; F. E.coli J53- 2
producing TEM-E3 (RMH); G. same as A; H. E.coli J53-2 producing TEM-E4.
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Tbble 30. *Relative Wax values for TIM enzymes for a range of
beta-lactams.
Beta-lactam substrate
Beta-lactamase. MP CARB CER CXM CAZ CIX
OEM-5 100 51 410 102 135 26
TEM-E3 (RMH) 100 51 61 2.7 44 1.9
TEM-E3 (KMH) 100 30 63 5.1 43 3.2
OEM- TO 100 48 58 2.0 30 2.2
TEM-9 100 46 73 1.8 115 6.3
TEM-1 100 11 23 LM UM 0
Tbble 31. +Km values for TEM enzymes for a range of beta-lactams.
Beta-lactam substrate
Beta-lactamase. MP CARB CER CXM CAZ CIX
TEM-5 69 38 143 250 330 21
TEM-E3 (RMH) 91 38 91 250 167 11
TEM-E3 (KMH) 76 33 125 286 167 21
TEM-10 111 39 100 167 100 15
TEM-9 128 43 200 167 500 40
TEM-1 167 100 167 UM LM 286
+
Km measured in uM
Values expressed as a percentage of the value with ampicillin.
LM = unmeasurahle because hydrolysis of substrate was too lew.
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Ohble 32. *Relative efficiency of hydrolysis (Rel Vmax/Km) values for
HM en2ynies.
Beta-lactam substrate
Beta-lactamase. AMP CARB CER CXM CAZ crx
TEM-5 100 93 198 28 28 85
1EM-E3 (RMH) 100 122 61 1.0 24 16
TEM-E3 (KMH) 100 69 38 1.4 20 12
OEM-10 100 137 64 1.3 33 16
am-9 100 137 47 1.4 29 20
OEM-1 100 18 23 UM UM 0.
Values expressed as a percentage of the value with ampicillin.
IM = lineasurable because hydrolysis of substrate was too low.
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TEM-9 differed from the TEM-E3 and TEM-10 beta-lactamases by its much
higher Vmax value for ceftazidime. However, this enzyme hydrolysed all the
substrates tested with similar efficiencies to TEM-E3 (NMH), TEM-E3 (RMH)
and TEM-10 (tables 30 and 32).
TEM-5 vas distinguished from TEM-10 and the TEM-E3 beta-lactamases by its
higher Vmax for the hydrolysis c£ cefuroxime, cefotaxime and ceftazidime.
However, the affinities c£ TEM-5 for each cf the substrates examined were
similar to the other 3GC hydrolysing beta-lactamases. Lastly, TEM-5
hydrolysed oephaloridine, cefuroxime and cefotaxime far more efficiently
than TEM-E3 (NMH), TEM-E3 (RMH), TEM-10, and TEM-9 (tables 30-32).
All the 3GC hydrolysing enzymes in tables 30-32 had similar molecular
weights and ID^q values for clavulanic acid (tables 2 5 and 26
respectively).
3.4.4. Beta - lactamase TEM-E4.
The isolation details of the strain producing TEM-E4 are shown in
table 20.
a. Conjugation experiments.
The conjugation cf the ceftazidime resistant S.marcescens 7919 and E.coli
J53-2 gave rise to ceftazidime resistant E.coli transconjugants
(table 21). Analysis cf the plasmid DNA in these transconjugant strains
showed a single plasmid band of 56Kb, this was designated pUK724
(fig. 18).
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Fig. 18. Agarose gel electrophoresis c£ plasmid DNA of strains producing
TEM-E4 or Mutant beta-lactamase D (0.5% agarose).
A. R6K plasmid; B. R1 plasmid; C. E.oali J53-2 producing TEM-2 mediated by
plasmid RP4 (used as the wild type strain in mutation experiments; D.
E.coli J53-2 transconjugant of S.marcescens 7919; E. E.coli J53-2
producing Mutant beta-lactamase D (derived from the TEM-2 gene in the RP4
plasmid).
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This plasmid was also visualized in the S .marcescens strain.
b. Antimicrobial susceptibilities.
With the exception cf imipenem, the S.marcescens 7919 strain was resistant
to all the antibiotics tested in table 33. However, the E.coli
transconjugant of this strain was resistant to ceftazidime but sensitive
to all the other third and second generation cephalosporins tested. The
ceftazidime and ampicillin resistances, expressed by the E.coli
transconjugant, were diminished with the addition of clavulanic acid
(2mg/L) to the media. This illustrated that the beta-lactam resistance of
the E.coli J53-2 transconjugant of S.marcescens 7919 must be
beta - lactamase mediated.
It was also noted that an E.coli J53-2 strain, producing Mutant
beta-lactamase D, exhibited a similar profile of beta-lactam resistance to
the E.coli transconjugant of S.marcescens 7919 (table 33).
c. Isoelectric focusing.
Both the original S.marcescens isolate and the E.coli transconjugant
produced the TEM-E4 beta-lactamase which focused marginally above TEM-2
(pi 5.6) and aligned with Mutant beta-lactamase D (fig. 19). Further
investigations demonstrated that TEM-E4 focused below TEM-6 (fig. 20)
which illustrated the novelty of this beta - lactamase.
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Tahle 33. MICs conferred by UM-E4 and the Rrtant beta-lactamase D
(10-5 inoculum).
Mininum Inhibitory Concentrations (mg/L)
Beta-lactam E.ooli E.coli J53-2 Serratia Serratia E.ooli
anti hi otic J53-2 producing 7919 7919 X J53-2
(TEM-2) J3-lactamase D E.ooli J53-2
Atpicillin >250 >250 >250 >250 4
A +clav 8 8 >32 8 4
Carbenicillin >250 >250 >250 >250 8
Cephaloridine 32 16 >250 32 2
Cephalexin 4 8 >250 8 8
Cefoxitin 1 4 125 4 4
Cefuroxime <1 4 >125 4 4
Ceftazidime <1 8 32 16 <1
A +clav <0.06 0.25 2 0.25 0.13
Cefotaxure <1 <1 32 <1 <1
A +clav <0.06 <0.06 >4 <0.06 <0.06
Ceftriaxone <1 <1 16 <1 <1
Aztreonam <1 <1 8 <1 0.25
Imipenan <0.06 0.13 2 <0.25 <1
A +clav = in combination with 2mg/L clavulanic acid.
ND = Not done.
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Fig. 19. IEF gel comparing the focusing positions of TEM-E4, Mutant




ABCDE F G H I
A. TEM-1; B. TEM-2; C. S.marcescens 7919; D. E.coli J53-2 transconjugant
of S.marcescens 7919; E. TEM-2; F. E.coli J53-2 producing Mutant
beta-lactamase D; G. E.coli K12 (SA 10) transconjugant producing Mutant
beta-lactamase D (selected on 2mg/L ceftazidime); H. E.coli K12 (SA10)
transoonjugant producing Mutant beta-lactamase D (selected on 40mg/L
Kanamycin); I. TEM-2.
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Fig. 20. IEF gel demonstrating that TEM-E4 is different from TEM-6.
A. E.ooli J53-2 producing CTX-1; B. E.coli J53-2 producing TEM-E4; C.
E.coli J53-2 producing TEM-6 and SHV-1; D. same as B; E. E.coli J53-2
producing Mutant beta-lactamase D; F. same as C; G. same as E; H. E.coli
J53-2 producing TEM-1.
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d. Biochemical characterisation of TEM-E4.
Tables 34 and 35 show the Km and Vmax values determined for the
hydrolysis of six different beta-lactam substrates by TEM-E4, Mutant
beta-lactamase D and TEM-1. Mutant beta-lactamase D and TEM-E4 have
similar kinetic constants for all the beta-lactams tested, they exhibit
lower rates of hydrolysis for cefotaxime than ceftazidime (table 34),
although they have a much higher affinity for cefotaxime (table 35).
TEM-E4 and Mutant beta-lactamase D hydrolyse cefotaxime more efficiently
than ceftazidime (table 36) which is paradoxical as these enzymes confer
only a small degree of resistance to cefotaxime. Mutant beta-lactamase D
and TEM-E4 had similar ID5q values for clavulanic acid (table 26) and
similar molecular weights to TEM-1 (table 25).
e. Comparison of plasmids encoding TEM-E4 and Mutant beta - lactamase D.
Fig. 21 shows EcoR I digests of pUK724, RP4 encoding Mutant beta-lactamase
D and RP4 encoding TEM-2. Plasmid pUK724 has at least three EcoR I
restriction sites compared to the one EcoR I restriction site of RP4.
Barth and Grinter (1977) showed that RP4 had only one EcoR I restriction
site, therefore, these results confirm that the gene encoding Mutant
beta-lactamase D was located on the RP4 plasmid.
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Thhle 34. ^Relative Viiax values Mutant beta-lactamase D and TPM-E4.
Beta-lactam substrate
Beta-lactamase. AMP CARB CER CXM CAZ CIX
Mutant p-lactamase D 100 30 82 2.5 7.4 2.8
HM-E4 (7919) 100 38 98 1.3 6.3 2.1
TEM-1 100 11 23 UM UM 0.06
Values expressed as a percentage of the value for anpicillin.
Tbble 35. +Km values for Mutant beta-lactamase D and TEM-E4.
Beta-lactam substrate
Beta-lactamase. AMP CARB CER CXM CAZ CIX
Mutant J3-lactamase D 37 139 100 250 1000 71
TEM-E4 (7919) 29 73 80 200 1500 77
TEM-1 167 100 167 UM UM 286
+Km values in uM.
LM=Unmeasurable because hydrolysis of substrate was too low.
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Tbble 36. *Relative efficiency of hydrolysis (Rel Vmax/Km) values
TEM-E4 and Mitant beta-lactanase D.
Beta-lactam substrate
Beta-lactamase AMP CARB CER CXM CAZ crx
Mitant J3- lactamase D 100 8 30 0.37 0.27 1.50
TEM-E4 100 15 36 0.19 0.12 0.79
HM-1 100 18 23 UM UM 0.04
^Values expressed as a percentage of the value for anpicillin.
UM=Uimeasurahle because hydrolysis of substrate vas too lew.
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Fig. 21. Agarose gel electrophoresis of EcoR I digests of RP4 encoding
Mutant beta-lactamase D or TEM-2 and pUK724 encoding TEM-E4 (1% agarose).
A. Lambda restricted with Hind III; EcoR I digests of: B. RP4 plasmid
encoding TEM-2; C. Clinically derived plasmid encoding TEM-E4 (pUK724); D.
RP4 plasmid encoding Mutant beta - lactamase D.
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3.5. Manufacture of a radio - labelled TEM-E1 gene probe.
3.5.1. Manufacture of Polymerase Chain Reaction (PCR1 primers.
In order to amplify a gene by PCR two primers must be synthesised which
encode for a small piece of the DNA sequence either side of the gene. The
3' ends cf each of these primers must point towards each other with the
gene to be amplified in the middle. From previous experiments the
reasonable assumption that the TEM-E1 gene was almost identical to TEM-1
was made. Therefore, analysis cf the TEM -1 sequence suggested that the PCR
primers 439E and 440E should be made. Their sequences are shown below.
Primer 439E.
5'- AAT TCT TG A AGA CG A AAG GGC CTC G -3'
Primer 440E.
5'- TTA CCA ATG CTT AAT CAG TGA GGC A -3'
Primer 439E (21 pmol/ul) and 440E (28.6 pmol/ul) were manufactured by the
Oswell DNA Service, University of Edinburgh, Department of Chemistry.
-138-
Fig. 22 shows that primer 440E anneals to a section of the TEM-1 gene at
the start of the structural gene and primer 439 E anneals to a section in
the promoter region cf the gene. Therefore, the 3' ends of primers 439E
and 440E point towards each other with the TEM gene in between.
3.5.2. Amplification of TEM-E1 gene bv PCR.
Table 37 shows the ingredients of the PCR stock solution. This stock
solution is sufficient for 15 PCR reactions. Aliquots of this stock
mixture (89.7ul) were placed into 15 eppendorf tubes. One ul of a 1:10
diluted DNA preparation cf plasmid pUK720, which contains the TEM-E1 gene,
was added to each of the tubes. This was followed by 4.8ul of Primer 439E
and 3.5ul of Primer 440E. These aliquots of primers provided 100pmols of
each primer for each PCR reaction. Finally, 4.2U (1ul) of Tag Polymerase
Type in (Cambio) was added to each of the reaction tubes. Sterile mineral
oil (50ul) was then added to each of the reaction mixtures to prevent
evaporation, and the bottom of each of the tubes was dipped in mineral oil
to ensure maximum heat transfer from the heating block. The 15 tubes were
then placed in a Cambio Intelligent Heating Block and the heating



















150.0 Tris-HCl, 0.1M, pH8.4.
22.5 100nM 2'Deo>^adenosine 5' Triphosphate (dAIP)
22.5 100irM 2'Deoxycytidine 5'Triphosphate (dCTP)
22.5 100nM 2'Deoxyguanosine 5 "Triphosphate (dGTP)
22.5 100rrM 2'Deoxythymidine 5'Triphosphate (dTIP)
Idhle 38. PCR protocol adopted for the amplification of the TEM-E1 gene.
Itncerature Purpose. Time period
{ C). (minutes).
1. 95 Denaturation. 10
50 Annealing of primers. 5
2. 70 Extension of target ENA. 2
95 Denaturation. 1
50 Annealing of primers. 1
3. 70 Extension of all
incarpleted strands.
Step 2. was repeated 30 times.
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On completion cf the PCR reaction, 5ul was removed from each of the tubes
and mixed with 2ul of loaling buffer and loaded onto a 1% agarose gel with
standard molecular weight markers.
Fig. 23 shows that 14 out cf the 15 reactions produced a PCR fragment of
approximately 1070bp. Analysis cf the sequence of the TEM-1 beta-lactamase
predicted that PCR primers 440E and 439E would produce a fragment of
1071bp. Therefore, these PCR cycles had yielded a DNA fragment of the
correct size.
3.5.3. Extraction of mineral oil from PCR preparations.
After a PCR fragment of the correct size had been obtained 0.5ml of
diethyl ether was added to each preparation. This mixture was vortexed and
spun at high speed for 5 seconds. The diethyl ether fraction (top) was
then removed and the procedure repeated twice. These tubes were then left
for 15 minutes to allow any remaining diethyl ether to evaporate.
3.5.4. Checking the integrity of the PCR fragment.
In order to confirm that the 1071bp fragment actually contained the TEM-E1
gene, diagnostic restrictions with endonuclease enzymes were performed on
three of the PCR preparations. It was assumed that TEM-E1 differed from
TEM-1 by only a few point mutations. Therefore, from analysis of the TEM-1
nucleotide sequence, restriction endonuclease enzymes were selected that
would cut the 1071bp into fragments which could be easily visualised on an
agarose gel.
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Fig. 23. Agarose gel electrophoresis of the amplified fragment obtained
from PCR of pUK720.
A. (j) X 174 RF DNA restricted with Hae IH; (B.- P., aliquots of the 15 PCR
preparations obtained from pUK 720); B. PCR preparation number 1; C. PCR
prep. 2; D. PCR prep. 3; E. PCR prep. 4; F. PCR prep. 5; G. PCR prep. 6;
H. PCR prep. 7; I. PCR prep. 8; J. PCR prep. 9; K. PCR prep. 10; L. PCR
prep. 11; M. PCR prep. 12; N. PCR prep.'13; 0. PCR prep. 14; P. PCR prep.
1 5.
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It was deduced that if the 1071 bp fragment contained a TEM derived
beta-lactamase then Rsa I, Ssp I and Dra I should each have one
restriction site (fig. 22). The sizes c£ the fragments which each of these
restriction reactions should yield are shown in table 39.
The restriction with Rsa I gave two fragments of similar size and fig. 24
shows that there was a larger band of approximately 500bp suggesting that
the two bands had not been resolved on this particular gel.
Fig. 24 shows that the Ssp I restriction endonuclease gave a large
fragment cf 878bp along with a small fragment of 193bp which is just
visible.
Analysis of the TEM -1 structural gene suggested that Dra I should give
fragments cf 651bp and 420bp, these two fragments are clearly seen in fig.
24.
The diagnostic restrictions confirmed that the 1071 bp fragment obtained
fron pUK720 contained a TEM-like gene which differed from TEM-1 by only a
few amino acid residues.
3.5.5. Purification of the PCR fragment.
The 14 PCR preparations were bulked together into three eppendorf tubes.
These three samples were then completely dried in a Speed Vac Concentrator
(Savant). Each cf the samples were then resuspended in 25ul of TE buffer
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Table 39. Diagnostic restrictions performed on PCR product.
Restriction Fragments
endonuclease. expected.
Rsa I 554, 51 7
Ssp I 878, 1 93
Dra I 651, 420
Fig. 24. Agarose gel electrophoresis of diagnostic restrictions of the
PCR product (1% agarose).
A. PCR prep. 1 restricted with Rsa I; B. PCR prep. 5 restricted with
Rsa I: C. PCR prep. 10 restriction with Rsa I; D. PCR prep. 1 restricted
with Ssp I; E. PCR prep. 5 restricted with Ssp I; F. PCR prep. 10
restricted with Ssp I; G. PCR prep. 1 restricted with Dra- I; H. PCR prep.
5 restricted with Dra I; I. PCR prep, restricted with Dra I; J. Lambda DNA
restricted with Hind III.
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(10raM Tris acetate, 2mM disodium EETA pH 8.0) and loaded onto a 1% Low
Melting Point Agarose gel (fig. 25). The main PCR band from each
preparation was cut out of the gel and resuspended in 1ml of elution
buffer (500mM ammonium acetate, 10mM magnesium acetate, 1mM EDTA, 0.1%
SDS, pH 8.0) and left at 37°C overnight. The three preparations were
then spun at high speed for five minutes to remove the agarose. In each
case the supernatant was split into two 0.5ml aliquots 0.5ml of a 1:1
mixture of *phenol:chloroform/isoamyl alcohol (24 parts chloroform to
one part isoamyl alcohol) was added to each preparation and mixed
thoroughly. The mixture was then spun at high speed for two minutes and
the top layer removed and placed in a clean eppendorf tube. This procedure
was then repeated after which ethanol was aided to give a final ratio of
ethanol to DNA preparation c£ 3:1. The DNA was precipitated at -70°C for
20 minutes then harvested by spinning at high speed for 15 minutes, and
the supernatant was discarded. The DNA was washed with 70% ethanol and
spun at high speed for two minutes, the supernatant was removed and the
pellet dried for five minutes in a Speed Vac Concentrator. The final
pellets were combined and resuspended in a total of 50ul of TE buffer.
3.5.6. Restriction of the PCR product.
Fig. 22 shows that there is a Ssp I restriction site less than twenty base
pairs away from the start of the TEM structural gene. Consequently, the
purified PCR fragment was restricted with Ssp I to provide a fragment
*saturated with TE buffer.
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Fig. 25. Low Melting Agarose Electrophoresis cf combined PCR preparations
obtained from pUK720.
A.; B.; C.; combined PCR preparations obtained from pUK720.
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which contained predominantly the TEM structural gene. This would allow
for the construction of a more discriminating TEM probe. The 50ul of
purified PCR fragment was split into two 25ul aliquots and these were
loaded onto a low melting agarose gel. Fig. 26 shows that the Ssp I
restriction had yielded a fragment of 878bp and a fragment of 193bp. The
878bp fragment was extracted and purified as described previously. This
preparation was finally resuspended in 30ul of TE buffer.
3.5.7. Radio labelling of the 878bp TEM-E1 fragment.
The Bio-Rad Random Labelling Primer DNA Labelling kit was used to radio
label the TEM-E1 gene. Table 40 shows the ingredients of the labelling
mix. These solutions were provided by the Bio-Rad kit and were mixed in a
sterile eppendorf.
Five ul of the solution containing the TEM-E1 gene were mixed with 25ul cf
sterile water, boiled for 10 minutes and cooled rapidly in an ice/water
bath. This mixture was then added to the labelling mixture and 1ul of
Klenow Polymerase to give a final volume of 50ul. This solution was
incubated for 4 hours at 37°C. The reaction was terminated by the
addition of 10ul of 10mM Tris pH 7.5, 100mM EDTA.
3.5.8. Blotting of agarose gel.
Following the electrophoresis of a range of TEM, and non-TEM
beta-lactamase encoding plasmids the agarose gel was cut to the smallest
possible size.
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Fig. 26. Agarose electrophoresis of the PCR fragment restricted with
S5P I.
ABC Kb











A. and B. PCR fragments restricted with Sso I; C. d) X 174 RF DNA
restricted with Hae III.
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Table 40. The ingredients of labelling mix.
Ingredient. Volume
(ul)





[a 32P] - dCTP 1
The gel was then incubated at room temperature in the following solutions.
1. 0.25M HC1 for 15 minutes (depurination).
2. 0.4M NaOH, 0.6M NaCl for 2X15 minutes (denaturation).
3. 1.5M NaCl, 0.5M Tris, pH 7.5 for 30 minutes (neutralisation).
A piece of Genescreen Plus (Biotechnology Systems Duponfc) was cut to the
exact size of the agarose gel. Once the membrane was cut it curled up, and
it is the concave side which must be laid on the agarose gel, this side
was marked 'b'. The membrane was then submerged in distilled water and
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transferred to 10X SSC (Salt Sodium Citrate, 1.5M sodium chloride; 0.15M
sodium citrate) buffer for 15 minutes. The treated agarose gel was placed
on a 3MM wick (Whatmann Chromatography Paper) soaked in 10X SSC. The
membrane was then placed on top of the agarose gel (side 'b' in contact
with the gel) and all air bubbles were removed. Short circuits were
prevented by the addition of paraffin around the agarose gel. The
following were then placed on top of the membrane;
1. 1 sheet of 3MM paper, this must be the exact size of the gel.
2. Approximately 7cm of absorbent tissues.
3. A 500g weight.
This was then blotted overnight, ensuring that there was plenty of 10X SSC
in the reservoir.
On the following day the membrane was carefully removed from the gel and
immersed in the following solutions;
1. 0.4M NaOH for 30 seconds.
2. 0.2M Tris, pH 7.5, 2X SSC for 30-60 seconds (neutralisation).
The filter was then left at room temperature until dry.
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3.5.9. Hybridisation procedure.




Made up to 200ml with distilled water.
The ingredients were dissolved by heating to 90°C. Sufficient
pre-hybridisation solution was added to cover the membrane and this was
left at 65°C for five hours. Ten ulaf a 10mg/ml salmon testes DNA were
then added to the 50ul cf the radio-labelled DNA probe made in section
3.5.7. This mixture was boiled for three minutes and cooled rapidly in an
ice/water bath. The entire preparation was then added to the
pre-hybridisation mixture and the hybridisation left overnight at 65°C.
The following washes were then performed on the membrane;
(200ml per wash)
1. 2X SSC, 1% SDS, room temperature, 2X5 minutes.
2. 2X SSC, 1% SDS, 65°C, 2 X 30 minutes.
3. 0.1X SSC, 65°C, 1 X 30 minutes.
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3.5.10. Probing of TEM-E1. TEM-E3. TEM-E4. TEM-1 and non-TEM
beta - lactamases with a TEM-E1 probe.
Fig. 27 shows the agarose gel electrophoresis of plasmid DNA encoding TEM
and non-TEM beta-lactamases. Fig. 28 shows the Southern blot of this gel
probed with the TEM-E1 probe. The plasmid encoding TEM-E1 (pUK720) was
restricted with Sso I. In previous experiments employing this restriction,
only a 4.3Kb DNA band hybridised with the TEM-E1 probe. However, in this
case, although this band showed much stronger hybridisation than any
other, other bands also showed some hybridisation but this was probably
due to the incomplete restriction of the plasmid.
A non-restricted preparation of the TEM-E3 plasmid (pUK723) appeared to
break up during the plasmid preparation. However, a faint band 19.1Kb did
show some hybridisation. When the plasmid was restricted with EcoR I one
fragment, (5.9Kb), showed strong hybridisation. Similarly, the
non-restricted preparation of the TEM-E4 plasmid (pUK724) also appeared to
have broken up during preparation but an EooR I digest of this plasmid did
produce fragments of 13.8Kb and 8.5Kb which strongly hybridised with the
TEM - E 1 probe.
Ssp I and EcoR I restrictions of the R6K plasmid encoding TEM -1 yielded
fragments of 19.1Kb and 4.9Kb respectively, which hybridised with the
TEM-E1 probe.
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Fig. 27. Agarose gel electrophoresis of plasmids encoding TEM-like or
non-TEM beta-lactamases.
ABCDEFGHI JKLMNOPQ Kb
A. Plasmid R1010 (encodes for SHV-1) restricted with BamH I; B. R1010
restricted with Hind IH; C. R1010 restricted with EcoR I; D. Plasmid R46
(encodes for OXA-2) restricted with Bgl I; E. R1010 non - restricted; F. R46
restricted with Sma I: G. R46 non - restricted; H. (J) X RF DNA restricted
with Hae HI; I. Lambda DNA restricted with Hind HI; J. Plasmid R6K
(encodes for TEM-1) restricted with EooR I; K. R6K restricted with Ssp I;
L. R6K non-restricted; M. pUK724 (encodes TEM-E4) restricted with EcoR I;
N. p(JK724 non-restricted; 0. pUK723 restricted with EcoR I; P. pUK723
non - restricted; Q. pUK720 (encoding TEM-E1) restricted with Ssp I.
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Fig. 28. Southern blot of the agarose gel in fig. 27.
JKLMNOPQ Kb
-4.3
Tracks A-H were negative controls and showed no hybridisation with the
TEM-E1 probe, tracks A - H not shown in figure.
A. Plasmid R1010 (encodes for SHV-1) restricted with BamH I; B. R1010
restricted with Hind HE; C. R1010 restricted with EcoR I; D. Plasmid R46
(encodes for OXA-2) restricted with Bgl I; E. R1010 non - restricted; F. R46
restricted with Sma I: G. R46 non - restricted; H. (J) X RF DNA restricted
with Hae HI; I. Lambda DNA restricted with Hind HI; J. Plasmid R6K
(encodes for TEM-1) restricted with EcoR I; K. R6K restricted with Ssp I;
L. R6K non-restricted; M. pUK724 (encodes TEM-E4) restricted with EcoR I;
N. pUK724 non-restricted; 0. pUK723 restricted with EcoR I; P. pUK723
non - restricted; Q. pUK720 (encoding TEM-E1) restricted with Ssn I.
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The R46 plasmid, encoding OXA-2 showed no hybridisation with the TEM-E1
probe. Restrictions of the OXA- 2 encoding plasmid with Bql I and Sma I
also failed to yield fragments which hybridised with the TEM-E1 probe,
even though these restrictions gave well defined bands on the original
agarose geL Similarly, the TEM-E1 probe did not hybridise with the R1010
plasmid which encodes for SHV-1 nor with any cf the fragments produced by
restrictions of this plasmid with EcoR I or Bql I.
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3.6. Ceftazidime resistant E.coli from Pakistan.
The work In the following three paragraphs was performed in conjunction
with the Antibiotic Reference Laboratory, PHLS Colindale.
E.coli SHAFIQ Bilal (E.coli SB) was isolated from a patient at Queen
Mary's University Hospital, London (table 20). The patient had previously
been hospitalised in Pakistan. The strain was resistant to 3GC and it was
found to possess three plasmids of approximate sizes, 80, 46, and 36Mdal.
Mating experiments showed that the resistance to 3GCs was transferable to
E.coli J62-1. This transoonjugant possessed the 80Mdal plasmid along with
a 28Mdal plasmid. The nature of the latter, which could not be
demonstrated in the donor strain, was unclear, but may represent a
deletion of a portion of one of the other parent strain plasmids.
Seocndary matings were then conducted in an attempt to assess which of the
two plasmids encoded the 3GC resistance determinant. The resultant E.coli
J53-2 transoonjugant, from this experiment, possessed only the 28Mdal
plasmid. It was concluded that this plasmid encoded the transferable 3GC
resistance. This E.coli J53-2 transconjugant was studied further to
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characterise the factor responsible for transferable resistance to
extended spectrum cephalosporins.
The 3GC resistance expressed by the E.coli J62-1 transconjugant
(possessing the 80 and the 28Mdal plasmids) was shown to be transferable
to recipient strains of Enterobacter cloacae 417, and Klebsiella oxvtoca
478. These mating experiments yielded transconjugants with similar
resistance profiles to E.coli SB. However, the resistance could not be
transferred to either Proteus sop, or Serratia sop.
3.6.1. Conjugation experiments.
The E.ooli J53-2 transconjugant (possessing only the 28Mdal plasmid) was
mated with E.coli J62-2. Agar containing ampicillin (20mg/L) or
ceftazidime (1mg/L), and the appropriate nutrients, was used to select for
the transconjugants. However, these conjugation experiments were
unsuccessful and no transconjugants were detected.
3.6.2. Antibiotic sensitivities.
The E.ooli J53-2 transconjugant was resistant to all the first, second,
and third generation cephalosporins tested (including cefoxitin) and, out
of the 11 beta-lactam antibiotics studied, the strain was only sensitive
to imipenem. The MICs of ceftazidime, cefotaxime, and ampicillin were not
substantLally reduced by the addition of clavulanic acid to the medium
(table 41).
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Thhle 41. MICs of E.ooli SB and its E.ooli J53-2 transoonjugant.
E.ooli ,753-2 E.coli S.B.+ E.coli J53-2
★
recipient. transconjugant .
Ampicillin 4 64 >250
Aimp +clav 4 ND >32
Carhenicillin 8 256 250
Cephaloridine 2 ID 125
Cephalexin 8 ND >250
Cefoxitin 4 ND 64
Cefuroxinne 4 >32 125
Ceftazidime <1 >16 64
Caz +clav 0.13 ND >4
Cefotaxime <1 >16 16
Ctx +clav <0.06 ND >4
Ceftriaxone <1 ND 32
Aztreonam <1 ND 16
Imipenam 0.25 ND 0.25
+clav = in combination with clavulanic acid (2mg/L).
Possesses only the 28Mdal plasimid.
+
MICs performed by the Antibiotic Reference Laboratory, PHLS Golindale.




Isoelectric focusing revealed that both the clinical isolate and the E.coli
i\t
J53-2, E.clcacae 417, and K.oxvtoca 478 transconjugants all produced a
A
beta-lactamase which had a pi cf 8.8 (fig. 29). This enzyme was given the
preliminary designation of beta-lactamase BIL-1 after the patient it was
isolated from.
3.6.4. Molecular weight.
The molecular weight of the beta-lactamase BIL-1 was determined as 29 000
by gel filtration with a Sephadex G-75 column. This was larger than any
of the TEM- or SHV-derived 3GC hydrolysing beta - lactamases (table 25).
3.6.5. Hydrolysis of beta-lactam antibiotics bv BIL-1.
Enzyme BIL-1 had no detectable hydrolytic activity against cefotaxime,
ceftazidime, cefuroxime, carbenici 11 in or ampicillin. However, hydrolysis
of nitrocefin and cephaloridine was detectable (table 42).
BIL-1 hydrolysed nitrocefin and cephaloridine at similar rates but had a
greater affinity for nitrocefin. BIL-1 and TEM -1 hydrolysed cephaloridine
with similar efficiencies.
3.6.6. Inhibition of beta - lactamase BIL-1.
To test whether the novel enzyme was inhibited by the unhydrolysable
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Fig. 29. IEF c£ novel enzyme and standard plasmid beta-lactamases c£ known
pi.
A. E.ooli J53-2 producing SHV-1; B. Original clinical isolate (E.coli SB)
producing BIL-1; C. E.coli J62-1 producing SHV-5; D. E.coli J53-2
producing BIL-1; E. K.oxvtoca 478; F. K.oxvtoca 478 transconjugant
producing BIL-1; G. CEP-1 (pi 8.2); H. Ent.cloacae 471; I. Ent.cloacae 471
transoonjugant producing BIL-1; J. Ent .cloacae chromosomal beta-lactamase
type A (pi 8.8); K. Ent.cloacaechromosomal beta - lactamase type B (pi 7.8).
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Tbhle 42. Kinetic constants for the hydrolysis of nitrocefin and
cephaloridine ty HM-1 and BIL-1.
Nitrocefin Cephaloridine
\imax Km Vimax/Km \irax Km Mnax/Kn
1EM-1 2.44 77 100 2.00 166 38
Enzyme BIL-1 6.25 250 100 6.25 500 50
Efficiency of hydrolysis values (\faiax/Kn) are expressed as a percentage of
the value for nitrocefin.
Km value is measured in uM.
Wax is measured in umoles/minute/ml of enzyme preparation.
Thble 43. Concentration (uM) of beta-lactam antibiotics and clavulanic
acid required to inhibit hydrolysis of nitrocefin by 50% (H>5q values).




Clavulanic acid 0.5 1995.,00
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substrates, the hydrolysis c£ nitrocefin was assayed in the presence of
increasing concentrations c£ different beta-lactam compounds. The same
assays were also performed on the TEM-1 beta-lactamase (table 43).
These results show that ampicillin, ceftazidime, and cefuroxime are much
more potent inhibitors of BIL-1 than TEM-1. Beta-lactamase BIL-1 was also
almost 4000 times more resistant to inhibition by clavulanic acid than
TEM- 1.
3.6.7. Specific activity of BIL-1.
The specific activities of BIL-1 were compared with TEM-3 to TEM-10,
TEM-E1 to TEM E4, and Mutant beta-lactamase A to E. The crude samples used
in these assays all originated from E.coli J53-2 transconjugants of the
original clinical isolates. These data revealed that the specific activity
of BIL-1 was between 2 and 11 times greater than any of the other
beta-lactamases investigated. This demonstrated that BIL-1 possessed the
H
highest activity out of all the previously reported 3GC hydrolysing
beta-lactamases.
-163-
3.7. Separation cf plasmid mediated extended spectrum beta-lactamases by
Fast Protein Liquid Chromatography System.
The 3GC resistant Klebsiella pneumoniae 8825 was isolated from a lymphoma
patient at the Tate Memorial Hospital, Bombay, India (table 20). It was
found to produce 4 beta-lactamases and the genes encoding 3 of these
enzymes were transferred to an E.coli J53-2 recipient strain with a
concomitant transfer of ceftazidime and cefotaxime resistance.
Extensive experimentation would normally be required to ascertain which of
the 3 beta-lactamases w<xs conferring transferable resistance to broad
spectrum cephalosporins. Consequently, to investigate one of these enzymes
it is imperative that it is separated from each of the other
beta-lactamases. In the past these separation procedures were based on the
enzymds ionic charge, because many of the beta-lactamases had similar
molecular weights. For example, preparative IEF was used to separate TLE-2
fromTEM-1 and SHV-1 (Reid et al.. 1987) and as described previously
electrodialysis has been used to separate TEM-E2 from TEM-1. This section
discusses the development of a Fast Protein Liqmd Chromatography System
(FPLC System) technique for the rapid separation of three different
beta-lactamases produced by the same strain. Previously, reverse phase
High Performance Liquid Chromatography (HPLC) techniques have been used to
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purify beta-lactamases such as SHV-1 (Barthelemy et al.. 1988a), and FPLC
System has been implemented to purify an inducible beta-lactamase produced
by Proteus vulgaris (Cullmann and Seibert 1986), and a beta-lactamase from
r.lostrirHum butvricum (Kesado et al. 1989) but neither procedure has ever
been used to separate three plasmid-enccded beta-lactamases produced by
the same strain.
3.7.1. Conjugation experiments and plasmid analysis experiments.
E.coli J53- 2 transconjugants cf K.oneumoniae 8825 were detected on agar
plates containing ceftazidime or carbenicillin. The frequency of transfer
/T
cxi the ceftazidime and rifampicin containing media was 1.18 X 10 per
donor cell and the transfer frequency for the selection on carbenicillin
and rifampicin was 3.53 X 10"6 per donor cell. Analysis of the plasmid
DNA in the E. coli J53-2 transconjugant revealed plasmids of 100Kb and
2.5Kb (fig. 30). This suggested that the beta-lactamase genes conferring
resistance to carbenicillin and ceftazidime were either one and the same
or they were located on the same plasmid.
3.7.2. Antibiotic susceptibilities.
The K.pneumoniae 8825 strain was resistant to all the penicillins and to
first, second and third generation cephalosporins tested, with the
exception cf cefoxitin. All these resistance determinants were transferred
to the E.coli J53-2 in the conjugation experiments (table 44). In
addition, the clinical strain and the transconjugant were both sensitive
to imipenem. The K.pneurooniae 8825 and its transconjugant were sensitive
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Fig. 30. Agarose gel electrophoresis c£ plasmid DNA from the E.coli J53-2




A. Lambda restricted with Hind III; B. R6K; C. R1; D. Plasmid isolated
from E.coli transconjugant of K,pneumoniae 8825.
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Thhle 44. Antibiotic susceptibilities of strains.
Minimjm inhibitory concentrations (ma/L1
Beta-lactam K.mgumoniae 8825 K.meumoniae 8825 E.coli J53-2
X E.coli J53-2
Arpicillin >250 >250 4
+ clav* 8 8 4
Carbenicillin >250 >250 8
Cephaloridine 125 32 2
Cephalexin 125 64 8
Cefoxitin 4 4 4
Cefuroxime 32 125 4
Ceftazidime 125 64 <1
+ clav* 0.25 0.25 0.13
Cefotaxime 8 8 <1
+ clav* <0.06 <0.06 <0.06
Ceftriaxone 16 4 <1
Aztreonam 125 32 <1
Imipenan 0.13 0.25 0.25
*
in combination with clavulanic acid (2mg/L)
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to ampirrillin, ceftazidime and cefotaxime in the presence of clavulanic
acid (2mg/L), inferring that the beta-lactamases responsible for
resistance to these drugs were either of the TEM or SHV groups.
3.7.3. Identification of beta - lactamases.
The original K.pneumoniae isolate produced four beta-lactamases which
focused at pi 5.4, pi 6.5, pi 7.7 and pi 7.9. The band at pi 5.4 aligned
with TEM-1, the enzyme of pi 6.5 focused between TEM-3 (pi 6.3) and SHV-3
(pi 7.0) and the enzyme of pi 7.7 aligned with SHV-1/2. Crude enzyme
preparations of the E.ooli J53-2 transoonjugants selected on carbenici 111 n
and rifampicin or ceftazidime and idfampicin possessed the beta-lactamases
which focused at pi 5.4, pi 6.5 and pi 7.9. However, they additionally
produced another beta-lactamase which focused at pi 8.1 (fig. 31). This
high pi band aligned directly with the E.coli J53-2 chromosomal
beta -lactamase.
3.7.4. Preparation of beta-lactamase sample for FPLC System analysis.
As described in the methods section, a concentrate of sonicated cells from
a 1 litre broth culture of the E.coli J53 - 2 transoonjugant of K.pneumoniae
8825 was applied to a Sephadex G-75 column. Each fraction was examined for
beta-lactamase activity. It was observed that, following purification by
gel filtration, the intensities of the beta-lactamases of pi 7.9 and pi
8.1 were reduced. The fractions which exhibited beta-lactamase activity
were pooled and dialysed against 50mM Tris-HCl buffer (pH 8.2) overnight.
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Fig. 31. IEF cf beta-lactamases produced by K,pneumoniae 8825 and its
E.coli J53-2 transconjugant.
ABC
A. Beta-lactamases produced by the E.coli transconjugant of K.pneumoniae
8825 selected on ceftazidime and rifampicin; B. Beta-lactamases produced
by K.pneumoniae 8825: C. Beta-lactamases produced by the E.coli J53-2
transcon jugant of K.pneumoniae 8825 selected on carbenicillin and
rifampicin.
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3.7.5. FPLC System analysis.
Separation of the beta-lactamases was carried out with the Pharmacia FPLC
System consisting af a LCC 500 Plus Controller, UV-M Monitor, and FRAC 100
with an HR5/5 Mono Q column. The column was equilibrated with 50mM
Tris-HCl buffer (pH 8.2). Separation was achieved by elution with a
linearly increasing concentration of sodium chloride (in the above buffer)
to a maximum concentration of 1M.
Two ml of the Sephadex G-75 purified beta-lactamase sample were separated
through the Mono Q column in each run. Approximately, 34 fractions (1ml)
were collected from each 30 minute separation. Each aliquot was tested for
beta-lactamase activity by the chromogenic cephalosporin nitrocefin spot
test. This process was repeated until sufficient quantities of the
different enzymes were obtained. In each FPLC System separation,
beta-lactamase activity was detected in the following fractions: 2, 3,
and 4 (the void volume), 11/10, and 13/14 (fig. 32). When these fractions
were examined by IEF the beta-lactamases of pi 7.9 and pi 8.1 were eluted
in fractions 2, 3, 4, the enzyme of pi 6.5 in fractions 10/11, and the
beta-lactamase of pi 5.4 in fractions 13/14 (fig. 33). The FPLC trace
shows the position where each of the fractions were eluted, and
demonstrates the relatively huge quantities of other proteins present in
this partially purified beta - lactamase preparation (fig. 34). All the
fractions, from the individual separations, containing the same
beta-lactamase were combined so that sufficient enzyme could be
characterised biochemically.
Fig.32Microtitreplatshowingnitr c fspottestsfractionselutedm theFPLCSystem. 1234567891012 $888S888698E 1345617892012234 Thedarkwellsdenotebeta-lactamasectivitywherethni rocefinsb nhydroly d andtur edfromyellowtor .Nitrocefinspott stsfFPLCSystemf a ti ns( umber denotetheumb rfthfrac ionelutedfromtheFPLCSys m).
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Fig. 33. IEF gel of beta - lactamases separated by FPLC System.
P'
ABCDEFGH I J K
A. Beta-lactamases produced by the E.coli J53-2 transconjugant of
K.pneumoniae 8825 purified by Sephadex gel filtration; B. Fraction 2
eluted from FPLC System; C. Fraction 3; D. Fraction 4; E. Crude
beta-lactamase preparation of the E.coli J53-2 transconjugant of
K.pneumoniae: F. Fraction 14 eluted from FPLC System; G. Fraction 13; H.
Fraction 15; I. As for E; J. Fraction 10 eluted from FPLC System; K.
Fraction 11.
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Fig. 34. FPLC System trace for the separation of the beta-lactamases
produced by the E.coli J53-2 transconjugant of K.pneumoniae 8825.
The broken line represents the increase in sodium chloride concentration.
The solid line represents protein concentration, measured at 280nm.
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3.7.6. Characterisation of beta - lactamases.
The hydrolytic activity cf each cf the three enzymes against six different
beta-lactam antibiotics are shown in table 45. The beta - lactamase which
focused at pi 5.4 aligned with TEM-1, it also had no hydrolytic activity
against ceftazidime or cefotaxime and was therefore assumed to be TEM-1.
The beta-lactamase of pi 6.5 had hydrolytic activity against cefuroxime,
cefotaxime, ceftazidime and had a greater activity for cephaloridine than
TEM--1. The fractions containing enzymes cf pi 7.9 and pi 8.1 had a similar
pattern of hydrolytic activities but the activity against the newer
cephalosporins must result from the enzyme of pi 7.9 and not the upper
E.coli J53-2 chromosomal beta-lactamase band, as control studies have
shown that this chromosomal enzyme has no hydrolysing activity against
these beta-lactam antibiotics. The beta-lactamase cf pi 7.9 was designated
as DJP-1.
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Thhle 45. *Relative rates of hydrolysis of FPUS System fractions.
Fraction: +Pooled 2-4 10-11 13-14
Beta-lactam pi: 7.9 & 8.1 6.5 5.4 (TEM-1)
Arpicillin 100.0 100.0 100.0 100.0
Carhenicillin 16.0 29.0 18.0 17.0
Cephaloridine 5.9 114.0 125.0 20.0
Ctefuroxime 2.9 4.3 17.0 LM
Cefotaxime 4.2 17.0 9.2 IM
Ceftazidime 1.5 4.6 14.0 LM
Values expressed as a percentage of the value for aitpicillin.
LM = unmeasurahle due to insufficient hydrolysis.
+Booled fractions = ocmbmed hydrolytic activity of Sephadex G-75
extract before purification by FPLC System.
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3.8. Studies on the satellite bands of beta - lactamases.
The isoelectric focusing of most beta - lactamases yield a main
beta-lactamase band along with smaller bands of slightly different pis
from the main band. These additional bands have been referred to as
beta-lactamase satellite bands. Simpson and Plested (1983) showed that the
different satellite bands of beta-lactamases produced by Citrobacter
diversus and Branhamella catarrhalis had similar substrate profiles,
molecular weights and susceptibilities to inhibitors. However, there is
little other documentation on the nature of these beta-lactamase bands.
The experiments discussed in section 3.8.1. led to an extensive
investigation of beta - lactamase satellite bands.
3.8.1. Investigation of the inducibilitv of the TEM-5 beta-lactamase.
K/pneumoniae CF504 produced the TEM-1, TEM-5 and SHV-1 beta-lactamases.
The genes encoding TEM-1 and TEM-5 were transferred to an E.coli J62-2
recipient strain. Both K.pneumoniae CF504 and the E.coli transconjugant
(designated E.coli Nb) were grown at different concentrations of
ceftazidime to establish whether TEM-5 was an inducible beta-lactamase.
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a. Procedure implemented to study the induction of TEM-5.
Qie hundred ml nutrient broth cultures of K.pneumoniae CF504 and E.mli Nb
were grown overnight in an orbital shaker at 37®C. Thirty ml of each of
the overnight cultures were added to two separate flasks containing 300ml
cf pre-warmed nutrient broth. These cultures were left on the orbital
shaker until the optical density of each culture reached 0.7 OD50q.
E.ooli Nb reached this absorbance after 3 hours and 50 minutes, whereas
the K.pneumoniae reached an absorbance of 0.8 in 2 hours. Fifty ml of
sterile nutrient broth were added to six 250ml conical flasks. Table 46
shows the volume cf a 6.4mg/ml ceftazidime solution which was added to
each flask to obtain the desired range of ceftazidime concentrations.
Finally, 50ml of the E.coli Nb culture were added to each of the six
flasks. This procedure was repeated with K.pneumoniae CF504. These
cultures were then incubated in the orbital shaker for 2 hours. The cells
from each broth culture were then harvested by centrifugation and crude
beta-lactamase preparations were made from each of the cell pellets (as
described in section 2.7). The protein concentrations of each of the 12
different enzyme samples were determined and their beta-lactamases
examined by IEF.
b. Isoelectric focusing of crude beta -lactamase preparations.
The volume of beta-lactamase sample loaded onto the IEF gel was
standardized so that an equal amount cf protein was added from each cf the
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Thhie 46. Composition of media used in induction experiments and the
absorhance reading of each culture prior to centrifugation.
Strain. Volume of 6.4mg/ml Concentration of Absorbance
ceftazidime ceftazidime of culture when
solution added (ml). in flask after harvested
culture added (CD500)•
(mg/L).
E.ooli Nb - - 0.80
E.ooli Nb 0.064 4 0.75
E.ooli Nb 0.125 8 0.70
E.ooli Nb 0.250 16 0.70
E.ooli Nb 0.500 32 0.70
E.ooli Nb 1.000 64 0.70
K.meumoniae CF504 - - 0.85
K.meumoniae CF504 0.125 8 0.80
K.meumoniae CF504 0.250 16 0.80
K.meumoniae CF504 0.500 32 0.71
K.meumoniae CF504 1.000 64 0.70
K.meumoniae CF504 2.000 125 0.71
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beta-lactamase preparations obtained from the different growth conditions.
The IEF gel is shown in fig. 35. K.pneumoniae CF504 appeared to express a
larger SHV-1 band as the concentration of ceftazidime was increased (not shown)„
However, no change in the intensities of the TEM-1 or TEM-5 bands were
observed in the preparations originating from either K.pneumoniae CF504 or
E.coli Nb.
However, as the concentration of ceftazidime in the broth cultures
increased there was a reciprocal increase in the intensity of a
beta-lactamase band of pi 5.2, this phenomenon was identified with both
the K.pneumoniae CF504 and E,coli Nb (fig. 35).
c. Antibiotic sensitivities.
In the following experiment, E.coli Nb was grown in a range of ceftazidime
concentrations as described in section 3.8.1a. but, just before the cells
were harvested, 5ml aliquots of each of the different cultures were
removed and their MICs of ceftazidime were directly determined. A loopful
from each of these 5ml aliquots was plated onto a nutrient agar plate and
incubated overnight at 37°C. The MICs of ceftazidime were also performed
on each of these strains.
The MICs of ceftazidime for each of these strains showed no significant
differences (table 47).
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Fig. 35. IEF of beta-lactamases produced by K. -pneumoniae CF504 and E.ooli
Nb grown with increasing concentrations of ceftazidime (narrow range IEF).
5.2 ■
ABC D E F G H I J K L M
Track M = TEM-2
Track Nb. A B C D E F G H I J K L
Strain. E.ooli Nb TEM- 1 K.meumoniae CF504
Gone, of CAZ
in broth (mg/L).
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Thhle 47. MICs of ceftazidime for E.ooli Nb strains grown at different
ooncentrations of ceftazidime.
Concentration Minimum inhibitory concentration of ceftazidime (mg/L).
of ceftazidime
in original MICs performed directly MICs performed on strains











d. Kinetic characteristics of beta - lactamase preparations.
The beta-lactamases produced by the E.coli Nb at each of the ceftazidime
concentrations were assayed for their ability to hydrolyse ceftazidime and
cephaloridine. All of these beta-lactamase preparations had similar rates
of hydrolysis against ceftazidime, when hydrolysis of cephaloridine was
taken as 100%. The values ranged between 3.6% and 4.3% with no significant
relationship with the increase in ceftazidime concentration (table 48). In
addition to this no significant trend was observed for the specific
activities of each beta - lactamase preparation for ceftazidime or
cephaloridine.
These experiments concluded that TEM-5 was not an inducible beta-lactamase
but a satellite band was induced as the concentration of ceftazidime was
increased.
3.8.2, Investigation of beta - lactamase satellite bands.
Experiments were set up to determine if satellite bands induced in the
experiments described in section 3.8.1. were actually caused by
ceftazidime interaction with the beta - lactamase proteins produced by
E.coli Nb or K.pneumoniae CF504.
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Tbhle 48. Brief biochemical characterisation of beta-lactamases produced
by E.coli Nb grown at different concentrations of ceftazidime.
Concentration of
CAZ in original 0 4 8 16 32 64 125 250
culture (mg/L).
Rate of hydrolysis
of CAZ (rate with 3.7 4.0 3.9 3.8 3.6 3.9 4.2 4.3
CER = 100%).
Specific ^ CER 6.85 9.04 6.89 8.27 8.14 6.34 4.16 4.29
activities .
CAZ 0.25 0.36 0.26 0.31 0.30 0.24 0.18 0.19
CAZ = ceftazidime.
£ER = cephaloridine.
measured in nmoles of substrate hydrolysed/minute/mg of protein.
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The beta-lactamase sample obtained from the E.coli Nb culture, grown in
the absence of ceftazidime, did not possess the satellite band of
approximate pi 5.2. This preparation was divided into six 0.1ml aliquots.
Table 49 shows the volume cf a 10mg/ml solution of ceftazidime which was
added to each 0.1ml aliquot to achieve a range of beta-lactamase samples
containing an increasing concentration of ceftazidime. Each of these
enzyme samples were immediately applied to an IEF gel. The volume of each
preparation leaded onto the gel was adjusted to take into account the
dilution caused by the addition of the ceftazidime solution.
The IEF gel (fig. 36) illustrates that the addition of ceftazidime to the
beta-lactamase samples promoted the same satellite band which was induced
by growing E.coli Nb in increasing concentrations of ceftazidime.
a. Effects of ceftazidime on the IEF of TEM-1.
The procedure described above was repeated with the TEM-1 beta-lactamase
derived from E.coli J53-2. 2136E. The amounts of a 40mg/ml solution of
ceftazidime added to each aliquot c£ enzyme, and the volumes loaded on to
the IEF gel are shown in table 50. The IEF illustrated that ceftazidime
had induced a satellite band from TEM-1 which had the same pi as the band
induced from the beta - lactamases of E ,coli Nb (fig. 37).
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T&hle 49. Composition of enzyne sanples electrophoresed in fig. 36.
Volume of 10mg/ml Concentration of Volume loaded
ceftazidime ceftazidime in onto IEF gel (ul).










Fig. 36. IEF gel illustrating how ceftazidime causes the production of an
extra satellite band.
P'
ABCDEFGH I J K
Tracks A-E are beta-lactamases prepared from E.ooli J62-2 transconjugant
of K.pneumoniae 2977E grown in increasing concentration of ceftazidime, A.
0, B. 4, C. 8, D. 16, E. 32 (mg/L of ceftazidime).
Tracks F-L are beta-lactamase preparations from the E.coli J62-2
transoonjugant of K.pneumoniae 2977E containing increasing concentrations
of ceftazidime, F. 0.1, G. 0.2, H. 0.4, I. 0.9, J. 1.7, K. 5.0 (mg/ml of
ceftazidime).
The TEM-5 band (pi 5.5) appeared to dissociate into two bands after
storage of the beta - lactamase preparation.
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b. Effects of incubation on the induction of beta-lactamase satellitp
bands.
A TEM-1 beta-lactamase preparation containing 5mg/ml was divided into two
aliquots, one of these aliquots was left at room temperature and the other
was incubated at 37°C for 2 hours. IEF analysis of these two samples
revealed that the incubation period had resulted in the induction of a
larger satellite band.
c. Effects of different beta-lactams on the TEM-1 beta-lactamase.
A TEM-1 beta-lactamase sample derived from E.ooli J53-2. 2136E was divided
into 13 0.1ml aliquots. 10ul of a 70mg/ml solution of 12 different
beta-lactam antibiotics were added to each of the aliquots to obtain a
final ceftazidime concentration of 6.4mg/ml. These preparations, including
the TEM-1 aliquot containing no ceftazidime, were incubated at 37°C for
2 hours. Each aliquot (5ul) was then loaded onto an IEF gel. Fig. 38
shows that each beta-lactam induced slightly different satellite bands
when compared with the TEM-1 control (containing no beta-lactam).
d. Effects of the addition of ceftazidime to other TEM derived 3GC
hvdrolvsinq beta - lactamases.
Beta-lactamase preparations of 16 TEM derived beta-lactamases were
prepared as described in section 2.7. The beta-lactamase activity of each
-189-
Fig. 38. Hie effect of different beta-lactams on the isoelectric focusing
of TEM-1.
Track. Beta-lactam added Cone, of beta-lactam in
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sample was determined by the nitrocefin spot test method (section 2.8) and
this determined the volume loaded onto the IEF gel. Two 0.1ml aliquots
were removed from each preparation and 0.01ml of a 70mg/ml solution of
ceftazidime was added to one of the aliquots to give a final ceftazidime
concentration of 6.4mg/ml. Both 0.1ml aliquots were then incubated at
37°C for 2 hours.
An equal volume of both aliquots, from each of the different
beta-lactamases, was examined by IEF. With the exception of the TEM-3 and
TEM-4 beta-lactamases, ceftazidime induced a satellite band in the region
of pi 5.2 with all the TEM derived beta-lactamases (figs. 39-41).
e. Examination of the satellite bands produced bv non-TEM like
beta-lactamases.
By implementing the same protocol as explained in section 3.8.2c the
effects of ceftazidime on the induction of satellite bands from PSE-1,
PSE-2, K-1 (chromosomal beta-lactamase from K.aerogenes 1082E), SHV-2, and
SHV-3 beta-lactamases were investigated. Fig. 42 showed that ceftazidime
induced no extra satellite bands from the PSE-1, or PSE-2 beta-lactamases.
The addition c£ ceftazidime to the chromosomal klebsiella beta-lactamase,
K-1, induced a beta-lactamase satellite band which was similar to the band
induced from the TEM beta-lactamases. SHV-2 and SHV-3 produced extra
satellite bands when mixed with ceftazidime but these were different to
those bands induced by ceftazidime from the TEM beta-lactamases.
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Fig. 39. Isoelectric focusing patterns of TEM like beta-lactamases, with
and without ceftazidime (Mutant beta - lactamase A - TEM-7).
P>
A. Mutant beta-lactamase A; B. Mutant beta-lactamase A + CAZ; C. TEM-E2;
D. TEM-E2 + CAZ; E. TEM-1; F. TEM -1 + CAZ; G. TEM-E1; H. TEM-E1 + CAZ; I.
Mutant beta-lactamase B; J. Mutant beta-lactamase B + CAZ; K. TEM-7; L.
TEM-7 + CAZ (+ CAZ = 7mg/L ceftazidime.
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Fig. 40. Isoelectric focusing patterns of TEM like beta-lactamases, with
and without ceftazidime (TEM-7 - TEM-2).
A. TEM - 7; B. TEM- 7 + CAZ; C. TEM - 9; D. TEM-9 + CAZ; E. TEM - 5; F. TEM-5 +
CAZ; G. TEM-E3; H. TEM-E3 + CAZ; I. TEM-10; J. TEM-10 + CAZ; K. TEM -2; L.
TEM- 2 + CAZ.
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Fig. 41. Isoelectric focusing patterns cf TEM like beta-lactamases, with
and without ceftazidime (TEM-2 - TEM-3).
A. TEM-2; B. TEM-2 + CAZ; C. Mutant beta - lactamase D; D. Mutant
beta-lactamase D +CAZ; E. TEM-E4; F. TEM-E4 + CAZ; G. Mutant
beta-lactamase D; H. Mutant beta-lactamase D + CAZ; I. TEM-4; J. TEM-4 +
CAZ; K. CTX-1; L. CTX-1 + CAZ (the arrow denotes the TEM-4 band).
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A. PSE-1; B. PSE-1 + CAZ; C. PSE-2; D. PSE-2 +CAZ; E. TEM-E4 +CAZ; F. K-1
(klebsiella chromosomal beta-lactamase); G. K-1 + CAZ; H. SHV-3; I. SHV-3
+ C AZ; J. SHV-2; K. SHV-2 + CAZ.
- 1 95-
f. Isolation of beta - lactamase satellite bands.
Fig. 43 track 1 shows the beta-lactamases produced by E.coli Nb grown in
the presence of ceftazidime (125mg/L). The E.coli Nb strain produced
TEM-1, TEM-5 and two prominent beta-lactamase satellite bands which
focused below TEM-1. Satellite band 1 was the band induced by the presence
of ceftazidime and has been fully described in the former sections.
Satellite band 2 focused between satellite band 1 and TEM-1 with an
approximate pi 5.3.
Each of these four bands were cut out of the IEF gel and separated from
the polyacrylamide gel by electrodialysis (as described in section
3.4.2d). The purified TEM-1 and TEM-5 aligned with the TEM-1 and TEM-5
bands of the original beta-lactamase preparation in track 1. When the
satellite band 1 was re-focused both the original satellite band and a
band which focused with a similar pi to TEM-1 were observed, a similar
phenomenon was demonstrated with the re-focusing of satellite band 2.
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Fig. 43. Illustration of how electrodialysis can be used to purify
beta-lactamase satellite bands from an analytical IEF gel.
A B C D E
A. TEM-5, TEM-1 and satellite bands 1 and 2 produced by E.coli Nb
grown at 125mg/L ceftazidime; B. Satellite band 1 (induced by ceftazidime,
pi 5.2) extracted from IEF gel by electrodialysis; C. Satellite band 2
extracted from IEF gel by electrodialysis (approximate pi 5.3); D. TEM-1
band extracted from IEF gel by electrcdialysis; E. TEM-5 band extracted
from IEF gel by electrodialysis.
-197-
4.0. DISCUSSION
It has been considered that the 3GC hydrolysing beta-lactamases occurred
from the TEM and SHV-1 resistance genes. This section discusses the
experiments which were performed to substantiate this theory, along with a
review of all the 3GC hydrolysing beta-lactamases which have been
identified.
4.1. Mutation experiments.
4.1.1. Comparison of mutants from this Thesis with those previously
reported.
All the mutant 3GC hydrolysing enzymes obtained spontaneously from
beta-lactamase producing strains which originally conferred no resistance
to 3GCs are listed in table 51.
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Previous reports of 3GC resistant mutants arising spontaneously from
TEM-1, have detailed only one type of mutant, called TEM-101 by Gutmann et
al. (1988) and TEM-121 to TEM-124 by Sougakoff et al. (1988). Both of
these enzymes confer an MIC cf ceftazidime cf 4mg/L and have a pi of 5.3.
This enzyme has a similar pi to Mutant enzyme A but it does not focus as
two distinct bands of equal intensity. Other reported mutant enzymes,
which were derived from TEM-2 were called TEM-201 by Gutmann et al. (1988)
and TEM-221 to TEM-225 by Sougakaff et al.(1988). these enzymes had the
same pi as TEM-7. Mutant enzyme B has a pi below TEM-7 and was obtained
from TEM-1, illustrating that Mutant enzyme B is clearly different from
other mutant enzymes previously reported.
Mutant beta-lactamase C and TEM-226 - TEM-223 (Sougakoff et al.. 1988^
were both obtained from TEM-2 and had pis of 5.6. However, Mutant
beta-lactamase C confers a greater resistance to ceftazidime than TEM-226
- 22q which suggests that these two mutant enzymes may not be identical.
Mutant beta-lactamase D was obtained spontaneously from TEM-2 and focused
marginally above TEM-2 at pi 5.61. Consequently, it was different from any
of the other previously reported mutant beta-lactamases.
Mutant beta-lactamase E was obtained from a non-TEM beta-lactamase. This
implies the worrying possibility that other non-TEM beta-lactamases may be
capable of mutating to create beta-lactamases which can confer
transferable resistance to 3GCs.
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4.1.2. Transferability of plasmids encoding Mutant beta-lactamases A to
E.
Mutant beta-lactamase A and B were freely transferable, although at low
frequency. The ceftazidime resistance conferred by Mutant beta-lactamase C
oould not be transferred when kanamycin was the selecting agent. However,
ceftazidime resistant colonies, producing Mutant beta - lactamase C, were
detected when ceftazidime was the selecting agent. As these colonies
occurred at a very low frequency, it is possible that they were mutant
colonies rather than true transconjugants. Therefore, the gene encoding
Mutant beta-lactamase C was very possibly chromosomally mediated.
Transfer experiments with Mutant beta-lactamases D and E, each revealed
much higher transfer frequencies when the selection was performed with
kanamycin than when performed with ceftazidime. No transconjugants were
detected when kanamycin and ceftazidime were used in combination as the
selecting agents. Consequently, it appears that ceftazidime kills the
transconjugants before they can produce sufficient quantities of the
ceftazidimase to protect themselves from the antibacterial effects of the
drug. However, it must be considered that the difference in transfer
frequency may be the result of the presence of two plasmids, one of which
has remained undetected.
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4.1.3. Selection cf mutant enzymes conferring high level resistance to
3gCs.
The experiments performed to obtain a mutant enzyme conferring high level
resistance were unsuccessful. Similarly, it was not possible to obtain a
mutant enzyme from TEM-E1 which would confer both cefotaxime resistance as
well as ceftazidime resistance. However, Vuye et al. (1989) have shown
that a clinically derived 3GC hydrolysing beta - lactamase, CAZ-lo, can
mutate spontaneously to CAZ-hi which confers up to 16 times more
resistance to ceftazidime. This work also showed that CAZ-hi is produced
by clinical isolates.
4.1.4. Relevance of spontaneous mutation experiments.
Table 52 illustrates the similarities between mutant beta-lactamases and
clinically derived beta-lactamases. Consequently, these experiments have
Illustrated the possible origins of TEM-7, TEM-E1, TEM-E2 and TEM-E4.
Mutant beta-lactamase C and CAZ-lo have Identical pis and confer similar
resistances. It is therefore probable that the two enzymes were the same.
This Illustrates that CAZ-lo may have evolved spontaneously from a TEM-2
producing organism.
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Thble 52. Mutant beta-lactamases which are similar to clinically derived
beta -lactamases.
Beta-lactamase obtained Corresponding beta- Reference,
by spontaneous nutation lactamase produced
of TEM-1/2. by clinical isolates.
TEM-201 TEM-7 Gutmann et al.. 1988
TEM-221 TEM-7 Souaakoff et al.. 1988L
TEM-222 - 225 TEM-7 Souaakoff et al.. 1988k
Mutant beta-lactamase A TEM-E2 This Thesis
Mutant beta-lactamase B TEM-E1 This Thesis
Mutant beta-lactamase C CAZ-lo This Thesis
Mutant beta-lactamase D TEM-E4 This Thesis




4.1.5. The use cf mutagens to obtain 3GC hvdrolvsing beta-lactamases.
The beta-lactamases obtained from TEM-1 and TEM-2 were only selected at
low levels of the drug and confer only a low level of resistance to
ceftazidime. Therefore, there must be another factor responsible for the
occurrence of those TEM-like enzymes which confer higher and broader
levels of 3GC resistance.
The initial isolation of some of the high level resistance TEM enzymes
were from patients undergoing a cocktail of drug treatment including
methotrexate and metronidazole. The effects of methotrexate and
metronidazole on the selection of 3GC hydrolysing beta-lactamases were
investigated but neither of these drugs gave any conclusive results.
However, further experimentation may reveal that other anticancer drugs or
drug combinations are the additional factors required to select for TEM-
Ifke beta-lactamases which give higher levels of 3GC resistance. It may be
that only powerful mutagens yield mutant beta-lactamases which confer high
level resistance to 3GCs. Indeed, it has been shown that CAZ - hi could be
obtained from CAZ-lo with more ease when using N-methyl-N'- nitro-
N- nitrosoguanidine (Vuye et al.. 1989).
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4.2. Clinically derived 3GC hvdrolvsing beta - lactamases.
All the 3GC hydrolysing beta-lactamases which have been previously
reported, along with those characterised in this Thesis, are summarised in
table 53.
As explained in the Introduction there have been a number of reports of
3GC hydrolysing beta-lactamases which have derived from the TEM
beta-lactamase gene. These enzymes have been designated TEM-3, TEM-4 and
so on. However, at the time when this work was performed there was
confusion in the literature over the next available TEM number.
Consequently, to avoid different beta-lactamases being assigned the same
TEM number, the "TEM-E" series of beta-lactamases was used. This
nomenclature denotes that the beta-lactamase is TEM-like and characterised
in Edinburgh. It is hoped that this will avoid the situation which arose
with TEM-10, this enzyme was originally referred to as TEM-8 (Quinn ^t
al.. 1988; Chanal et al.. 1989a), but later re-named TEM-10 (Quinn et al.
1 989).
4.2,1. The TEM-E1 beta - lactamase.
This enzyme is different to any of the previously reported 3GC hydrolysing
beta-lactamases, and has not been identified in any other strain, other
than the E.coli 7891 isolated in Belgium in 1987.
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4.2.2. The TEM-E2 beta - lactamase.
TEM-E2 was produced along with TEM-1, from which it was separated by the
quick and easy method of electrodialysis. It was shown that Mutant
beta-lactamase A has very similar properties to TEM-E2. The E.coli J53-2
strain producing Mutant beta-lactamase A exhibited a similar 3GC
resistance profile to the E.coli J53-2 transoonjugant producing TEM-E2 and
TEM-1. Therefore, as the mutant strain exhibited virtually no TEM-1
activity, it is apparent that the TEM-1 did not significantly contribute
towards ceftazidime resistance.
MIC studies and isoelectric focusing have revealed that TEM-E2 is probably
the same beta-lactamase as CAZ-3 (results not shown) but the isolation of
the strain producing TEM-E2 predates the discovery of CAZ-3 by five years.
The first plasmid mediated resistance to 3GCs was identified in Germany in
1983 (Knothe et_aL, 1983). This transferable resistance was later found
to be conferred by SHV-2. Therefore, as the original clinical isolate
producing TEM-E2 was isolated in 1982 the appearance of TEM-E2 represents
not only the earliest example of a transferable TEM-like beta-lactamase,
but also the first plasmid encoded beta-lactamase to confer resistance to
any of the new broader spectrum cephalosporins.
When K.oxvtoca 5445 was first isolated the ceftazidime resistance was
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quoted as "not being beta - lactamase mediated because only TEM-1 was
present". This illustrates that 3GC hydrolysing TEM-derived
beta-lactamases may have been in bacterial populations long before they
were actually identified, but they evaded correct identification because
they have pis very similar to TEM-1/2.
4.2.3. The TEM-E3 beta - lactamase.
Strains producing TEM-E3 have been isolated in two London Hospitals in
1987. A year after these strains were identified TEM-E3 was identified in
the USA, designated TEM-10 by Quinn et al. (1989). The similarities of the
TEM-E3 beta-lactamases were confirmed by their resistance profiles and
standard biochemical assays. These tests also successfully distinguished
TEM-E3 from TEM - 5 and TEM-9.
It is hard to conclude whether the occurrences of TEM-E3 in the two
different London hospitals were independent of each other because little
is known about the patient at the Royal Marsden Hospital from which
Enterobacter cloacae 7923 was isolated. It is not known whether the
patient had any indirect or direct contact with the North Middlesex
Hospital. Moreover, although the strains encoding TEM-E3 from the
different London hospitals were distinctly different, the plasmids
aicoding the two TEM-E3 beta-lactamases were very similar in size and they
could be related. It is more probable that the occurrence a£ TEM-E3 in the
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LBA vas an lrdeperdait event as the plasmid enocding the TEM-E3 enzyme was
significantly different from either pUK722 or pUK723.
4.2.4. The TEM-E4 beta - lactamase.
This beta-lactamase is different from any of the other previously reported
3GC hydrolysing beta-lactamases and has not been Identified in any other
strain other than the strain of Serratia marcescens 7919 isolated in
Belgium.
4.2.5. Properties of TEM-E1. TEM-E2. TEM-E3 and TEM-E4.
TEM-E1 to TEM-E4 show strong similarities with TEM-1 and many of the other
3GC hydrolysing TEM-like beta-lactamases. Furthermore, TEM-E1, TEM-E2 and
TEM-E4 can all be obtained spontaneously from a TEM-1 or TEM-2 producing
organism, which is strong evidence that all three of these enzymes were
TEM-derived. Also TEM-E1, TEM-E3 and TEM-E4 hybridise with a TEM-E1 probe
which hybridises with TEM-1 but not with SHV-1 or OXA-1 genes. There is a
68% homology between the amino acid sequences of TEM and SHV (Barthelemy
et al. 1988a). Therefore, the probe is fairly specific to TEM sequences.
The mutation and probing experiments confirm that the genes encoding
TEM-E1 to TEM-E4 are highly homologous with the nucleotide sequence of
TEM - 1/2.
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4.3. K.pneurooniae 8825 and the use cf Fast Protein T.irjmri Chromatography
System 1FPLC System) to purify beta - lactamases.
This work has shown that Fast Protein Liquid Chromatography System is the
most powerful method to date in the separation of multiple beta-lactamases
produced by the same strain. Its rapid, complete separation cf the enzymes
enabled the biochemical characterisation of each individual beta-lactamase
and permitted an assessment of how each beta-lactamase contributed to the
range c£ beta-Iactam resistances expressed by the host strain. It was thus
possible to show that two of the enzymes produced by the clinically
derived K.pneumoniae 8825 strain confer resistance to cefuroxime,
cefotaxime, ceftriaxone and ceftazidime. Evaluation of the biochemical
profile cf each of these enzymes strongly suggests that the beta-lactamase
pi 7.9 (beta-lactamase DJP-1) is a novel 3GC hydrolysing enzyme. However,
the plasmid mediated beta-lactamase of pi 6.5 may be the same as CAZ-hi
(Vuye et al.. 1989) or CAZ-6 (Chanal et al.. 1989b), both of which have a
reported pi of 6.5. The majority of transferable 3GC resistance has arisen
in France, Germany, and the UK. where broad spectrum cephalosporin usage
is high. However, these two broad spectrum enzymes were found to be
produced by a strain isolated in India where the use of these newer
cephalosporins is much lower. The occurrence of these two beta-lactamases
is the first report cf transferable 3GC resistance in either India or even
Asia. It is also the first example of two broad spectrum beta-lactamases
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encoded by the same plasmid.
4.4. The BIL-1 beta - lactamase.
The original clinical isolate which produced BIL -1 contained a number of
plasmids. BIL-1 was shown to be transferable from this strain to a number
of other recipient strains from a range of different species (work
performed by the Antibiotic Reference Laboratory, PHLS Colindale).
However, following a series of conjugation experiments involving the
transfer of the BIL-1 gene, a transoonjugant which expressed BIL-1, was
fcund to possess a single 28 Mdal plasmid. This plasmid could not be
transferred to another E.coli recipient. This suggested that BIL -1 was
encoded by a plasmid which was not freely transferable and possibly relied
on the presence of other plasmids to mobilise its transfer.
Previously, all the other plasmid mediated beta-lactamases which confer
resistance to 3GCs have been shown to have derived from the ubiquitous
TEM-1/2 and SHV-1 resistance genes. All of these TEM- or SHV- derived
beta-lactamases are sensitive to clavulanic acid and hydrolyse penicillins
and certain cephalosporins.
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However, BIL-1 differs from TEM-1/2 or SHV derived beta-lactamases for the
following reasons;
a. It confers transferable resistance to clavulanic acid, cefoxitin as
well as all generations of cephalosporins.
b. It is resistant to inhibition by clavulanic acid.
c. It does not hydrolyse ampirn 111 n, cefuroxime, ceftazidime or cefotaxime
although it confers resistance to all these beta-lactams.
d. Ampirn 11 in, cefuroxime and ceftazidime (at concentrations less than
10uM) inhibit the hydrolytic activity of BIL-1.
BIL-1 closely resembles the isoelectric focusing characteristics and
biochemical hydrolysis profiles of the chromosomally mediated
beta-lactamases of Enterobacter cloacae (Seeberg et al.. 1983) and E.coli
(Minami et al.. 1980b). Therefore, BIL-1 is the first example of a
beta-lactamase which confers transferable resistance to all generations of
cephalosporins, cefoxitin, and clavulanic acid. This work also illustrates
the first report c£ a gene encoding a Class C-like (Ambler, 1980), or a
Class I chromosomal beta-lactamase (Richmond and Sykes, 1973) which has
migrated into plasmid DNA.
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The plasmid- carriage c£ the HTL-1 gene and the in vitro transfer studies
to bacteria c£ different species raises the worrying possibility that this
resistance gene may well be capable cf migrating into diverse genera of
clinical bacteria by in vivo transfer. Although no direct patient-to-
patient spread of the strain or the resistance gene was observed it is
possible that this could take place, especially if patients who are prone
to infection are in close proximity. Therefore, it is suggested that
patients transferred from outside the UK and harbouring bacteria with
unknown resistance genes should be kept separate from patients prone to
infection.
Shannon et al. (1990) expressed a similar concern when they suspected that
strains producing 3GC hydrolysing SHV-like beta-lactamases, isolated from
patients at St. Thomas Hospital London, were acquired by the patients in
Egypt and Greece.
4.6. Classification of plasmid mediated 3GC hvdrolvsing beta-lactamases.
The 3GC hydrolysing beta-lactamases can be categorised into three groups
by virtue of their efficiency of hydrolysis values for ceftazidime and
cefotaxime relative to ampicillin or penicillin. This method of
classification was chosen because it takes into account both the binding
and the hydrolysis capabilities of the enzymes with ceftazidime and
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oefataxime. These two beta-lactams were selected because they were the two
substrates most consistently tested by other workers and they produced a
relatively varied effect with each cf beta-lactamases listed in table 53.
As there are not efficiency of hydrolysis values for all the 3GC
beta-lactamases not all the 3GC beta-lactamases have been classified in
this scheme. Those enzymes which have had their hydrolytic capabilities
measured only in terms of Vmax or rate of hydrolysis are listed in a
separate table.
4,6.1. Group I (table 54).
All cf these enzymes hydrolyse both cefotaxime and ceftazidime with very
low efficiency. In most cases they hydrolyse cefotaxime with slightly
greater efficiency than ceftazidime. This is a paradox as all the
beta-lactamases confer far greater resistance to ceftazidime than
cefotaxime. This phenomenon will be discussed in greater detail in section
4.6.5.
-218-
Ibhle 54. Group I
TEM-E1 TEM-E2 1EM-E4 TEM-7 CAZ-3
(1EM-E2)
Benzylpenicillin 100
Atpicillin 100 100 100 100
Ceftazidime 1.1 0.7 0.1 0.4 0.3
(32) (32) (16) (16) (32)
Cefotaxime 2.5 1.5 0.8 0.3 0.4
(0.13) (0.25) (<1) (0.06) (0.5)
Reference a a a b c





Arpicillin 100 100 100
Ceftazidime 29 33 20 6.1
(250) (64) (125) (256)
Cefotaxime 20 16 12 1.8
(2) (0.5) (1) (4)
Reference a a a c
See end of table 56 for references.
MICs shewn in parenthesis; in all cases MTC values are for
E.ooli K12 transoonjugants of the original clinical isolates.
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4.6.2. Group II (table 55).
These beta-lactamases all hydrolyse ceftazidime more efficiently than
cefotaxime and confer high level resistance to ceftazidime. However, TEM-9
and the TEM-E3 beta-lactamase all have significant efficiency of
hydrolysis values for cefotaxime but confer almost no resistance to the
drug.
4.6.3. Group III (table 56).
All these enzymes hydrolyse cefotaxime more efficiently than ceftazidime.
However, the majority of the beta-lactamases confer a greater resistance
to ceftazidime than cefotaxime (see section 4.6.5.).
4.6.4. Those beta-lactamases not classified in Groups I-III.
Seme 3GC hydrolysing beta-lactamases have only been characterised by their
Vmax or relative rates of hydrolysis of different beta-lactam substrates.
These enzymes are listed in table 57. As discussed previously such data
does have deficiencies but can be used in rough approximations of the
specificities of different beta - lactamases.
DJP-1 hydrolyses ceftazidime, cefotaxime and cefuroxime, but the strain
producing DJP-1 produces one other 3GC hydrolysing beta-lactamase.
Therefore, it is not possible to deduce the MICs conferred by just this
-220-
Idble 56. Group III.





Penicillin 100 100 100 100 100 100
Tmpicillin 100 100
Ceftazidime 2 17 11 17 1 3 5.6 0.06
(16) (64) (128) (512) (4) (128) (128) (13)
Cefotaxime 18 23 51 21 10 16 25 67
(8) (16) (2) (8) (4) (32) (8) (200)
Reference d d c c e f f g
MICs shewn in parenthesis; in all cases MIC values are for
E.coli K12 transoonjugants of the original clinical isolates.
References.
a This Thesis
b Gutmann et al. 1988
c Chanal et al. 1989b
d Chanal et al. 1988b
e Gutmann et al. 1989
f Sirot et al. 1989
g tfetsumoto et al. 1988
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enzyme. TEM-4 and SHV-3 appear to have a higher hydroiytLc activity with
cefotaxime than ceftazidime and may be Group III 3GC hydrolysing
beta-lactamases. Conversely, CAZ-hi and TEM-6 have a greater hydrolytic
activity with ceftazidime. Both these enzymes confer a greater resistance
to ceftazidime than to cefotaxime. This suggests that these enzymes may be
Group II 3GC hydrolysing beta-lactamases.
CAZ-lo has low activity with the 3GCs tested and confers greater
resistance to ceftazidime than to cefotaxime. This implies that CAZ-lo is
a Group I beta-lactamase.
FUR has a much higher rate of hydrolysis cf cefuroxime than ceftazidime or
cefotaxime, and confers high level transferable resistance to cefuroxime.
This enzyme may represent the start of a new series of plasmid mediated
beta-lactamases.
The values listed for MJ -1 and MJ - 2 and the enzyme characterised by
Deschaseaux et al. (1988) suggests that all these enzymes confer
transferable resistance to 3GCs, but insufficient data are available to
make any other conclusions.
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4.6.5. Correlation between MICs and efficiency of hydrolysis of
ceftazidime and cefotaxime.
The majority cf these beta-lactamases either hydrolyse cefotaxime more
efficiently than ceftazidime or hydrolyse cefotaxime and ceftazidime with
fairly similar efficiencies. However, most of the 3GC hydrolysing
beta-lactamases confer a greater resistance to ceftazidime than
cefotaxime. This suggests that cefotaxime is more permeable to the
bacterial cell than ceftazidime and can reach its antibacterial target
more efficiently.
Nikaido (1989) verified this hypothesis when he showed that cefotaxime
diffused into liposomes reconstituted with E.coli Omp F or Omp C proteins
at higher relative rates than ceftazidime. Nikaido et al. (1990) also
showed that cefotaxime permeated intact E.coli cells at a greater rate
than ceftazidime and that cefotaxime permeated liposomes reconstituted
with Enterobacter cloacae F porin at greater rates than ceftazidime.
Likewise, cefotaxime also had a higher permeability coefficient for intact
Ent.cloacae cells than ceftazidime (Nikaido et al.. 1990). Although the
outer membrane proteins of the E.coli transconjugants used for MICs in
tables 54-57, were not known in any great detail, Nikaido's results prove
that cefotaxime is more permeable than ceftazidime. This helps to explain
the paradox concerning the efficiency of hydrolysis values and MIC values
for ceftazidime and cefotaxime.
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4.6.6. Correlation between sequences of the TEM enzymes and their
hvdrolvtic activities.
Many cf the 3GC hydrolysing beta-lactamases have been sequenced (reviewed
by Philippon et al.. 1989) and, like TEM-3, they differ from either
TEM-1/2 or SHV-1 by only a few amino acid residues. The majority- of these
amino acid changes are distant from the active serines which represent the
catalytic centres of the SHV-1 and TEM -1 beta-lactamases. However, these
slight changes allow these new enzymes to hydrolyse 3GC, which the former
TEM-1/2 or SHV-1 beta-lactamases cannot achieve. As there is a significant
homology between the amino acid sequences of the Staphylococcus aureus PC1
beta-lactamase and the TEM beta-lactamase it has been postulated that the
tertiary structure of the TEM protein is very similar to the three
dimensional structure of the PC1 enzyme which has been deduced by Herzberg
and Moult (1987). This has enabled the amino acid changes which facilitate
hydrolysis cf 3GCs to be visualised on a three dimensional model of the
TEM enzyme. Therefore, although the amino acid changes seemed distant from
the active serines, when presented as a linear sequence, the tertiary
folding of the TEM-1/2 beta-lactamase illustrated that these changes were
actually in close proximity to the active serines of the TEM
beta -lactamases.
At the moment it is difficult to correlate a particular amino acid change
with a particular type of hydrolysis. For example it is not known which
amino acid change is essential for a highly efficient hydrolysis of
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ceftazidime. As more TEM or SHV enzymes are sequenced this will supply a
wealth of information which will build up a greater understanding of the
active sites of this new series of beta - lactamases.
However, it must be noted that there is only 30% homology between the
amino add sequences cf the S. aureus PC1 enzyme and TEM -1 (Arakawa st
al.. 1986). Therefore, accurate assumptions regarding the active sites of
these new enzymes can only be made when studying the three dimensional
structure of the TEM beta-lactamase.
4.6.7. Consideration of other factors which mav be responsible for the
resistances conferred bv the 3GC hvdrolvsing beta -lactamases.
o.
The work of Sougakaff et al. (1988) on TEM-3 showed that the amino acid
K
changes may not be the only factors responsible for the resistances
conferred by 3GC hydrolysing beta-lactamases.
TEM-3 differs from TEM-2 by only two amino acid residues (table 58). Table
59 shows the resistances conferred by each of these amino acid changes
with different promoters. Promoter Pa+Pb is identical to the promoter
encoding TEM-3 and promoter P3 is the beta-lactamase promoter of pBR322
which is 10 times less effident than the Pa +Pb promoter. These results
show that the two amino acid changes in TEM-3 are not sufficient for the
high level resistance to 3GCs. A strong promoter initiating transcription
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Thble 58. Carparison of the amino acid sequences of TEM-2 and TEM-3.
Amino acid residue No. 104 238
Beta-lactamase
IBM-2 glutamate (glu) glycine (gly)
TEM-3 lysine (lys) serine (ser)
Ttihle 59. The effects of praroters on the 3GC resistance oonferred fcy
TEM-3.
Amino acid changes








MIC cefotaxime >64 0.125 1 1
MIC ceftazidime >64 2.0 0.5 32
Thken from Sougakoff et al. (198^).
The numbering system is that of Arihler, 1980.
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cf the structural gene for the new enzyme is also required (Sougakoff gt
£l. 1 9 8 8*.
A
4.7. 3GC hvdrolvsing beta-lactamases - are thev currently a problem ?
There have been about 60 plasmid mediated beta-lactamases characterised
since 1974; surprisingly almost half this number have been 3GC hydrolysing
beta-lactamases characterised in only the last five years. However, out of
the 28 beta-lactamases listed in table 53 only 7 have been reported to be
expressed by more than 10 strains. 3GC hydrolysing beta-lactamases have
created few problems in the UK and, on every reported case in this country
there has been almost no spread of the strain or resistance plasmid. In
contrast the 3GC hydrolysing beta-lactamases, and in particular TEM-3,
have created major problems in French hospitals. The emergence cf TEM-3 in
France appeared not only related to the selective pressures of 3GCs but
also to those of amikacin or netilmicin (Sirot et al. 1988). So the
emergence and spread of new TEM enzymes may not be directly related to the
increase in use of 3GCs. Although these outbreaks initially create huge
prohlems, Brun-Buisson et al. (1987) showed that the attack rate of a
TEM-3 producing, multiresistant K.oneumoniae was reduced from 6% to 1% in
six months. This was achieved by a regime of hand washing and use of
disposable gloves for handling urine from infected or colonised patients.
- 228 -
4.8. 3GC hvdrolvsinq beta-lactamases - are they a future threat to the
use of 3GCs.
The 3GC hydrolysing beta-lactamases have created the most severe problems
in France. Indeed, the majority cf initial reports of the enzymes in table
53 have come from French hospitals. In the UK, which has not had major
problems with 3GC hydrolysing beta-lactamases, far less 3GCs are used than
in France. Therefore, it is logical to suggest that as the future use of
3GCs increases because of the increased resistance to first and second
generation cephalosporins, so the occurrence of both novel and established
3GC hydrolysing beta-lactamases will increase also. However, it is also
possible to obtain strains producing ceftazidimases and cefotaximases in
countries where 3GCs are not widely available and where selective pressure
is low. For example BIL-1 and Ttpnenmnniap 8825, which produces two 3GC
hydrolysing beta-lactamases, both came from third world countries where
3GC availability is restricted by cost.
As discussed previously, the 3GC hydrolysing SHV and TEM beta-lactamases
can be obtained spontaneously from SHV-1 and TEM-1/2 beta-lactamases
respectively. Therefore, any strain which produces TEM-1 or SHV-1 are
potential producers of 3GC hydrolysing beta-lactamases. Table 5
(Introduction) shows that TEM-1 and SHV-1 are two of the most ubiquitous
beta-lactamases found in bacterial populations. Moreover, calculations
from a survey conducted by Wiedemann et al. (1989) on 802 clinical
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isolates, showed that 17% cf clinical isolates produce either TEM-1/2 or
SHV-1. Therefore, a quarter of all clinically derived strains are
potential producers of 3GC hydrolysing beta-lactamases. Consequently, it
is surprising that those beta-lactamases such as TEM-7, TEM-E1, and
TEM-E4, which have been shown to be obtainable from TEM-1/2 spontaneously,
are not more prevalent. Conversely, the worldwide reports cf SHV-2 may be
explained by the fact that SHV-2 can be obtained spontaneously from SHV-1.
Hie occurrence c£ novel plasmid mediated 3GC hydrolysing enzymes appear to
crop up as "chance mutations" and, in most cases, they do not spread
throughout bacterial populations. The spread of one of these enzymes
through bacterial populations appears to depend more on the pathogenicity
of the strains involved, stability of the plasmid encoding the
beta-lactamase, the other resistance markers on the plasmid and the
consistency cf the selective pressure to stabilise the resistance plasmid
(not necessarily a 3GC). If all these factors are satisfied then a
particular 3GC hydrolysing beta-lactamase could, cause a significant threat
to 3GC therapy .
Mother worrying possibility is that the 3GC hydrolysing beta-lactamases
may have the selective advantage to become as successful as their
predecessors. The evidence to date does not suggest this but, if the use
of 3GCs increases significantly, then the situation may well change. It
could also be hypothesised that because of the similarities with other
non-3GC hydrolysing beta-lactamases, many of these ceftazidimases and
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cefotaxiraases may have remained undetected in current bacterial
populations. Lastly, all the SHV and TEM derived beta-lactamases are very-
sensitive to beta-lactamase inhibitors such as clavulanic acid, sulbactam
or YTR 830, and special emphasis has been placed on this fact in many
publications (Kit zis et al.. 1988; Paul et al.. 1989; Gutmann et al..
1989). However, if BIL-1 represents a new series of plasmid mediated
beta-lactamases then both the future of beta-lactams and beta-lactamase
inhibitors will be under threat.
4.9. Studies on satellite bands of beta-lactamases.
This work illustrated that the mixing of beta-lactam antibiotics with
beta-lactamases produced beta-lactamase satellite bands. Extraction of TEM
satellite bands, induced by the addition of ceftazidime, from an
isoelectric focusing gel and the subsequent re-focusing of this
preparation revealed not only the satellite band but also a band which
focused in close proximity to TEM-1. It is probable that this was TEM -1,
but, because of irregularities in the polyacrylamide gel, it did not align
exactly with the TEM-1 from the original preparation. Therefore, during
the extraction of the satellite protein it had probably reverted back to
the TEM-1 protein. This suggested that both these proteins must be very
similar in structure. This provides the proof for the hypothesis that
beta-lactamase satellite bands differ only very slightly from the main
beta - lactamase protein.
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It is prdbahle that on mixing the beta-lactam with the beta-lactamase,
some cf the beta-lactam molecules bind to the beta-lactamase causing some
distortion in its three dimensional structure. It is proposed that these
distorted proteins may have slightly different physicochemical constants
to the main beta-lactamase protein which is why they reveal themselves as
satellite bands with different pis from the main beta - lactamase band.
It was shown that different beta-lactams caused satellite bands of
different pis to be produced. It was surprising that ceftazidime and
cefotaxime did not produce the same satellite band, as it would be
expected that they would bind to similar positions on the TEM-1 protein
and cause a similar distortion. However, it may be that different
beta-lactams bind to different sites on the same beta - lactamase or that
the range of beta-lactams studied all bind at the same site but cause
different types of distortions to the protein.
It was noted that when ceftazidime was added to most TEM-like
beta-lactamases it produced the same satellite band of pi 5.2. When
ceftazidime was added to a selection of non-TEM beta-lactamases this
satellite band was not normally seen. However, it was seen that the
klebsiella chromosomal beta-lactamase, K-1, produced a similar satellite
band at pi 5.2 but this may result from the fact that there is significant
amino acid homology between K-1 and TEM-1 (Emanuel et al.. 1986).
Consequently, the addition of ceftazidime to a beta-lactamase preparation
can help to verify whether the enzyme is TEM derived.
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4.10. Conclusions.
1. It has been shown that some of the 3GC hydrolysing beta-lactamases
produced by clinical isolates are obtainable spontaneously from TEM-1/2
beta-lactamases. This strongly implies how they originated in bacterial
populations.
2. The characterisation cf TEM-E1, TEM-E2, TEM-E3, TEM-E4, DJP-1, and
BIL-1 has shown that all these beta-lactamases confer transferable
resistance to 3GCs. At the time when these enzymes were characterised they
were novel to any of the previously reported beta-lactamases.
3. Klebsiella oxvtoca 5445 was isolated in 1982 and shown to produce
TEM-E2. This suggests that plasmid mediated resistance to 3GCs existed in
bacterial populations many years before it was actually reported.
4. The 3GC hydrolysing beta-lactamases can be classified into three groups
by virtue cf their efficiency of hydrolysis of ceftazidime or cefotaxime.
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Group I.
Those beta-lactamases which hydrolyse both cefotaxime and ceftazidime with
low efficiency.
Group II.
Those beta-lactamases which hydrolyse ceftazidime with greater efficiency
than cefotaxime.
Group III.
Those beta-lactamases which hydrolyse cefotaxime with greater efficiency
than ceftazidime.
5. Electrodialysis of beta-lactamases from polyacrylamide gel and Fast
Protein Liquid Chromatography System are both major advances for the
efficient purification and separation of multiple beta-lactamases produced
by the same strain.
6. It has been proved that the proteins which produce satellite bands on
isoelectric focusing of beta-lactamases can revert back to the parent
protein. Also the binding of beta-lactams to beta-lactamases cause the
production of specific satellite bands.
Transferable resistance to 3GC at this present time does not appear to be
a major clinical problem. However, the next five years will reveal the
true nature of this threat and whether any of these enzymes have the
capabilities to become as prevalent as the TEM-1/2 or SHV-1
beta -lactamases.
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1. SUMMARY
A novel /3-lactamase, conferring resistance to
ceftazidime, has been identified to be encoded by
a 31 kb plasmid (pUK720) in a clinical E. coli
strain isolated in Belgium. The /3-lactamase, new
designated TEM-E1, has a p/ of approximately
5.4 and lies in between the iso-electric focused
bands of the ^-lactamases TEM-1 and TEM-7.
The TEM-E1 /3-lactamase has a similar molecular
weight of 22000 to the TEM-1 and it is also
inhibited by clavulanic acid. However, the TEM-
E1 enzyme differs from TEM-1 by its low rates
and efficiency of hydrolysis for ceftazidime and
cefotaxime, TEM-E1 has similar efficiency of hy¬
drolysis values for ceftazidime and cefotaxime, but
only confers resistance to ceftazidime.
2. INTRODUCTION
There have been a number of recent reports on
the novel plasmid-mediated /3-lactamases TEM-3
to TEM-7, RRH-1, and CAZ-2 [1,2,3]. Although
some of these enzymes are known, by nucleotide
sequence analysis, to have evolved from TEM-
l/TEM-2 /3-lactamases [1,4,5], they differ from
these two prototype enzymes because they confer
resistance to third generation cephalosporins. This
communication reports a novel TEM-like enzyme,
identified in a clinical E. coli strain isolated in
Belgium, which confers resistance to ceftazidime
and is distinct from the other 3GC hydrolysis
enzymes previously reported.
3. MATERIALS AND METHODS
Antibiotic sensitivity tests and plasmid trans¬
fers were determined on solid media as before [6].
The minimum inhibitory concentrations (MIC) for
ampicillin, ceftazidime and cefotaxime were also
measured in the presence of clavulanic acid (2
mg/1) or sulbactam (2 mg/1). The method of
Takahashi and Nagano [7] was used to extract,
separate and visualize plasma DNA. /3-lactamase
preparations were obtained from 1 litre cultures of
the ceftazidime resistance transconjugant strain E.
coli J53-2. The enzyme was identified by analyti¬
cal isoelectric focusing [8] with sonicated bacterial
extracts. /3-lactamase activity, substrate profile,
Michaelis-Menten kinetics and the effect of in¬
hibitors were determined by spectrophotometric
assays [9-11]. The molecular weight of the /3-
lactamase was determined on a calibrated Sep-
hadex G075 column (2 cm2 X 90 cm) eluted with
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4. RESULTS
The clinical strain E. coli 7891 was isolated
from the urine of a patient attending a hospital in
Belgium in 1987. The ceftazidime resistance gene
could be transferred easily into the rifampicin-re-
sistant strain E. coli J53-2. This transconjugant
was resistant to ceftazidime (MIC = 32 mg/1 at
105 cfu) but sensitive to all the other third genera¬
tion cephalosporins tested.
4.1. Conjugation experiments
E. coli J5302 transconjugants were selected on
agar containing ceftazidime (4mg/l) and rifampi-
cin (50 mg/1) after overnight mixed incubation of
the donor and recipient strains. When the original
clinical isolate, E. coli 7891, was examined for
plasmic DNA, to DNA bands were identified
(sizes 31 kb, and 3 kb) and these two bands were
also seen in the ceftazidime resistant transcon¬
jugant. The ceftazidime-resistance gene was be¬
lieved to be located on the 31 kb plasmid which
we have designated pUK720.
4.2. Antibiotic sensitivity
The MIC data shows that both the clinical
strain and the E. coli J5302 transconjugant were
ceftazidime resistant, which is the only additional
resistance conferred when compared to a TEM-1
producing strain (Table 1). The strains expressing
the novel enzyme were seen to be sensitive to
ceftazidime in the presence of clavulanic acid (2
mg/1) or sulbactam (2 mg/1). Clavulanic acid was
the more efficient inhibitor when used in combi¬
nation with ampicillin, but the two inhibitors
seemed to be equally effective when third genera¬
tion cephalosporins were used as substrates.
4.3. Isoelectric Focusing
Then /(-lactamase produced by E. coli 7891 and
the E. coli J5302 transconjugant were examined
by analytical isoelectric focusing (IEF) employing
a broad range ampholine (pH 3.5-10). Both strains
produced identical enzymes of low p7 which were
barely distinguishable from the TEM-1 /(-lacta¬
mase. The /(-lactamase band was, however, quite
clearly distinguishable from the other transferable
third generation cephalosporin hydrolysing en-
Table l
Antibiotic susceptibilities of strains
(8-lactam Minimum inhibitory concentrations (mg/1)
E. coli E. coli *E. coli E. coli
7891 7891 J53-2 J53-2
X J53-2 2136E
Ampicillin > 250 > 250 > 250 4
A + clav 4 2 2 2
B + sulb 32 8 ~ 250 4
Methicillin > 250 > 250 > 250 8
Carbenicillin > 250 > 250 > 250 4
Cephaloridine 64 32 8 4
Cephalexin 16 8 4 8
Cefoxitin 8 1 1 2
Cefuroxime 16 2 2 2
Ceftazidime 16 32 < 0.06 0.13
A + clav 0.5 0.25 < 0.06 0.13
B + sulb 1 0.25 < 0.06 <0.06
Cefotaxime 0.25 0.13 < 0.06 < 0.06
A + clav < 0.06 <0.06 < 0.06 <0.06
B + sulb < 0.06 <0.06 <0.06 <0.06
Ceftriaxone 0.25 0.13 <0.06 <0.06
Aztreonam 1 0.13 <0.06 <0.06
Imipenem 0.25 0.5 0.13 0.25
Augmentin 32 16 16 8
A + clav = in combination with clavulanic acid (2 mg/1);
B + sulb = in combination with sulbactam (2 mg/1).
* E. coh J53-2 2136 E produces TEM-1.
zymes. The enzyme from strain 7891 was re-ex¬
amined by IEF with a 1:1 mixture of pH 4-6 and
pH 3.5-10 ampholines to increase the sensitivity.
The TEM-1, TEM-2 and TEM-7/(-lactamases were
used as standard p7 markers and the novel /(-
lactamase was found to focus between TEM-1 and
TEM-7 enzymes (Fig. 1).
4.4. Molecular weight determination
A crude extract of the ceftazidime resistant
transconjugant was applied to a sephadex G-75
column, calibrated with the standard proteins
ovalbumin, chymotrypsinogen and cytochrome C.
The size of the novel enzyme was 22000 which
was indistinguishable from the TEM-1 n/(-lacta-
mase when estimated by the same method.
4.5. Kinetic characteristics
The substrate profiles of the TEM-1 /(-lacta¬
mase and that from the E. coli J53-2 transcon¬




Fig. 1. Isoelectric focusing pattern of the plasmic encoded
/^-lactamase derived from strain 7891, compared with the en¬
zymes TEM-1, TEM-2 and TEM-7 over a narrow pH range. A.
E. coli J53-2 producing TEM-1; B. E. coli 7891 producing
TEM-E1; C. E. coli J53-2 transconjugant of E. coli 7891
producing TEM-E1; D. E. coli BM694 producing TEM-7; E.
as C. F. E. coli J53-2 producing TEM-2.
are similar for carbenicillin, ampicillin, and
cephaloridine. However, the novel enzyme showed
a low but significant rate of hydrolysis of ceftazi¬
dime and cefotaxime, whereas the TEM-1 enzyme
Table 2










* Rate for ampicillin = 100%.
Table 3








N.D. not done because break down was insufficient.
* Efficiency with ampicillin = 100%.
showed no hydrolysis of either substrate. The Km,
Fmax and the relative efficiency of hydrolysis
(Vmax/Km, ampicillin = 100%) values for TEM-1
and TEM-E1 for five /8-lactam substrates are
shown in Table 3. The efficiency of hydrolysis of
ceftazidime and cefotaxime by TEM-E1 were very
similar; equal to or less than 2.5% of the rate for
ampicillin.
4.6. Inhibition studies
When assayed for the hydrolysis of nitrocefin,
the novel /3-lactamase was sensitive to inhibition
by clavulanic acid (ID50 = 0.63 jttM).
5. DISCUSSION
The properties of the enzyme from strain 7891
and, in particular, its isoelectric focusing pattern
confirm that this plasmid-mediated enzyme from
Belgium is not identical to any of the other trans¬
ferable /^-lactamases responsible for third genera¬
tion cephalosporin resistance [1]. The kinetic
parameters of enzyme TEM-E1 were very similar
to those of the TEM-7 //-lactamase [13] and the
rates and efficiency of hydrolysis of ceftazidime
and cefotaxime observed for both these enzymes
are low but very similar. However, both the en¬
zyme derived from 7891 and the TEM-7 /J-lacta-
mase confer much higher resistance to ceftazidime
than cefotaxime. It was found that TEM-7 enzyme
and the //-lactamase from strain 7891 could be
effectively distinguished by their different isoelec¬
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Characterisation of a unique ceftazidime-hydrolysinger
lactamase, TEM-E2 l^(%
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Summary. A strain of Klebsiella oxytoca, originally isolated in Liverpool in 1982, has
been found to produce a novel transferable /(-lactamase, TEM-E2. This enzyme
confers resistance to ceftazidime and focused as a doublet band with an iso-electric
point (pi) of 5-3. The strain also produced the TEM-1 /(-lactamase. Both TEM-1 and
TEM-E2 /(-lactamases were encoded by a transferable 103 kb plasmid; these two
enzymes also had similar molecular weights, were inhibited by clavulanic acid, and
hydrolysed ampicillin, carbenicillin and cephaloridine at similar rates. However,
unlike the TEM-1 enzyme, the TEM-E2 /(-lactamase hydrolysed ceftazidime and
cefotaxime with similar efficiency, although it conferred much greater resistance to
ceftazidime in the host strain. This is the earliest documented example of a TEM-like
enzyme which confers transferable resistance to ceftazidime and related cephalo¬
sporins.
Introduction
When cefotaxime and ceftazidime were first
introduced, they were resistant to hydrolysis by
most of the plasmid-mediated /(-lactamases that
were known at that time, including the TEM-1 and
TEM-2 enzymes.1'2 However, there have since
been several reports of /(-lactamases, which differ
from TEM-1 and TEM-2 by only a few amino
acids, that are able to hydrolyse these and related
cephalosporins.3 Between 1984 and June 1987, 490
strains producing TEM-3 (which exhibits high
activity against cefotaxime) were isolated in
France.4 In 1987 and 1988 the novel enzymes TEM-
4, 5, 6, 7, 9 and CAZ-2 were identified;5-7 all
appear to be related to the TEM group of /(-
lactamases. We now describe a ceftazidime-resist-
ant strain of Klebsiella oxytoca, isolated in 1982,
which produces a /(-lactamase that hydrolyses




K. oxytoca strain 5445 was isolated from the blood and
cerebrospinal fluid of a baby in the Neonatal Intensive
Received 5 June 1989; revised version accepted 29 Nov. 1989.
/•Correspondence should be sent to Dr S. G. B. Amyes.
Care Unit of Liverpool Maternity Hospital on Feb. 5,
1982. Rifampicin-resistant Escherichia coli J53-2 was
used as the standard recipient strain in the conjugation
experiments.8 E. coli 153-2 transconjugants were selected
on agar containing rifampicin 100 mg/L and ceftazidime
4 mg/L after overnight incubation of a mixture of the
donor and recipient strains.9
Antibiotic sensitivities andplasmid analysis
Minimum inhibitory concentrations (MICs) of /(-
lactam antibiotics were determined by the agar incorpo¬
ration method in Iso-Sensitest Agar (Oxoid), with a
bacterial inoculum of 10s cfu. In certain experiments,
clavulanic acid or sulbactam was included in the medium
at a concentration of 2 mg/L. The method of Takahashi
and Nagano10 was used to extract, separate and visualise
plasmid DNA.
/3-Lactamase studies
Bacteria were grown overnight in 1 L ofNutrient Broth
No. 2 (Oxoid) containing ceftazidime 4 mg/L, and /(-
lactamase preparations were obtained from sonicated
extracts of the concentrated bacterial pellet.11 The /(-
lactamases were identified by analytical iso-electric
focusing (IEF) of these extracts;12 /(-lactamases PSE-4,
TEM-1, TEM-2 and TEM-7 were used as standard pi
markers. /(-Lactamase activity, substrate profile, Michae-
lis-Menten kinetics and the effect of inhibitors were
determined by spectrophotometric assays according to
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published methods.13-15 The relative molecular mass
(Mr) of the //-lactamase was determined on a Sephadex
G-75 column (2 cm2 x 90 cm) eluted with 25 mM phos¬
phate buffer (pH 7-0) at a flow rate of 16ml/h.16
Ovalbumin, chymotrypsinogen and cytochrome C were
used as standard Mr markers.
Purification of the TEM-E2 (3-lactamase by
electrodialysis
A crude //-lactamase solution, prepared from the E.
coli J53-2 transconjugant of K. oxytoca 5445, was spread
on to an analytical IEF polyacrylamide gel containing
pH 6-8 and pH 4-6 ampholines (LKB Pharmacia) in a
1:1-5 ratio. Care was taken not to cover the area of the
gel where the //-lactamase bands focused. After focusing,
a 1-cm wide strip of filter paper soaked in a solution of
nitrocefin (0-5 mg/ml) was placed from the cathode to the
anode of the gel to identify the //-lactamase bands. The
portion of the gel containing the TEM-E2 enzyme was
cut out and placed in dialysis tubing with a minimal
amount of 25 mM sodium phosphate buffer (pH 7-0). The
dialysis sack was placed in the cathode reservoir of a Bio
Rad Mini Sub Cell with 25 mM phosphate buffer (pH 7-0)
as running buffer. A charge of 150 V was applied for
lOmin. The dialysis sack was then removed and the
polyacrylamide gel was discarded. The purity of the
enzyme remaining in the sack was analysed by IEF.
Results
Conjugation experiments
The ceftazidime-resistant transconjugants of E.
coli J53-2 were obtained by conjugation with K.
oxytoca 5445 at 37°C for 6 h. Analysis of the
plasmid DNA in the transconjugant strains showed
a single large plasmid band of 103 kb, designated
pUK721, similar to that found in the original
clinical strain.
Antibiotic sensitivities
K. oxytoca 5445 and the E. coli J53-2 transconju¬
gant were resistant to ceftazidime but sensitive to
cefotaxime and ceftriaxone. Indeed, ceftazidime
resistance was the most significant additional fI-
lactam resistance conferred by plasmid pUK721
when compared with a TEM-1 //-lactamase produc¬
ing strain (table I). Susceptibilities to ceftazidime
were restored in the presence of clavulanic acid
(2 mg/L) or sulbactam (2 mg/L). However, clavu¬
lanic acid was more efficient than sulbactam in
reducing MICsof ampicillin.
Table I. Antibiotic sensitivities of test strains
Minimum inhibitory concentrations (mg/L)
E. coli E. coli
K. oxytoca J53-2 J 5 3-2 E. coli
Antibiotic 5445 x 5445 2136E* J 5 3-2
Ampicillin >250 >250 >250 4
+ clav 16 8 2 2
+ sulb 125 250 >250 4
Carbenicillin >250 >250 >250 8
Cephaloridine 250 64 8 4
Cephalexin 16 8 4 4
Cefoxitin 16 4 1 2
Cefuroxime 16 4 2 2
Ceftazidime 64 32 <0-06 0-13
+ clav 1 0-25 <0-06 0-13
+ sulb 2 0-5 <0-06 <0-06
Cefotaxime 0-5 0-25 <0-06 <0-06
+ clav <0-06 <0-06 <0-06 <0-06
+ sulb <0-06 <0-06 <0-06 <0-06
Ceftriaxone 0-5 0-13 <0-06 <0-06
Aztreonam 2 1 <0-06 <0-06
Imipenem 0-25 0-25 0-13 0-25
+ clav, in combination with clavulanic acid 2 mg/L;
+ sulb, in combination with sulbactam 2 mg/L.
*Strain 2136E produces TEM-1.
fj-Lactamase studies
Analytical IEF with a broad range ampholine
(pH 3-5-10) revealed that K. oxytoca 5445 and the
E. coli J53-2 transconjugant produced //-lactamases
of low pi. IEF with a 1:1 mixture of pH 4-6 and
pH 3-5-10 ampholines showed that the clinical
isolate and the E. coli transconjugant each produced
a band which co-focused with TEM-1 and a novel
//-lactamase which focused as a doublet band at
pi 5-3 (figure). This novel //-lactamase, TEM-E2,
was clearly distinguishable from any of the other
ceftazidime-hydrolysing //-lactamases.1' The
TEM-E2 doublet band produced by K. oxytoca
5445 was separated from the TEM-1 band by
electrodialysis from the IEF polyacrylamide gel
(figure).
The Vmax and Km values of the TEM-E2 and
TEM-1 enzymes are shown in table II. Neither
enzyme had any measurable activity against cefu-
roxime. TEM-1 had no activity against ceftazidime
but showed some affinity for cefotaxime. TEM-E2
showed activity against both substrates but had a
greater affinity for cefotaxime. Both enzymes
showed similar relative efficiency of hydrolysis of
ampicillin, carbenicillin and cephaloridine (table
II). However, the novel enzyme paradoxically
hydrolysed ceftazidime less efficiently than cefotax-
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ime. Hydrolysis of nitrocefin by TEM-E2 was
inhibited by clavulanic acid (ID50 0-8 /iM). The Mr
of TEM-E2, purified by electrodialysis from an
analytical IEF gel, was 23 500. Under the same
experimental conditions, the Mr of the TEM-1
enzyme was 22 000. However, this difference may
not be significant. The crude TEM-E2 enzyme
preparation (i.e., with the TEM-1 enzyme) was
analysed by gel filtration and fractions were
collected from either side of the peak of /i-lactamase
activity; examination of each of these fractions by
IEF showed that they all contained the TEM-1
band and the doublet band, thus confirming their
identical Mr.
Discussion
The novel //-lactamase, TEM-E2, is different
from any of the previously reported enzymes that
hydrolyse cephalosporins of the cefotaxime type.
Its kinetic characteristics appear similar to those of
other TEM-like enzymes such as TEM-E118 and
TEM-719 in that it hydrolysed cefotaxime and
ceftazidime with similar, low efficiencies although
it conferred resistance only to ceftazidime. The
novel enzyme showed similarities with TEM-1,
from which it could be separated by electrodialysis.
An enzyme with very similar properties to TEM-
E2 has been obtained from a TEM-1 producing
strain by spontaneous mutation.17 This strongly
suggests that TEM-E2 has been derived from the
TEM-1 /I-lactamase. Moreover, as themutant strain
exhibited virtually no TEM-1 activity, it is apparent
that the TEM-1 enzyme did not contribute towards
ceftazidime resistance. The first example of plas-
mid-mediated resistance to cefotaxime was identi-
Tabie II. Kinetic constants of TEM-E2 compared to those of TEM-1
TEM-E2 TEM-1
Km Km
Antibiotic (/iM) V *" max Vma</Kmt (fM) V "T max Vmax/Kmt
Ampicillin 119 100 100 167 100 100
Carbenicillin 83 23 32 100 11 18
Cephaloridine 500 87 20 167 23 23
Cefuroxime UM UM UM UM UM UM
Cefotaxime 181 0-84 0-55 286 0-06 0-04
Ceftazidime 500 0-87 0-21 UM UM UM
UM, unmeasurable.
"Relative to ampicillin as 100%.




A B C D
Figure. 1EF of /1-lactamases. A, E. coli J53-2 producing TEM-1;
B, TEM-E2 ^-lactamase purified from TEM-1 by electrodialysis
from IEF gel; C, E. coli J53-2 transconjugant of K. oxytoca 5445
producing TEM-1 and TEM-E2; D, K. oxytoca 5445 producing
TEM-1 and TEM-E2.
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fled in Germany in 1983.20 This transferable
resistance was later found to be conferred by the
SHV-2 ^-lactamase.21 Since the K. oxytoca 5445
strain discussed in this study was isolated in 1982,
TEM-E2 is the earliest example of a TEM-like
enzyme which can hydrolyse ceftazidime, and also
the first plasmid-encoded ^-lactamase to confer
resistance to any of the new broader-spectrum
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Mutants of the TEM-1 /^-lactamase conferring resistance to ceftazidime
"Department of Bacteriology, The Medical School, University of Edinburgh, Teviot
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Ltd, Greenford Road, Greenford, Middlesex UB6 OHE, UK
Spontaneous ceftazidime resistant mutants were obtained from an Escherichia coli
K12 J62-2 expressing the TEM-1 /(-lactamase (mutation frequency = 10 9). These
mutants produced /(-lactamases with similar molecular weights, kinetic parameters
and isoelectric points (pi) to the /(-lactamases produced by ceftazidime resistant
clinical isolates which have recently been identified in this laboratory. Mutant
enzyme A focused as a doublet band at pi 5-3 with an additional weak pi 5-4 band.
The doublet co-focused with the TEM-E2 /(-lactamase, produced by a ceftazidime
resistant Klebsiella oxytoca isolate, which was originally obtained in a Liverpool
hospital. Mutant enzyme B had a pi identical to the TEM-E1 /(-lactamase produced
by a ceftazidime resistant clinical isolate of E. coli found in Belgium. These results
suggest that the two /(-lactamases in the clinical strains may have come from simple
mutations of the TEM-1 /(-lactamase gene.
Plasmid mediated /(-lactamases conferring resistance to third generation cephalosporins
were present as early as 1982 (Payne, Marriott & Amyes, submitted for publication).
Since then TEM-3 to TEM-7, RHH-1 and CAZ-2 /(-lactamases have been reported
(Chanal et al., 1988; Sougakoff et ai, 1988; Spencer et al., 1988). Kinetic analyses of
these enzymes have shown that they have distinct similarities to the TEM-1 and TEM-2
/(-lactamases. Moreover, amino-acid sequencing performed on some of these enzymes
has provided evidence that they differ from TEM-1 and TEM-2 enzymes by only a few
amino-acid residues (Collatz et al., 1988; Petit et al., 1988a; Sougakoff et al., 1988). It
has been reported that TEM-1 and -2 enzymes can give spontaneous mutants that
hydrolyse third generation cephalosporins (Gutmann et al., 1988; Sougakoff et al.,
1988). In this study two novel mutant enzymes have been obtained directly from
TEM-1 /(-lactamase. These mutants differ from all those found in other studies but are
identical to two novel /(-lactamases which we have recently found in clinical isolates.
Bacterial strains
Klebsiella oxytoca 5445 was isolated in 1982 at a Liverpool hospital and produces
TEM-E2 /(-lactamase. This is believed to be the earliest example of a plasmid mediated
*Corresponding author.
D. J. Payne", M. S. Marriott* and S. G. B. Amyes" *
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//-lactamase conferring resistance to third generation cephalosporins (Payne, Marriott
& Amyes, submitted for publication). Escherichia coli 7891 was isolated from the urine
of a patient attending a hospital in Belgium and produces the novel third-generation
cephalosporin hydrolysing enzyme TEM-EI (Payne, Marriott & Amyes, 1989). Rifam-
picin resistant E. coli K12 J53-2 (pro- met ) and E.coli K12 J62-2 (pro- his- trp ~)
strains were used as recipients in conjugation experiments (Bachmann, 1972). An E. coli
J62-2 transconjugant of Klebsiella pneumoniae CF504 (Petit et al., 1988b) which
produced only TEM-1 //-lactamase and not the TEM-5 enzyme present in the K. pneu¬
moniae strain was used as the parent in the spontaneous mutation experiments.
Spontaneous mutation experiments
A 10-ml overnight nutrient broth culture (Oxoid No. 2) of E.coli K12 J62-2,
harbouring the TEM-1 //-lactamase coding plasmid was harvested by centrifugation
and resuspended in 1 ml of 25 mM phosphate buffer (pH 7 0). Aliquots (01 ml) of this
suspension were inoculated on to ten Isosensitest Agar (Oxoid) plates containing
0-7 mg/1 ceftazidime. This was the lowest ceftazidime concentration that eradicated all
the ceftazidime sensitive bacteria at this abnormally high inoculum. Ceftazidime
resistant colonies were purified on fresh ceftazidime-containing plates and the growth
requirements of each selected colony were checked to verify that they were E. coli J62-2.
The identity of the mutants was further checked by API 20E strips. These strains were
then examined for any change in //-lactamase profile.
Antibacterial drug susceptibilities and plasmid analysis
Minimum inhibitory concentrations (MIC) of antibacterial drugs were determined on
solid media at a cell concentration of 10s cfu as described previously by Amyes &
Gould (1984). The MICs of ampicillin, ceftazidime and cefotaxime were additionally
measured in the presence of clavulanic acid (2 mg/1) and sulbactam (2 mg/1). The
method of Takahashi & Nagano (1984) was used to extract, separate and visualise
plasmid DNA.
Conjugation experiments
In all mating experiments 01 ml of an overnight culture of the donor strain was mixed
with 1 ml of an overnight culture of the recipient strain in 4-5 ml of nutrient broth, as
described previously by Amyes & Gould (1984). This mixture was then incubated at
37°C for 6h. E.coli J53-2 transconjugants of the two clinical stains were selected on
agar containing rifampicin (50 mg/1) and ceftazidime (4 mg/1). E. coli J53-2 transconju¬
gants of the TEM-1 mutants were selected on Davis-Mingioli minimal agar (Davis &
Mingioli, 1950) containing proline (50 mg/1), methionine (50 mg/1) and ceftazidime
(4 mg/1). All kinetic studies were performed on enzymes isolated from the ceftazidime-
resistant E. coli J53-2 transconjugants.
//-Lactamase studies
//-Lactamase preparations were obtained from ultrasonicates of overnight Oxoid
Isosensitest broth cultures containing ceftazidime (4 mg/1) (Simpson, Harper & O'Cal-
laghan, 1980). The //-lactamases were identified by analytical isoelectric focusing (IEF)
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(Matthew et al., 1975) of bacterial sonicates. The /^-lactamases TEM-1, TEM-2, TEM-7
and PSE-4 were used as standard pi markers. The enzymes were first examined on
polyacrylamide gels containing a broad range ampholine (pH 3-5-10). They were
subsequently re-examined on similar gels containing a 1:1 mixture of pH 4-6 and
pH 3-5—10 ampholines, to provide a narrow pH range and increase sensitivity. Enzyme
substrate profile, Fmax, Km, and inhibitor studies were determined by spectrophoto¬
metry assay (Sykes et al., 1981; Eliasson & Kamme, 1985; Reid & Amyes, 1986). The
relative molecular masses (Mr) of the /^-lactamases were determined on a calibrated
Sephadex G-75 column (2 cm2 x 90 cm) eluted with 25 mM phosphate buffer (pH 7 0) at
16 ml/h (Andrews, 1964).
Results
Preparation of TEM-1 fl-lactamase parent strain
K. pneumoniae CF504 was a clinical strain isolated in Clermont-Ferrand, France. It was
resistant to ceftazidime and cefotaxime and the gene encoding these resistances was
located on a 150 kb plasmid (pCFF14) (Petit et al., 1988b). Isoelectric focusing showed
that this strain also produced TEM-1 /I-lactamase as well as the TEM-5 enzyme
responsible for the cephalosporin resistances. This strain was conjugated with the
rifampicin-resistant E. coli J62-2 and transconjugants were selected on Isosensitest agar
plates containing rifampicin and ceftazidime. The transconjugants were purified and
their purity checked. Analysis of the plasmid DNA revealed that the transconjugant
had lost the 150 Kb plasmid (pCFF14), which encodes the TEM-5 /I-lactamase (Petit et
al., 1988b), and possessed only a 100 Kb plasmid along with two smaller plasmids. This
transconjugant reverted to the normal characteristics of a TEM-1 ^-lactamase
producing E. coli J62-2. This strain was used as the parent in the spontaneous mutation
experiments. The rationale for this was that there should be a higher chance of
obtaining a third generation cephalosporin-hydrolysing mutant enzyme from a TEM-1
/^-lactamase gene in a strain that was host to a TEM-like third generation cephalo¬
sporin-hydrolysing ^-lactamase than a standard laboratory strain hosting only the
TEM-1 /f-lactamase gene.
Selection ofmutants
The ceftazidime-resistant mutants, which appeared at a frequency of 1 in 109, were
purified and examined for any change in /^-lactamase profile. In all the colonies studied,
ceftazidime resistance was associated with the mutation of the TEM-1 /^-lactamase gene
to produce one of two different /^-lactamases (mutant enzymes A and B). We examined
20 colonies and the mutant ^-lactamases they produced. This revealed that the ratio of
occurrence of enzyme A to enzyme B was 4:1. The genes encoding the mutant /?-
lactamases were transferred by conjugation into E. coli J53-2, with selection of the
transconjugants on ceftazidime-containing plates. The transfer of the plasmids elevated
the MIC of ceftazidime for the E. coli J53-2 recipient more than 60-fold, from 013 to 8-
16mg/l (Table I). The transferability of the resistance determinant confirmed that the
mutation had occurred to a plasmid encoded gene and not on the chromosome. Both
the original mutants and their J53-2 transconjugants possessed the 100 Kb plasmid, but
the two smaller plasmid bands were seen only in the original mutant strains.
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Isoelectric focusing
Mutant enzyme A focused as a doublet band at pi 5-3 with an additional weak band
that cofocused with TEM-1 enzyme. The TEM-E2 /^-lactamase expressed by the
ceftazidime resistant isolate, K. oxytoca 5445 produced an identical doublet band at
pi 5-3, but exhibited a much stronger TEM-1-cofocusing band. Mutant enzyme B
showed distinct similarities to enzyme TEM-E1 produced by the clinical isolate E. coli
7891. Mutant enzyme B and TEM-E1 co-focused and had a pi marginally above the
TEM-1 enzyme but below the TEM-7 /1-lactamase (Figure 1).
Minimum inhibitory concentrations
E. coli J53-2 transconjugants expressing the mutant enzymes and the transconjugants
expressing the clinically obtained extended spectrum ^-lactamases were all resistant to
ampicillin, carbenicillin, cephaloridine, ceftazidime, and aztreonam. However, they
were sensitive to all other cephalosporins tested including cefotaxime (Table I). Clavu-
lanic acid and sulbactam were similar in their activity when cefazidime was used as the
principal antibiotic. However, clavulanic acid was seen to be the more efficient /?-
lactamase inhibitor when used in combination with ampicillin (Table I).
ABCO EFG H
Figure 1. Isoelectric focussing patterns of mutant enzymes and ^-lactamases from clinical isolates over a
narrow pH range. A, PSE-4; B, mutant A; C. TEM-E2; D, TEM-1; E, mutant B; F, TEM-E1; G, TEM-7; H,
TEM-2.
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Table II. "Relative rates of hydrolysis and molecular masses of //-lactamases TEM-1, TEM-E1,
TEM-E2, and mutant enzymes A and B
Relative rates of hydrolysis of //-lactams
//-lactamase M® ampicillin carbenicillincephaloridine cefuroxime ceftazidime cefotaxime
TEM-E1 22.0 100 29.8 42.1 0.25 0.31 1.48
Enzyme B 24.0 100 17.4 68 0.55 1.11 1.36
TEM-E2 25.5 100 19.3 41.6 0.22 0.23 0.58
Enzyme A 23.5 100 26.3 38.2 0.52 0.92 2.27
TEM-1 22.0 100 10.9 18 0.014 0.017 0.014
"Rate for ampicillin= 100%.
Molecular mass.
Biochemical profiles of the mutant (I-lactamases, TEM-E1, and TEM-E2
The two mutant enzymes and the two enzymes from clinical isolates all had molecular
masses indistinguishable from the TEM-1 //-lactamase (Table II). The substrate profiles
of these four enzymes are compared to TEM-1 in Table II. The profiles were similar to
TEM-1 for ampicillin, carbenicillin and cephaloridine. However, both the mutant
enzymes and the //-lactamases from clinical strains showed a low but significant rate of
hydrolysis of ceftazidime and cefotaxime, whereas the TEM-1 enzyme showed no
hydrolysis of either of these substrates. The relative Fmax and the Km values for these
enzymes against a number of //-lactams were determined. These values were combined
to give the relative efficiency of hydrolysis values (relative compared with
ampicillin = 100%) which takes into account both the binding and the hydrolysis
capabilities of the enzyme for a particular //-lactam. The relative efficiency of hydrolysis
values for ceftazidime and cefotaxime by TEM-E1, TEM-E2, mutant A, and mutant B
were very similar (Table III). All the enzymes were inhibited by clavulanic acid with I50s
in the region of 0-5-0-8 pu.
Discussion
Previous reports of third generation cephalosporin resistant mutants arising sponta¬
neously from TEM-1, have detailed only one type of mutant, called TEM-101 by
Gutmann et al. (1988) and TEM-121 to TEM-124 by Sougakoff et al. (1988), for which
the MIC of ceftazidime was 4 mg/1 and the //-lactamase pi 5-3. This enzyme had a
Table III. "Relative efficiency values for TEM-E1, TEM-E2, and the mutant
enzymes A and B
//-Lactam //-Lactamases
antibiotic TEM-E1 enzyme TEM-E2 enzyme TEM-1
B A
Ampicillin 100 100 100 100 100
Carbenicillin 18 7 9 16 18
Cephaloridine 134 76 78 81 110
Ceftazidime 1.1 2.1 0.69 3.3 ND
Cefotaxime 2.5 0.9 1.5 6.1 0.16
"Efficiency with ampicillin = 100%.
ND, Not done because breakdown was insufficient.
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similar pi to mutant enzyme A but it did not focus as two distinct bands of equal
intensity. Other reported mutant enzymes, derived from TEM-2, were called TEM-201
by Gutmann et al. (1988) and TEM-221 to TEM-225 by Sougakoflf et al. (1988). These
enzymes had the same pi as TEM-7. Mutant enzyme B differed in having a pi below
TEM-7 and in being obtained from TEM-1. Thus mutant enzyme B was clearly
different from other mutant enzymes previously reported. The mutant enzymes and the
clinically derived enzymes all hydrolysed both ceftazidime and cefotaxime at similar
rates and efficiencies but, surprisingly, only conferred resistance to ceftazidime and not
cefotaxime. Amino-acid sequencing has shown that TEM-4 and TEM-5 are more
similar to TEM-1 than TEM-2 (Petit et al., 1988u) and, consequently, these two
enzymes are believed to have been derived from TEM-1. However, the sequences of the
TEM-3 and TEM-7 enzymes (Collatz et al., 1988; Sougakoff et al., 1988) include the
one amino-acid change which distinguishes TEM-2 from the TEM-1 enzyme and they
are therefore thought to have evolved from the TEM-2 //-lactamase. This study has
shown how two //-lactamases, indistinguishable from similar enzymes present in clinical
strains, have been obtained in vitro from a TEM-1 producing organism, suggesting that
TEM-E1 and TEM-E2 had similarly evolved from TEM-1.
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1. SUMMARY
We have devised a reliable procedure for the
separation of three //-lactamases of isoelectric
focusing points (pi), 5.4, 6.5, and 7.9 by Fast
Protein Liquid Chromotography (FPLC System).
All of these enzymes were transferable and
originated from a ceftazidime and cefotaxime re¬
sistant Klebsiella pneumoniae isolated in Bombay,
India. The complete separation of the enzymes,
achievable by this method, allowed each of the
different individual //-lactamases to be char¬
acterised biochemically. This analysis revealed that
the enzymes of p7 6.5 and pi 7.9 hydrolysed
ceftazidime and cefotaxime, and were responsible
for the resistance of K. pneumoniae, and its
Escherichia coli J53-2 transconjugant to third gen¬
eration cephalosporins. The enzyme of pi 5.4 was
the TEM-1 //-lactamase. The //-lactamase of p7
Correspondence to: S.G.B. Amyes, Department of Bacteriology,
The Medical School, University of Edinburgh, Teviot Place,
Edinburgh EH8 9AG, U.K.
FPLC System is a Registered Trade Mark of Pharmacia LKB
Biotechnology.
7.9 appears quite different from any previously
reported third generation cephalosporin hydrolys-
ing //-lactamase, and consequently given the pre¬
liminary designation DJP-1. This is also the first
example of extended spectrum hydrolysing //-
lactamases found in Asia.
2. INTRODUCTION
There have been recent reports of transferable
//-lactamases which confer resistance to broad
spectrum cephalosporins [1-8]. These enzymes
have been derived from the SHV and TEM //-
lactamase genes [1], In some cases these new en¬
zymes are produced along with other transferable
//-lactamases of different isoelectric points and
sometimes these distinct //-lactamases are encoded
by the same plasmid. Consequently, the investiga¬
tion and characterisation of these enzymes would
prove to be very difficult as they must be com¬
pletely separated from the other //-lactamases. As
many of these enzymes have similar molecular
sizes, separation techniques based on the enzyme's
ionic charge have been employed. This can be
0378-1097/90/S03.50 © 1990 Federation of European Microbiological Societies
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achieved by techniques such as preparative iso¬
electric focusing (IEF) which was used to isolate
TLE-2 from TEM-1 and SHV-1 [9] and electro-di¬
alysis which was used to separate TEM-E2 from
TEM-1 [8]. However, these methods are time con¬
suming and the amount and purity of the enzyme
recovered is unsatisfactory. We have developed a
Fast Protein Liquid Chromatography (FPLC Sys¬
tem) technique for the rapid separation of three
different //-lactamases produced by a ceftazidime
and cefotaxime resistant Escherichia coli J53-2
transconjugant of a Klebsiella pneumoniae strain.
In the past reverse phase High Performance Liquid
Chromatography (HPLC) techniques have been
used to purify //-lactamases such as SHV-1 [10],
and FPLC System has been implemented to purify
an inducible //-lactamase produced by Proteus
vulgaris [11], and a //-lactamase from Clostridium
butyricum [12], but neither procedure has ever
been used to separate three plasmid encoded //-
lactamases produced by the same strain.
3. MATERIALS AND METHODS
3.1. Strains
Klebsiella pneumoniae 8825 was isolated from a
lymphoma patient at the Tate Memorial Hospital,
Bombay, India. The rifampicin resistant E. coli
J53-2 was used as the recipient strain in conjuga¬
tion experiments.
3.2. Conjugation experiments
One ml of an overnight nutrient broth (Oxoid)
culture of E. coli J53-2 and 0.1 ml of an overnight
culture of K. pneumoniae were incubated with 4.5
ml of nutrient broth for 6 h at 37 °C. The E. coli
J53-2 transconjugants were selected on agar con¬
taining ceftazidime (1 mg/1) and rifampicin (50
mg/1) or carbenicillin (100 mg/1) and rifampicin
(50 mg/1).
3.3. Antibiotic susceptibilities
Minimum inhibitory concentrations (MIC) of
antibacterial drugs were determined on Diagnostic
Sensitivity Test Agar (Oxoid) at a concentration
of 105 cfu as described previously by Amyes and
Gould (1984) [13]. The MICs of ampicillin.
cefotaxime and ceftazidime were additionally
measured in the presence of clavulanic acid (2
mg/1).
3.4. (3-lactamase preparation
One litre of nutrient broth containing ceftazi¬
dime (4 mg/1) was inoculated with the E. coli
J53-2 transconjugant of K. pneumoniae 8825 and
grown overnight at 37 ° C. The cells were harvested
by centrifugation for 15 min at 6000 X g. The
bacterial pellets were washed in 25 mM sodium
phosphate buffer (pH 7.0) and the centrifugation
was repeated as described before. One ml of 25
mM sodium phosphate buffer (pH 7.0) was then
added to the final pellet and the cells were resus-
pended to give 3 ml of cell suspension which was
disrupted by ultrasound [14], The cell lysate was
cleared by centrifugation for one hour at 32000 X
g. All of this crude //-lactamase preparation was
applied to a Sephadex G-75 gel filtration column
(2 cm2 X 90 cm) and eluted with 25 mM sodium
phosphate buffer (pH 7.0) at 15 ml/h [15]. The
column was calibrated with chymotrypsinogen, cy¬
tochrome c, and ovalbumin. The fractions which
exhibited //-lactamase activity were pooled and
dialysed against 50 mM Tris-HCl buffer (pH 8.2)
overnight.
3.5. /3-lactamase identification
The //-lactamases were identified by analytical
IEF on polyacrylamide gels [16] containing a 1 :1
ratio of pH 3.5-10 and pH 4-6 ampholines (LKB).
The substrate profiles of the //-lactamases were
determined by assaying their hydrolytic activity
against fixed concentrations of six different (3-
lactam drugs [14], The rates of hydrolysis were
expressed relative to ampicillin.
3.6. Fast protein liquid chromatography
Separation of the //-lactamases was carried out
with the Pharmacia FPLC System consisting of
LCC 500 Plus Controller, UV-M Monitor, FRAC
100 with an HR5/5 Mono Q column. The column
was equilibrated with 50 mM Tris-HCl buffer (pH
8.2). Two ml of the //-lactamase sample (from the
pooled peak fractions obtained by gel filtration
with the Sephadex G-75 column) were added to
the column. Separation was achieved by elution
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with a linearly increasing concentration of sodium
chloride (in the above buffer) to a maximum con¬
centration of 1 M. Approximately, 34 fractions (1
ml) were collected from each 30 min separation.
Each aliquot was tested for /(-lactamase activity
by the chromogenic cephalosporin nitrocefin spot
test [17].
5.7. Preparation ofplasmid DNA
The method of Takahashi and Nagano [18] was
used to isolate and visualize the plasmid DMA of
the E. coli J53-2 transconjuganf of K. pneumoniae
8825. The plasmid samples were run on an 0.5%
agarose gel with plasmids R1 (89 kb), R6K (38 kb)
as standards for large plasmids.
4. RESULTS
4.1. Conjugation experiments and plasmid analysis
experiments
E. coli J53-2 transconjugants of K. pneumoniae
8825 were detected on agar plates containing
ceftazidime or carbenicillin. The frequency of
transfer on the ceftazidime and rifampicin was
1.18 X 10~6 per donor cell, and the transfer
frequency for the selection on carbenicillin and
rifampicin was 3.53 X 10"6 per donor cell. Analy¬
sis of the plasmid DNA in the E. coli J53-2
transconjugant revealed plasmids of 100 kb and
2.5 kb (Fig. 1). This suggested that the /(-lacta¬
mase genes conferring resistance to carbenicillin
and ceftazidime were either one and the same or
they were located on the same plasmid.
4.2. Antibiotic susceptibilities
The K. pneumoniae 8825 strain was resistant to
all the penicillins and first, second, and third
generation cephalosporins, which were tested, with
the exception of cefoxitin. All these resistance
determinants were transferred to the E. coli J53-2
in the conjugation experiments (Table 1). In ad¬
dition, the clinical strain and the transconjugant
were both sensitive to imipenem. The K. pneumo¬
niae 8825 and its transconjugant were sensitive to
ampicillin, ceftazidime and cefotaxime in the pres¬
ence of clavulanic acid (2 mg/1), inferring that the
Fig. 1. Agarose gel electrophoresis of plasmid DNA from the
E. coli J53-2 transconjugant of K. pneumoniae 8825 along with
standard size plasmids. 1. R6K; 2. Rl; 3. Plasmid isolated
from E. coli transconjugant of K. pneumoniae 8825.
Table 1
Antibiotic susceptibilities of strains









Ampicillin > 250 > 250 4
+ clav * 8 4 4
Carbenicillin > 250 >250 8
Cephaloridine 125 32 2
Cephalexin 125 64 8
Cefoxitin 4 4 4
Cefuroxime 32 125 4
Ceftazidime 125 64 <1
+ clav * 0.25 0.25 0.13
Cefotaxime 8 8 <1
+ clav * <0.06 < 0.06 <0.06
Ceftriaxone 16 4 <1
Aztreonam 125 32 <1
Imipenem 0.13 0.25 0.25
In combination with clavulanic acid (2 mg/1).
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Fig. 2. IEF of /^-lactamases produced by K. pneumoniae 8825
and its E. coli J53-2 transconjugant. A. ^-lactamases produced
by the E. coli transconjugant of K. pneumoniae 8825 selected
on ceftazidime and rifampicin; B. /?-lactamases produced by
K. pneumoniae 8825; C. ^-lactamases produced by the E. coli
J53-2 transconjugant of K. pneumoniae 8825 selected on
carbenicillin and rifampicin.
/(-lactamases responsible for resistance to these
drugs were either of the TEM or SHV groups.
4.3. Identification of f-lactamases
The original K. pneumoniae isolate produced four
/(-lactamases which focused at p7 5.4, pi 6.5, pi
7.7 and p7 7.9. The band at pi 5.4 aligned with
TEM-1, the enzyme of pi 6.5 focused between
TEM-3 (p/ 6.5) and SHV-3 (p7 7.0), and the
enzyme of p7 7.7 aligned with SHV-1/2. Crude
enzyme preparations of the E. coli J53-2 transcon-
jugants selected on either carbenicillin and
rifampicin or ceftazidime and rifampicin pos¬
sessed the /(-lactamases which focused at p7 5.4,
p7 6.5, and p7 7.9. However, they additionally
produced another /(-lactamase which focused at p7
8.1 (Fig. 2). This high p7 band aligned directly
with the E. coli J53-2 chromosomal /(-lactamase.
When the crude preparation of the transconjugant
strain selected on rifampicin and ceftazidime was
separated through the Sephadex G-75 column the
intensities of the /(-lactamases of p7 7.9 and p7 8.1
were reduced.
4.4. Fast protein liquid chromatography
Two ml of the Sephadex G-75 purified (3-
lactamase sample were separated through the
Mono Q column in each run. This process was
repeated until sufficient quantities of the different
enzymes were obtained. In each FPLC System
separation, /(-lactamase activity was detected in
the following fractions: 2, 3 and 4 (the void
volume), 10/11, and 13/14. When these fractions
were examined by IEF the /(-lactamases of p7 7.9
and p7 8.1 were eluted in fractions 2, 3 and 4, the
enzyme of p7 6.5 in fractions 10/11, and the
/(-lactamase of p7 5.4 in fractions 13/14 (Fig. 3).
All the fractions, from the individual separations,
containing the same /(-lactamase, were combined
so that sufficient enzyme could be characterised
biochemically.
4.5. Characterisation of ^-lactamases
The hydrolytic activity of each of the three
enzymes against six different /(-lactam antibiotics
are shown in Table 2. The /(-lactamase which
focused at p7 5.4 aligned with TEM-1, it also had
no hydrolytic activity against ceftazidime or
cefotaxime and was therefore assumed to be
TEM-1. The /(-lactamase of p7 6.5 had hydrolytic
activity against cefuroxime, cefotaxime, ceftazi-
Table 2
Relative rates of hydrolysis of FPLC system fractions *
/3-lactam Fraction: 2-4 10-11 13-14




Ampicillin 100 100 100
Carbenicillin 29 18 17
Cephaloridine 114 125 20
Cefuroxime 4.3 17 UM
Cefotaxime 17 9.2 UM
Ceftazidime 4.6 14 UM
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Fig. 3. IEF gel of /^-lactamases separated by FPLC System. A.
/3-lactamases produced by E. coli J53-2 transconjugant of K.
pneumoniae 8825 purified by G-75 Sephadex gel filtration; B.
Fraction 2 eluted from FPLC System; C. Fraction 3; D.
Fraction 4; E. Crude /3-lactamase preparation of E. coli J53-2
transconjugant of K. pneumoniae 8825; F. Fraction 14 eluted
from FPLC System; G. Fraction 13; H. Fraction 15; I. as for
E; J. Fraction 10 eluted from FPLC System; K. Fraction 11.
the biochemical characterisation of each individ¬
ual /3-lactamase and permitted an assessment of
how each /3-lactamase contributed to the range of
/8-lactam resistances expressed by the host strain.
We were thus able to show that two of the en¬
zymes produced by the clinically derived K. pneu¬
moniae 8825 strain confer resistance to cefuro-
xime, cefotaxime, ceftriaxone, and ceftazidime.
Evaluation of the biochemical profile of each of
these enzymes strongly suggests that the lacta¬
mase pi 7.9 (/S-lactamase DJP-1) is a novel third
generation cephalosporin hydrolysing enzyme.
However, the plasmid mediated /S-lactamase of p/
6.5 may be the same as CAZ-hi [4], or CAZ-6 [2],
both of which have a reported pi of 6.5. The
majority of transferable third generation cepha¬
losporin resistance has emergence in France,
Germany, and the U.K. where broad spectrum
cephalosporin usage is high. However, these two
broad spectrum enzymes were found to be pro¬
duced by a strain isolated in India where the use
of these newer cephalosporins is much lower. The
occurrence of these two /8-lactamases is the first
report of transferable third generation cepha¬
losporin resistance in India and Asia, and also the
first example of two broad spectrum /S-lactamases
encoded by the same plasmid.
dime, and had a greater activity for cephaloridine
than TEM-I. The fractions containing enzymes of
pi 7.9 and pi 8.1 had a similar pattern of hydro-
lytic activities but the activity against the newer
cephalosporins must result from the enzyme of pi
7.9 and not the upper E. coli J53-2 chromosomal
/8-lactamase band, as control studies have shown
that this chromosomal enzyme has no hydrolysing
activity against these /3-lactam antibiotics.
5. DISCUSSION
These results have shown that Fast Protein
Liquid Chromatography has been the most power¬
ful method to date in the separation of multiple
/3-lactamases produced by the same strain. Its
rapid, complete separation of the enzymes enabled
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LACK OF TRANSFERABLE THIRD GENERATION
CEPHALOSPORIN RESISTANCE IN SCOTLAND.
D.J. Payne, J. Hood, R. Paton & S. G. B. Amyes.
Department of Bacteriology, The Medical School,
University of Edinburgh, Teviot Place, Edinburgh, EH8
9AG, Scotland.
Four hundred and thirteen Gram-negative strains,
which appeared resistant to cefuroxime by disk
sensitivity testing, were isolated from patients of
the Royal Infirmary, Edinburgh, Scotland over a
period from January 1986 to January 1989. This
collection of strains excluded Pseudomonas spp..
Seventy-nine of these strains had MICs of
ceftazidime, cefotaxime or ceftriaxone of 4mg/L or
greater. The ^-lactamases produced by 54 of these
third generation cephalosporin (3GC) resistant
strains were examined by analytical isoelectric
focusing. This same group of 3GC resistant organisms
were also tested to see if they exhibited
transferable resistance to either ceftazidime or
cefotaxime.
This study revealed that none of the 54 3GC resistant
strains conferred transferable resistance to either
ceftazidime or cefotaxime. Indeed, none of these
strains produced any of the TEM or SHV derived
^-lactamases which have recently been reported to
confer transferable resistance to 3GCs. Consequently,
the 3GC resistance conferred by strains in this
survey most probably resulted from the production of
chromosomal cephalosporinases. This survey yielded
only one novel chromosomal ^-lactamase which was
produced by Xanthomonas maltophilia and focused as 3
distinct bands of pi 5.2 to 5.6 and possessed
different characteristics to the L-l or L-2
^-lactamases of X.maltophilia. In conclusion this
survey has illustrated that TEM or SHV derived
B-lactamases which mediate transferable resistance to
3GCs do not appear to be threatening the future use
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MUTANTS OF THE TEM-1 /^-LACTAMASE CONFERRING
RESISTANCE TO THIRD GENERATION CEPHALOSPORINS
D.J. Payne, M.S. Marriott and S.G.B. Amyes
Bacteriology Department, Medical School, University
of Edinburgh, Edinburgh & Chemotherapy Department,
Glaxo Group Research Ltd, Greenford, U.K.
There have been recent reports that a new series of
plasmid-mediated ^-lactamases, which confer
resistance to third generation cephalosporins (3GC),
have been derived from the TEM-2 enzyme. In this
study, two types of ceftazidime (CAZ) resistant
mutants have been obtained spontaneously from an
E. coll J62-2 expressing the TEM-1 enzyme (mutation
frequency « 10"^). These mutants produce
^-lactamases with similar molecular weights, kinetic
parameters and iso-electric points (pi) to novel
/S-lactamases produced by CAZ resistant clinical
isolates which have recently been identified in this
laboratory. The first mutant enzyme focuses as a
doublet band at pi 5.3 with an additional weak TEM-1
band (pi 5.4). This doublet co-focuses with a
/3-lactamase produced by a CAZ resistant Klebsiella
pneumoniae, which was originally isolated at a
Liverpool hospital, although the clinical strain had
a stronger TEM-1 band. The second mutant produced an
enzyme with a pi identical to an enzyme produced by a
CAZ resistant E. coli strain isolated in Belgium;
both these ^-lactamases focus between TEM-1 and
TEM-7. These results purport the view that some
plasmid-encoded>S-lactamases, which confer resistance
to 3GC, have evolved from the simple mutation of the
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C-like extended-spectrum cephalosporinase.4 In is
the first example of a beta-lactamase conferringlTShsferable
resistance to all penicillins, to first, second, and third generation
cephalosporins, and to clavulanic acid.
The transferability in vitro of this resistance to bacteria of
different genera raises the possibility that similar dissemination
might occur in vivo. This importation of an organism with
transferable resistance to beta-lactams lends further weight to the
view5 that patients from abroad should be screened
microbiologically, and that appropriate control measures should be
instituted until they prove to be clear of such carriage.
Transferable cephalosporin resistance not
inhibited by clavulanate in Escherichia coli
SIR,—We report the isolation of a strain ofEscherichia coli resistant
to penicillins and cephalosporins because of a plasmid-encoded
beta-lactamase that was not inhibited by clavulanic acid. The
organism was isolated in London from raw area swabs and a biopsy
specimen from a patient with 35% bums. The patient had been
treated in Pakistan with cefotaxime and amikacin for at least 15 days
before transfer to the UK. The strain was resistant to all
beta-lactams tested (table), except imipenem (sensitive by disc test),
and to chloramphenicol, tetracycline, and trimethoprim. On disc
testing, addition of clavulanic acid did not restore susceptibility to
ceftazidime. The strain was susceptible to aminoglycosides and
ciprofloxacin. Following grafting, the patient made steady progress.
Two episodes of clinical septicaemia were treated with imipenem
and ciprofloxacin, respectively, although no organisms were
isolated from blood cultures. The resistant strain was not isolated
subsequently from his bums. The patient was in isolation
throughout his two-month stay and secondary spread to other
patients was not observed.
The strain contained three plasmids of 80, 45, and 35 MD.
Resistance to beta-lactams was transferred readily to, and
maintained stably in, E coli, Emerobacter cloacae, and Klebsiella
oxytoca (table). These transconjugants acquired the 80MD plasmid
together with resistance to chloramphenicol and tetracycline. In
addition, Em cloacae transconjugants acquired the 35 MD plasmid
and E coli transconjugants acquired plasmids which varied from 28
to 45 MD. These plasmids may have been deletions of plasmids
carried by the original (donor) strain. These results suggest that the
resistance to beta-lactams was encoded on the 80 MD plasmid. No
transfer was detected to strains of Proteus mirabilis or Serratia
marcescens.
The E coli, K oxytoca, and Em cloacae transconjugants all
produced an identical beta-lactamase ofpi 88. This beta-lactamase
(designated BIL-1) hydrolysed nitrocefin and cephaloridine, but
not ampicillin, carbenicillin, cefuroxime, cefotaxime, and
ceftazidime. Unlike the TEM-1 beta-lactamase, the hydrolytic
activity of BIL-1 was inhibited by ampicillin, cefuroxime, and
ceftazidime. BIL-1 was not inhibited by clavulanic acid since this
compound did not render the E coli transconjugants sensitive to
ampicillin, cefotaxime, or ceftazidime (table). BIL-1 was almost
4000 times more resistant to inhibition by clavulanic acid than
TEM-1 (data not shown).
There have been reports of plasmid-mediated beta-lactamases
that confer resistance to the third generation cephalosporins, but
these are all derivatives of the ubiquitous TEM-1/2 and SHV-1
resistance genes' and are very sensitive to inhibition by clavulanic
acid. Our data indicate that BIL-1 is unrelated to these enzymes.
The characteristics of BIL-1 resemble more closely those of the
chromosomally mediated beta-lactamases of Em cloacae1 and
E coli.1 We are unaware ofother reports of a plasmid-encoded class
SUSCEPTIBILITY TO BETA-LACTAM ANTIBIOTICS OF E COU
AND TRANSFER OF RESISTANCE TO OTHER GENERA
Minimum inhibitory concentration (mg/l)*
Strain Amp Carb Cefo Ceft Cefu Pip
E coli
BS (clinical strain) 64 256 > 16 >16 >32 64
K12 (recipient) $4 ^ 16 ^0-25 05 s$2 ^4
(4) (<0 06) (0 13)
Transconjugant 64 128 8 > 16 >32 64
(>32) (>4) (>4)
K oxytoca
478 (recipient) > 641 128t ^0-25 ^0-25 4 16
T ransconjugant >64 128 2 4 32 64
Ent cloacae
471 (recipient) ^4 ^ 16 ^0-25 ^0-25 4 ^4
T ransconjugant >64 64 16 8 >32 16
We thank Mr J. A. Clarke for permission to report this case.
Division of Hospital Infection.
Central Public Health Laboratory.
London NW9 5HT. UK.
Department of Bacteriology,
University of Edinburgh Medical School
and Burns Unit,









S. G. B. Amyes
tChromosomally encoded resistance to penicillins.
*MIC in presence of 2 mg/l clavulanic acid shown in parentheses.
Amp = ampicillin. Carb = carbenicillin. Cefo = cefotaxime, Ceft = ceftazidime.
Cefu = cefuroxime. Pip = piperacillin.
1. Philippon A, Labia R, Jacoby G. Extended-spectrum beta-lactamases. Anwmcrod
Agents Chemother 1989; 33: 1131-36.
2. Seeberg AH, TolxdorfT-Neutzling RM, Wiedemann B. Chromosomal beta-
lactamases of Enterobacter cloacae are responsible for resistance to third generation
cephalosporins. Antumcrob Agents Chemother 1983; 23: 918-25.
3. Minami S, Inoue M, Mitsuhashi S. Purification and properties of cephalosporinase in
Escherichia coli. Antimicrob Agents Chemother 1980; 18: 77-80.
4. Ambler RP. The structure of beta-lactamase. Philos Trans R Soc Land fBiol i 1980;
289: 321-31.
5. Combined Working Party of the Hospital Infection Society and British Socicry for
Antimicrobial Chemotherapy. Guidelines for the control of epidemic methiollin-
resistant Staphylococcus aureus. J Hosp Infect 1986; 7: 193-201.
Cyclophosphamide versus ifosfamide in
paediatric oncology
Sir,—We concur with Dr Shaw and Dr Eden's (April 28, p 1022)
comments about ifosfamide and cyclophosphamide use in
paediatric oncology. For 15-20 years cyclophosphamide dose in
widely used regimens in paediatric oncology has been 0-9-1 -5 g m3
per course;1-3 "intensive" regimens use 1-8 g;m3 per course.4-5
Typical ifosfamide doses are 6-10 g.m3 per course,' which is the
equivalent of 1 -7-3-0 g, m3 ofcyclophosphamide—ie, up to 3-3 times
the "standard" cyclophosphamide dose. It is well established that
tumours that do not respond to low doses of alkylating agents
regress when the dose of the same agents is increased. Hence, it
should be no surprise that results are encouraging when ifosfamide
6-10 g/m3 per course is substituted for cyclophosphamide 1 -2 g m3
per course in otherwise equivalent regimens.6
Dr Jurgens and Dr Gobel (June 9, p 1399), commenting on Shaw
and Eden's report, state that ifosfamide has an advantage over
high-dose cyclophosphamide in that the latter produces greater
bone-marrow toxicity and necessitates supportive treatment with
cytokines.
We would point out that studies in children and young adults
from our institution . have demonstrated the feasibility of
administraton of multiple courses of very high dose
cyclophosphamide in conjunction with other cytotoxic agents.
Thus, on the basis ofprevious experience,7 we initiated in 1987 an
induction protocol for patients with poor-risk neuroblastoma that
included four consecutive courses of cyclophosphamide 140 mg, kg
(ie, 4200 mg.m3), doxorubicin 45 mg/m3, and vincristine.8 (This
cyclophosphamide dose is 2-3 times the intensive dose and up to 4-7
times the standard dose.) To achieve maximum dose intensity (high
doses, short term interval), courses were started when the
neutrophil count reached 500 pi and platelets were over 100 000 pi.
Most courses began by day 21. Grade 3—4 myelosuppression
occurred, yet, as evidence of the relative stem-cell sparing effect of
cyclophosphamide, bone-marrow harvested after the four courses
reconstituted haemopoiesis after subsequent myeloablative therapy
with autologous bone-marrow rescue. Extramedullary toxicities
were mild. This last finding, as well as analyses demonstrating the
Resistance to antibacterial drugs in commensal bacterial
flora in South India
fAJto£,hX(
S.Tait, L.S.Nandivada, D.J.Payne, C.J.Thomson, S.G.B. Amyes. Department of
Bacteriology, The Medical School, University of Edinburgh, Teviot Place,
Edinburgh EH8 9AG, Scotland.
In 1984 a study was carried out at the Christian Medical College Hospital
(CMCH) in Vellore, Tamil Nadu, South India to investigate resistance to
antibiotics in pathogens causing urinary tract infections. This investigation
reported high levels of resistance to ampicillin and trimethoprim. Resistance
to ampicillin (Minimum Inhibitory Concentration (MIC) >10mg/L) was found in 77%
of Escherichia coli isolated (Nandivada & Amyes 1987) and 64% were resistant to
trimethoprim (MIC > lOmg/L)(Young et al 1986).
In 1989, we returned to CMCH to establish if the reservoirs of the antibiotic
resistance genes were actually located in the commensal faecal flora of the
healthy population. Two cohorts of volunteers were recruited: an urban group
(U) from the people of the town of Vellore (pop. 150,000) and a rural group (R)
from villages situated about 40km from the town. Three villages were used;
Kilvayattarankuppam - a roadside village with good access to the town, Kavanur
- a riverside village with moderate access and Melmoil - a village in the
foothills with poor communications. In both study groups faecal specimens were
taken from volunteers who were at least five years old, apparently healthy and
had received no antibacterial chemotherapy in the previous week. Each specimen
(92 from the urban study and 122 from the rural group) was initially examined
for the presence of large Gram-negative rods (not Pseudomonas) which were
resistant to trimethoprim, ampicillin, chloramphenicol or nalidixic acid. The
faecal specimens were plated out onto a Maconkey-like agar containing each of
these drugs (at lOmg/L). There was almost universal carriage of enterobacteria
resistant to trimethoprim (U=98.3%, R=100%), ampicillin (U=98.9%; R=97.5%) and
chloramphenicol (U=96.8%; R=97.5%). There was neither any significant
difference between the proportions in the urban and rural study areas nor
between proportions from the individual villages, despite the varying degree of
remoteness. On the other hand, the carriage of nalidixic acid resistance was
considerably lower. However, it was significantly more common in the urban
population (29.7%) than in the rural (11.2%) Cv = 7.84; 0.01>p>0.001).
Further study on the trimethoprim resistant strains has revealed that 86% of
them were highly resistant (MIC >1000mg/L), which is indicative of a plasmid
origin of the gene. However, only a minority of these highly resistant strains
were capable of transferring trimethoprim resistance. None of the nalidixic
acid resistant strains tested were resistant to ciprofloxacin (lmg/L) despite
the free availability of this drug in India.
These results provide evidence that the commensal gut flora of the human
population, in this part of India, acts as a reservoir for antibiotic resist¬
ance genes which may then be acquired by pathogens. Such high carriage rates of
resistant commensals may be stimulated by the free availability of antibiotics
"over the counter" without prescription. Antibacterial drugs, bought in
Vellore, were examined by bio-assay and absorbance spectrum analysis and found
to be virtually identical to equivalent drugs obtainable in the UK and USA.
We are grateful to the Royal Society and the British Society for Antimicrobial
Chemotherapy for funding this research visit.
Nandivada ,L.S. & Amyes.S.G.B. (1987) J.Pharm.Pharmacol. 39:18P.
Young,H-K. et al (1986). J.Antimicrob.Chemother. 17:615-621.
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TEM-E4: A ^-lactamase which confers transferable
resistance to ceftazidime
1 2 3 1
D.J.Payne , M.S.Marriott , C.Christodoulou , S.G.B.Amyes Depart¬
ment of Bacteriology, Judical School, University of Edinburgh, Edinburgh EH8
9AG & Departments of Chemotherapy and Genetics, Glaxo Group Research Ltd,
Greenford, UB6 OHE, U.K.
When third generation cephalosporins (3GCs), such as ceftazidime and
cefotaxime, were first introduced they were resistant to hydrolysis by all the
plasmid-mediated p-lactamases known at that time. However, in the last four
years a number of plasmid mediated ^-lactamases have evolved which have the
ability to hydrolyse ceftazidime and cefotaxime and, consequently, promote
transferable resistance to 3GCs (Philippon et al 1989). Many of the 3GC
hydrolysing p-lactamases have been shown to have evolved from the ubiquitous
TEM-1/2 and SHV-1 resistance genes.
The ceftazidime resistant isolate of Serratia marcescens 7919 was isolated in
Belgium in 1987. Conjugation of strain 7919 with Escherichia coli J53-2
resulted in ceftazidime-resistant E. coli J53-2 transconjugants. Analysis of
the plasmid DNA in these transconjugant strains revealed a single plasmid band
of 56Kb, which was designated pUK724. This plasmid was also visualized in the
S. marcescens strain. With the exception of imipenem, the S. marcescens 7919
strain was resistant to all penicillins as well as first, second and third
generation cephalosporins but the E. coli J53-2 transconjugant was resistant
only to ceftazidime and remained sensitive to all the other third and second
generation cephalosporins tested. The ceftazidime and ampicillin resistances,
expressed by the E. coli transconjugant, were diminished with the addition of
clavulanic acid (2mg/L). This illustrated that the jp-lactam resistance of the
E. coli J53-2 transconjugant of S. marcescens 7919 must be ^-lactamase
mediated. Iso- electric focusing of bacterial extracts and visualisation with
the chromogenic cephalosporin, nitrocephin revealed that both the original
S. marcescens isolate and the E. coli J53-2 transconjugant produced a novel
p-lactamase, designated TEM-E4. This enzyme focused marginally above the TEM-2
(pi 5.6) and below the TEM-6 (pi 5.85) enzyme. In comparison with standards,
TEM-E4 was allocated a pi of 5.61. The TEM-E4 ^-lactamase exhibited low rates
of hydrolysis for ceftazidime and cefotaxime although it hydrolysed cefotaxime
more efficiently than ceftazidime. It was also shown that TEM-E4 and TEM-1 had
similar molecular weights and ID^q values for clavulanic acid.
In separate experiments, challenging E. coli J53-2 (RP4), a TEM-2 ^-lactamase
producing strain, with ceftazidime (2mg/L) resulted in spontaneous mutants
capable of resisting the drug. In these mutants, the TEM-2 enzyme had mutated
so that it was now capable of hydrolysing ceftazidime (Mutant ^-lactamase D).
Close comparison of Mutant ^-lactamase D and TEM-E4 showed that they had
similar resistance profiles to p-lactam antibiotics, they had identical pis and
similar kinetic constants for five different jl-lactam substrates. These results
infer that TEM-E4 resulted from direct mutation of the TEM-2 gene. Further
evidence for this has been obtained by DNA-DNA hybridization studies which
showed that the TEM-E4 gene hybridised with a radiolabelled TEM gene probe.
In conclusion, the TEM-E4 JB-lactamase is a unique plasmid-encoded enzyme,
capable of hydrolysing 3GCs, which is present in clinical bacteria. TEM-E4
could be obtained by spontaneous mutation of the common TEM-2 gene and seems to
have derived directly from it.
We thank the SERC for the CASE studentship to DJP.
Philippon,A. et al (1989) Antimicrob. Agents Chemother. 33:1131-1136.




Tn3701, PROTOTYPE OF A CLASS OF COMPOSITE CONJUGATIVE
ELEMENTS IN STREPTOCOCCI.
C.Le Bouguenec*, G. de Cespedes, and T. Horaud.
Laboratoire des Staphylocoques et des Streptocoques, Institut Pasteur,
Paris, France.
The plasmid-free Streptococcus pyogenes strain A454 contains a conjuga-
tive element, Tn3701, encoding resistance to erythromycin (Em), tetracycline
(Tc), and minocycline (Mn) (1). We have mapped a 50-kilobase (kb)
chromosomal region of A454 corresponding to the internal part of Tn3701.
Tn3701 includes a 19.7-kb structure, designated Tn3703, on which the
EmTcMn determinants were localized. Tn3703 which is very similar in struc¬
ture to the conjugative transposon Tn916 (2), is capable of transposition
but is not conjugative. By hybridization experiments, we revealed strong
homology between Tn3701 and the conjugative chromosomal elements
fl'. (cat-tet) (3) and Tn3951 (4) described in Streptococcus pneumoniae strain
BM6001 and in Streptococcus agalactiae strain B109, respectively. Like
Tn3701, (cat-tet) and Tn3951 are composite elements containing in their
internal region a structure similar to Tn916. Moreover, among eleven anti¬
biotic resistant plasmid-free clinical isolates tested (10 streptococci of
groups A,B and G and one S. pneumoniae) three showed homology to Tn3701
and four to Tn916, suggesting that these two types of conjugative chromo¬
somal elements are common in plasmid-free antibiotic resistant streptococci.
References
1. Le Bouguenec et al. , J. Bacteriol. , 1988,170,3930-3936.
2. Clewell and Gawron-Burke, Ann. Rev. Microbiol., 1986,40,635-659.
3. Vijayakumar et al., J. Bacteriol., 1986,166,978-984.
4. Inamine and Burdett, J. Bacteriol., 1985,161,620-626.
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XWO NOVEL PLASMID MEDIATED B-LACTAMASES WHICH CONFER RESISTANCE TO
CEFTAZIDIME
^ |
D.J.Payne , M.S.Marriott , and S.G.B.Amyes
Bacteriology Department, Medical School, University of Edinburgh,
Edinburgh & +Chemotherapy Department, Glaxo Group Research Ltd,
Greenford, U.K.
There have been a number of recent reports on the plasmid mediated
B-lactamases TEM-3 to TEM-7. These enzymes confer resistance to third
generation cephalosporins (3GC) and are believed to have evolved from
TEM-l/TEM-2. We have identified a further two novel plasmid mediated
B-lactamases which confer resistance to 3GC.
The first was derived from Klebsiella pneumoniae and isolated in 1982 at a
Liverpool hospital. This is believed to be the earliest example of a
plasmid mediated B-lactamase conferring resistance to a 3GC. This strain
contains a 103 kb plasmid which encodes TEM-1 (pi 5.4) and the novel
B-lactamase (doublet at pi 5.3). The second B-lactamase was expressed by
an E.coli strain isolated in Belgium. It is encoded by a 60 kb plasmid and
has a pi between TEM-1 (pi 5.4) and TEM-7 (pi 5.41). Both the original
isolates and their respective E.coli J53-2 transconjugants had much higher
MICs of ceftazidime (32mg/L at 10^ cfu) than for cefotaxime
(0.25-0.5mg/L at 10^ cfu). However,the relative efficiency of hydrolysis
(Vmax/Km [ampicillin = 100%]) of ceftazidime and cefotaxime were in the
order of 1-2% for both enzymes. The rates and efficiency of hydrolysis
observed for these two enzymes for ampicillin, carbenicillin, and
cephaloridine were also similar to TEM-1. Both enzymes were inhibited by
clavulanic acid and had molecular weights similar to TEM-1. This enforces
the view that these two enzymes (along with the 3GC hydrolysing
loEis-j.
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A-70 Comparison of TEM-E3 and TEM-10 ^-lactamases.
D.J. PAYNE*, M.S.MARRIOTT, S.G.B.AMYES. Med
School, Univ of Edinburgh, Edinburgh, & Glaxo Group
Research, Greenford, U.K.
Transferable resistance to ceftazidime has been found in a
South London Hospital (SLH) and the North Middlesex
Hospital (NMH). The ^-lactamases responsible (TEM-E3) were
shown to have identical isoelectric points (pi) and
similar Vmax, Km and efficiency of hydrolysis values for
six ^-lactam substrates. These assays were performed in
parallel with TEM-10, a )B-lactamase recently identified in
the USA, and demonstrated that TEM-10 and TEM-E3 were
identical. MIC data showed that E.coli J53-2 trans-
conjugants producing TEM-10, TEM-E3 (NMH), or TEM-E3 (SLH)
were resistant to ceftazidime (64-125 mg/L), aztreonam
(32-64 mg/L), and only slightly resistant to cefotaxime
(0.5-1 mg/L). TEM-E3 and TEM-10 had a greater affinity for
cefotaxime (Km 11-21 |iM), than for ceftazidime (Km 100-167
pM) although they hydrolyse cefotaxime at a much slower
rate (2-3% relative to the Vmax for ampicillin) than
ceftazidime (30-40%). However, the efficiency of
hydrolysis values for cefotaxime were relatively high
(12-16% relative to ampicillin and 20-33% for ceftazidime)
considering the enzyme confers no significant cefotaxime
resistance. This study confirms that the same gene is now
present in clinical bacteria in the USA and Europe and
this ^-lactamase differs from both TEM-5 and TEM-9.
